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ABSTRACT
Drug delivery to the brain can be enhanced via a prodrug approach utilizing the large
amino  acid  transporter  1  (LAT1),  which  is  highly  expressed  at  the  BBB.  LAT1  transports
amino acids and compounds mimicking amino acids, such as LAT1-targeted prodrugs, to
the brain. The main aim of this study was to enhance the BBB permeation of selected drugs
by LAT1-targeting. The LAT1 binding of the prodrugs was maximized by using unnatural
amino acids as promoieties. Another aim was to generate a 3D pharmacophore of LAT1 to
clarify the structure-activity relationships between LAT1 and its substrates.
The study demonstrates that meta-substituted phenylalanine can act as a high-affinity
LAT1  promoiety  which  could  increase  brain  delivery  of  both  anionic  (valproic  acid  and
kynurenic acid) and cationic (dopamine) drugs. Large amounts of the meta-substituted
phenylalanine prodrugs of valproic acid crossed the rat BBB via LAT1. However, a proper
prodrug bond for valproic acid was not easily found, since the ester prodrugs liberated
valproic acid too rapidly, whereas the amide prodrugs did not achieve an adequate
bioconversion rate in the rat brain. The amide prodrug of kynurenic acid bound also to
LAT1 with high affinity. However, its bioconversion rate in rats was not superior to that of
the valproic acid prodrugs. High amount of the meta-substituted phenylalanine prodrug of
dopamine was also able to cross the BBB via LAT1. However, the prodrug did not elevate
the striatal dopamine concentrations above those achieved by the corresponding levodopa
treatment even though dopamine was released from the promoiety in vitro. Finally, the 3D
pharmacophore generated in the present study highlights the most important molecular
features for efficient LAT1 binding and elucidates their 3D-characteristics in detail.
 In conclusion, the selection of high-affinity LAT1 promoieties was expanded in the
present study to both anionic and cationic parent drugs. In particular, the meta-substituted
phenylalanine could be utilized as a LAT1-targeting promoiety to improve the brain
delivery of drugs. However, more effort has to be conducted to optimize the release of the
active parent drug from the promoiety. The generated 3D pharmacophore clarifies the
structure-activity relationships of LAT1 substrates. The results can be further applied in the
design of novel efficient LAT1 substrates.
National Library of Medicine Classification: QU 55.7, QV 785, WL 200
Medical Subject Headings: Drug Delivery Systems; Prodrugs; Brain; Transporters; Large Neutral Amino Acid
Transporter 1; Blood-Brain Barrier; Permeability; Phenylalanine; Valproic Acid; Kynurenic Acid;  Dopamine;
Structure-Activity Relationship; Rats
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TIIVISTELMÄ
Lääkeaineiden aivokulkeutumista voidaan parantaa aihiolääketeknologian avulla
hyödyntämällä veri-aivoesteellä runsaasti esiintyvää kuljetusproteiinia (LAT1). LAT1
kuljettaa aivoihin suuria ja neutraaleja aminohappoja sekä monenlaisia aminohappo-
rakenteita, myös aihiolääkkeitä, joiden aihio-osana on aminohappo. Tämän tutkimuksen
tavoitteena oli hyödyntää LAT1:stä lääkeaineiden aivokulkeutumisessa aihiolääke-
teknologian avulla. Tutkimuksessa optimoitiin aihiolääkkeen sitoutumista LAT1:een.
Toinen tutkimuksen tavoite oli kehittää tietokoneavusteinen 3D-farmakoforimalli LAT1:stä.
 Väitöstutkimuksessa aihio-osina käytettiin ei-luonnollisia aminohappoja, jotka
sitoutuvat LAT1:een luonnollisia aminohappoja voimakkaammin. Tutkimuksessa
löydettiin erittäin hyvin LAT1:een sitoutuva aihio-osa, fenyylialaniinin meta-substituoitu
johdos, jota voidaan hyödyntää monipuolisesti sekä anionisten (valproehappo ja
kynureenihappo) että kationisten (dopamiini) lääkeaineiden aivokohdennuksessa. Kun
valproehappo liitettiin tähän aihio-osaan, aihiolääkkeet kulkeutuivat rotan aivoihin LAT1-
välitteisesti. Nämä amidisidokselliset aihiolääkkeet eivät kuitenkaan vapauttaneet
riittävästi valproehappoa rotan aivoissa, kun taas esterisidokselliset aihiolääkkeet
vapauttivat valproehappoa liian nopeasti. Myös vastaava amidisidoksellinen
kynureenihappojohdos osoittautui sekä LAT1-substraatiksi että huonosti malliainetta
vapauttavaksi yhdisteeksi. Dopamiiniaihiolääke, jossa aihio-osana oli meta-substituoitu
fenyylialaniini, kulkeutui myös veri-aivoesteen läpi LAT1-välitteisesti. Se ei kuitenkaan
lisännyt rotan striatumin dopamiinitasoja levodopahoitoa paremmin, vaikka dopamiinia
vapautui in vitro -olosuhteissa. Väitöstutkimuksessa kehitetyn 3D-farmakoforin avulla
pystyttiin määrittämään LAT1-substraatin tärkeimmät ominaisuudet LAT1-sitotumiselle
sekä näiden ominaisuuksien avaruudelliset sijainnit toisiinsa nähden.
Väitöstutkimuksessa kehitettiin monipuolisia LAT1-aihio-osia sekä anionisille että
kationisille malliaineille. Etenkin meta-substituoitua fenyylialaniinia voitaisiin hyödyntää
huonosti aivoihin kulkeutuvien lääkeaineiden aivokohdentamisessa. Lääkeaineen
vapautumista aihio-osasta tulisi kuitenkin edelleen optimoida. 3D-farmakofori lisää
ymmärrystä yhdisteiden sitoutumispaikasta LAT1:een, joten kehitettyä 3D-farmakoforia
voidaan hyödyntää uusien LAT1:n kautta kulkeutuvien yhdisteiden suunnittelussa.
Luokitus: QU 55.7, QV 785, WL 200
Yleinen suomalainen asiasanasto: lääkeaineet; aihiolääkkeet; aivot; veri-aivoeste; läpäisevyys; aminohapot;
mallintaminen
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1 Introduction
There are several serious diseases lacking effective drug therapies, especially in oncology
and neuropharmacology (Kola and Landis 2004, Berggren et al. 2012). Drug research and
development in general consist of many time-consuming and labor-intensive processes
(Kaitin 2008). In particular, the development of central nervous system (CNS) -acting new
medical entities is very challenging. New medical entities against CNS disorders have a
lower probability to reach the market and a higher risk of failure during clinical trials
compared with the average probability of non-CNS drugs. Although some CNS disorders,
e.g. insomnia, epilepsy, depression, chronic pain and schizophrenia, have even adequately
satisfactory symptomatic drug treatment, there is a serious unmet clinical demand for
disease modifying drug therapies against several CNS-related disorders, e.g. multiple
sclerosis, neurodegenerative diseases, glioblastomas and schizophrenia. The inability to
treat most of these CNS disorders is often due to ineffective drug delivery to the site of
action within the brain rather than lack of effective CNS drug targets (Pardridge 2012). A
drug cannot achieve its desired pharmacological activity in the brain if it does not reach the
brain at effective concentrations. In addition, there is a demand for valid biomarkers for
CNS disorders because many good biomarkers have only low CNS permeation.
The  demand  for  effective  drugs  against  CNS  disorders  is  high  as  the  CNS  disorders
represent 5 of the top 10 causes of long term disability in the United States and Europe and
account for over 30% of total health care spending (Olesen et al. 2012). The health care costs
of CNS disorders in 2010 were estimated at 798 billion Euros per year in Europe, which is
equal to the combined costs of cardiovascular diseases, cancer and diabetes. It has been
estimated that  every third individual  will  suffer  from a  diagnosable  CNS disorder  in  any
given year (Rajadhyaksha et al. 2011, Olesen et  al. 2012). With improved diagnostic
techniques and the current demographic development of an increasingly ageing
population, this number is expected to increase.
The entry of CNS-acting compounds to the brain is often impeded by the blood-brain
barrier (BBB), which is an efficient structural and functional barrier protecting and
regulating the nervous tissue homeostasis and controlling the selective and specific uptake,
efflux and metabolism of endogenous and exogenous molecules (Pardridge 2005a). The
structural barrier results from the capillary endothelial cells which are held closely together
by tight junctions. Due to the tight junctions, molecules can translocate across the BBB only
transcellularly, and thus only small and lipophilic molecules (i.e. molecular weight less than
400 Da and log P between 1 and 4) can cross the BBB by simple passive diffusion. Thus,
most of the CNS-active drugs in clinical use meet these criteria. In contrast, polar, water
soluble and larger pivotal molecules are transported across the BBB via carriers which are
specialized to transport specific endogenous molecules. Small polar molecules, such as
amino acids, glucose and vitamins, are ferried by the transporters, and macromolecules,
such as insulin, transferrin and other proteins, are transported by receptor-mediated
transcytosis.  The BBB expresses also many enzymes and efflux transporters which further
restrict the entrance of many drugs into the brain.
2Several strategies to overcome the problems related to drug delivery to the brain have
been devised (Gabathuler 2010, Pardridge 2012, Vlieghe and Khrestchatisky 2012). These
strategies include both invasive techniques and non-invasive strategies. There are several
disadvantages associated with the invasive strategies, i.e. need for hospitalization of the
patients and the risk of complications due to the disruption of the BBB, and therefore the
non-invasive strategies have been considered as more appropriate (Gabathuler 2010).
Conventionally, the most common non-invasive strategy to enhance the brain delivery of
small molecular weight drugs has been based on increasing the extent of passive diffusion
across the BBB (Pardridge 2012). However, the more lipophilic molecules face several
problems, i.e. off-targeted distribution to peripheral tissues, binding to plasma proteins and
non-specifically to tissues. Thus, novel non-invasive strategies utilizing either the
transporter- or receptor-mediated transport mechanisms have been introduced. Advances
in the knowledge of the transporters and receptors specifically expressed at the BBB have
given rise to new and more specific brain delivery strategies during recent years enabling
better brain specific targeting compared to the conventional lipidization approach. In
addition, the utilization of the receptor-mediated transport across the BBB has appeared to
be  promising  way  to  deliver  macromolecule  therapeutics  to  the  brain.  However,  none  of
these modern drug delivery strategies have yet been approved for clinical use to treat
human CNS disorders.
In  the  present  thesis,  amino  acid  prodrugs  of  valproic  acid,  kynurenic  acid  and
dopamine utilizing the large amino acid transporter 1 (LAT1) at the BBB were studied with
the overall objective to enhance the BBB permeation of these parent drugs. Modified,
unnatural amino acids were used in order to increase the affinity of the prodrugs for LAT1,
to diversify the selection of the promoieties and to optimize the releasing properties of the
LAT1-targeted prodrugs. A variety of in vitro, in situ and in vivo methods were used to
determine the physicochemical and biological properties of the prodrugs. The second
objective of this thesis was to clarify the structure-activity relationships (SARs) required for
the substrates binding to LAT1 by creating a ligand-based 3D pharmacophore of LAT1. The
generated predictive computer model of LAT1 can be used as a tool to find new LAT1
substrates to be used as promoieties to enhance drug penetration across the BBB by a LAT1-
mediated manner.
32 Review of the Literature
2.1 BLOOD-BRAIN BARRIER: A FUNCTIONAL AND STRUCTURAL
BARRIER FOR DRUG DELIVERY TO THE BRAIN
2.1.1 Structure and function of the blood-brain barrier
Drug entrance into the brain is efficiently impeded by two relatively insurmountable
physiological barriers, blood-brain barrier (BBB) and blood-cerebrospinal barrier (BCSFB),
which are located between the CNS and the blood circulation (De Boer and Gaillard 2007,
Abbott et al. 2010). The more extensive of these two barriers is the BBB which segregates the
blood from the extracellular fluid of the brain. Therefore, it is more an exception rather than
a rule that a drug will reach the brain in pharmacologically appropriate amounts
(Pardridge 2007). However, the billions of neurons at the brain need a constant supply of
energy, oxygen and nutrients, precise regulation of ions and neurotransmitters and
protection from toxic compounds and pathogens (Abbott et al. 2010). Thus, the BBB controls
the  brain  environment  by  protecting  the  brain  from  intrusive  chemicals,  by  taking  up
pivotal substances from the blood circulation, and by discarding harmful substances out of
the brain thereby regulating the brain homeostasis. The entry of therapeutic drugs across
the BBB is also prevented by the same mechanisms that protect the CNS against these
harmful  chemicals.  Since  the  function  of  the  BBB  is  not  only  to  prevent  chemicals  from
reaching the brain extracellular fluid but also to transport many pivotal molecules into the
brain via specific carrier-mediated mechanisms, the description “barrier” is somewhat too
simplistic (Habgood and Ek 2010).
History of the blood-brain barrier
The BBB was originally found by the Nobel Laureate Paul Ehrlich at the start of 20th century
(Hawkins and Davis 2005, Ribatti et al. 2006). He observed that intravenously injected
trypan blue -colored dye, aniline, stained most regions of the body except the brain and
spinal cord. At that time, Ehrlich concluded incorrectly that the CNS possessed a lower
affinity for the dyes than the tissues elsewhere in the body. A couple of decades later
Ehrlich’s student, Edwin Goldmann, found that when injecting the rat subarachnoid space
with trypan blue only  the  brain  and spinal  cord were  stained indicating that  there  was a
special membrane that restricted the dye from crossing the brain capillaries. This barrier is
today known as the BBB. In the later 20th century, other scientists confirmed the existence of
the BBB which restricted the entrance of toxins into the brain. The anatomical confirmation
of  the  BBB  by  electron  microscope  was  conducted  by  Reese  and  Karnovsky  in  1967,  and
these scientists were also able to reveal the tight junctions between the brain capillary
endothelial cells (Reese and Karnovsky 1967). Afterwards, the presence of the BBB has also
been demonstrated in all vertebrates (Cserr and Bundgaard 1984) and even in many insects
(Carlson et al. 2000).
4The 200–300 nm thick BBB is located in the wall of brain capillaries (Figure 1) (Zlokovic
2008). It includes both the abluminal and luminal lipid microvascular endothelial cell
membranes and the intracellular space between those membranes. As there are 100 billion
capillaries in the human brain, the length of the human BBB is about 650 km, and its surface
area is about 20 m2 (Abbott et al. 2010). The brain constitutes about 2% of the body weight
but it utilizes 20% of the cardiac output, which is 700–1000 mL/min in adults (Rolfe and
Brown 1997). The BBB can be distinguished from the most non-cerebral capillaries because
of the unique structural and functional features of the BBB as compared with those in the
peripheral cell membranes (Wolburg and Lippoldt 2002).
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Figure 1. Simplified structure of neurovascular unit (A), BBB (B) and tight junctions (C).
Tight junctions and adherens junctions
The BBB represents four unique structural elements, i.e. the tight junctions, a lack of
pinocytosis and fenestration and high electrical resistance (Abbott et  al. 2010). Structures
closely resembling these tight junctions have been found only between the cells of other
blood-tissue barriers, e.g. blood-retina barrier (Hughes et al. 2005) and blood-testis barrier
(Mita et al. 2011). The endothelial cells at the BBB are tightly held together by specific
junctional complexes, i.e. tight junctions and adherens interendothelial junctions (Figure
1C). At the BBB, the transendothelial electrical resistance (TEER) is 1500–2000 xcm2,
whereas the resistance in most non-cerebral capillaries is much less, 2–20 xcm2 (Butt et al.
1990), illustrating the impediment to movement of ions and other polar compounds across
the cerebral capillaries. The tight junctions consist of a complex of transmembrane proteins,
i.e. claudins 1–20, occludin and junctional adhesion molecules (JAMs) (Figure 1C) (Abbott et
al. 2010, Liu et al. 2012).  In  addition,  claudins  and  occludin  are  linked  to  the  intracellular
5scaffolding and regulatory proteins ZO-1, ZO-2, ZO-3 and cingulin, which are in their part
connected to actin. This confers both structural and functional integrity on the endothelial
cells.  The  barrier  function  of  the  tight  junctions  is  regulated  by  environmental  factors,  as
well as by the interaction between the proteins (Abbott et al. 2010). For example, changes in
either intracellular or extracellular concentration of calcium can evoke disorders in the tight
junctions (Brown et al. 2004). Proteins called catherins and cadherins form the adherens
junctions (Figure 1C), which have a key role in forming the BBB by providing the structural
support in addition to the tight junctions (Wolburg and Lippoldt 2002). Disruption in
adherens junctions leads to barrier dysfunction.
Neurovascular unit
The components surrounding the capillary endothelial cells, i.e. the basal lamina, pericytes,
astrocyte  endfoots  and  neurons  supports  the  structure  of  the  BBB  and  supplements  its
barrier functionality (Figure 1A) (McCarty 2005). The surrounding components together
with the endothelial cells form the neurovascular unit. The dynamic interactions and
communications between the cells of the neurovascular unit modulate events such as
synaptic activity, cerebral blood flow and tightness of the BBB regulating the transport of
molecules across the BBB and eventually maintaining the brain homeostasis and function
(Abbott et  al. 2010). Dysfunctions in the neurovascular unit have been linked to many
common CNS disorders, e.g. neurodegeneration, epilepsy, neuroinflammation and brain
tumors (Neuwelt et al. 2011). On the other hand, a temporary disruption of the BBB is one
way to  enhance the  drug delivery to  the  brain,  which will  be  described in  more detail  in
Chapter 2.3.
The capillary endothelial cells are completely covered by a basal lamina (Figure 1B). The
basal lamina is a membrane consisting of type IV collagen, glycoproteins and
proteoglycans, and it is the supporting structure of the neurovascular unit (Zlokovic 2008).
Pericytes, which comprise the glia cells surrounding the BBB, are embedded in the basal
lamina over the tight junctions, and they cover 20–30% of the endothelial cells at the BBB
(Lai and Kuo 2005). The pericytes regulate the activity of the endothelial cells, for example,
by releasing vasoactive substances and supporting the structure of the BBB. They have also
been associated with the metabolism of compounds in the BBB as they express several
enzymes (Frey et al. 1991, Song et al. 1993, Krause et al. 1993). In addition, the pericytes have
been shown to have a role in brain angiogenesis, in the formation of the interendothelial
tight junction and basal lamina components as well as in the endothelial cell differentiation
(Guillemin and Brew 2004, Dore-Duffy and LaManna 2007, Fisher 2009).
The vast majority, 90–99%, of the endothelial cells at the BBB are covered by astrocytes
(Pardridge 2005a). However, the astrocytes have not been shown to form a physical barrier
for drug brain entrance because there are gaps between the astrocyte endfoots, which
enable drugs to move freely into the brain extracellular fluid. Nevertheless, astrocytes play
a major role in modulating the function of the BBB properties and maintaining the integrity
of the tight junctions (Janzer and Raff 1987, Rubin et al. 1991). For example, astrocytes are
known to function as modulators of transporter and enzyme expression and their
localization at the BBB (Abbott et  al. 2006). Thus, astrocytes secrete growth factor , glial
derived neurotrophic factor and angiopoetin-1, which regulate the BBB phenotype. The
6endothelial cells have been postulated to secrete many of the factors involved in astrocyte
growth and differentiation (Mi et  al. 2001) indicating that the signaling between the
astrocytes  and  the  endothelial  cells  is  crucial.  Furthermore,  neuronal  signal  conduction  is
based on the interaction between neurons and astrocytes (Hawkins and Davis 2005). Thus,
astrocytes are located in a position that allows them to interact with both neurons and the
intercellular parts of the endothelium.
Functional blood-brain barrier
The endothelial cells at the BBB and the surrounding neurovascular unit are not only
considered as a static hindrance to the passive diffusion because of their tight junctions, but
also  as  a  functional  barrier  with  physiological  functions  for  the  specific  and  selective
membrane transport and metabolism of many compounds (Minn et al. 1991, Ueno et al.
2010). As a barrier function, the BBB expresses several active efflux transporters that
remove their substrates out of the brain and thus, protect the cells in the CNS from toxins.
Both influx and efflux transporters will be discussed in Chapter 2.1.2.
The functional BBB includes also enzymatic drug metabolism at the BBB. There are
several degrading or inactivating phase I (modification) and phase II (conjugation) enzymes
as well as phase III (excretion) transporters expressed at the BBB, and the number of
mitochondria is also increased in the endothelial cells of the BBB (Minn et al. 1991, Johnson
and Andersen 1996, Habgood and Ek 2010). Many enzymes such as -glutamyl
transpeptidases, alkaline phosphatases, adenosine deaminases, purine-nucleoside
phosphorylases and aromatic acid decarboxylases have been found at high concentrations
in the endothelial cells of the BBB. However, enzymes in the BBB may also produce reactive
metabolites and activate prodrugs. The enzymatic barrier function is controversial in that
sense.
2.1.2 Drug delivery to the central nervous system
The BBB act as a major hindrance for drug delivery to the CNS as it restricts the entrance of
many solutes from the systemic circulation to the brain. However, the solutes can cross the
BBB either by passive diffusion, carrier-mediated transport, or by fluid phase transport in
vesicles, and often by a net effect of all these transport mechanisms (Sugano et al. 2010, Di et
al. 2012). In addition to the ability of the solute to cross the BBB, there are several other
factors  which  may  influence  the  CNS  delivery  of  the  solute,  such  as  its  systemic
pharmacokinetics, intracranial distribution, possible individual variables or disease
conditions affecting the BBB functionality (Figure 2). As a consequence, the brain transport
of a drug is not only dependent on the structure of the drug but also on the individual
anatomical and physiological status of the human being treated with it.
7Figure 2. A summary of the factors affecting the drug delivery to the CNS.
Transport mechanisms across the BBB
In order to distribute from blood to the brain, a solute has to cross two membranes; the
luminal membrane and the abluminal membrane of the BBB (Figure 3). There are three
basic mechanisms by which compounds can be transported across those membranes: 1)
passive diffusion, 2) carrier-mediated transport by both influx and efflux transporters and
3)  fluid  phase  transport  by  vesicles  (i.e. receptor-mediated and adsorptive-mediated
endocytosis).  Most drugs are believed to be transported across the BBB by simple passive
diffusion. However, there are also estimates that drugs cross the BBB more probably by a
carrier-mediated mechanisms than by passive diffusion. Thus, it is controversial and still a
matter of debate which role the other transport mechanisms have in the brain transport of
drugs (Dobson and Kell 2008, Sugano et al. 2010, Di et al. 2012, Kell et al. 2013). However, it
has been demonstrated that the total brain exposure of a drug is the net effect of all of these
transport mechanisms. In theory, one single drug can be transported across the BBB by
passive diffusion, several transporters, and even in fluid phase vesicles and be removed out
of the brain by the active efflux transporters and metabolized by the enzymes at the BBB at
the same time.
Figure 3. The drug transport pathways across the BBB.
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8Passive diffusion
Passive diffusion is driven by the concentration gradient, i.e. from regions with a high drug
concentration to those with a low concentration. Thus, if a solute is transported across the
BBB only via passive diffusion the unbound drug concentrations in blood and the brain
extracellular fluid (ECF) will become equal in steady state situation. The ability of a drug to
diffuse across the BBB depends basically on two factors: the physicochemical properties of
the drug and the cerebral blood flow (Hammarlund-Udenaes et  al. 1997). Several criteria
based on the drug’s physicochemical properties have been introduced to estimate its ability
to cross the BBB via passive diffusion (Table 1). In general, a drug has enhanced potential to
cross the BBB via passive diffusion if it possesses low molecular weight (MW), low polar-
surface area (PSA), modestly high lipophilicity (log P) and few hydrogen bond donors
(HBD) and acceptors (HBA). The classical estimation of passive diffusion across
membranes is based on Lipinski’s rule of five, which was originally created to estimate the
bioavailability of drugs but later adapted also to CNS distribution (Lipinski 2004).
According to the classic Lipinski’s rule of five, a drug-like compound should not contain
more  than  five  HBDs  and  not  more  than  ten  HBAs,  the  MW  of  a  drug-like  compound
should be less than 500 Da and log P less than five (Lipinski et al. 1997). In addition, many
other criteria for good drug delivery to the CNS based on the physicochemical properties
have also been introduced (Van De Waterbeemd et al. 1998, Pajouhesh and Lenz 2005,
Wager et  al. 2010a, Ghose et  al. 2012). As a summary of those criteria, the maximal MW
should be around 400 Da, log P between 1 and 4, number of HBDs less than three, number
of  HBAs less  than seven and PSA less  than 90  Å2 (Table 1), which indicates that the ideal
physicochemical  properties  for  CNS  drugs  lie  within  a  smaller  range  than  for  drugs  in
general. These physicochemical properties of a drug can be used when roughly estimating
the BBB permeation of the drug via passive diffusion. In addition, more sophisticated linear
regression or least squared models for computer-aided CNS drug design to estimate the
extent of passive diffusion across the BBB have been introduced. Those models in general
will be discussed in Chapter 2.2.
Table 1. Physicochemical properties of a drug indicating the probability for passive diffusion
across the BBB
Study MW cLog P HBDs PSA
(Å2)
Other Data
Van de
Waterbeemd
et al.(1998)
< 450 1–3 n.a.a < 90 - 125 CNS drugs
Pajouhesh and
Lenz (2005)
< 450 < 5 < 3 < 60–70
HBAs < 7,
pKa 7.5–
10.5
Summary of studies
conducted by various
research groups
Wager et al.
(2010)
< 360 < 3 < 0.5 40–90 pKa < 8.0
119 CNS drugs and 108
CNS drug candidates
Ghose et al.
(2012)
140–
450
-0.55–
5.5
< 3 < 76 HBAs 1–7 317 CNS and 626 non-
CNS oral drugs
CNS drugs
mean values
(Wager et al. 2010)
303.5 2.7 1.1 48.5 pKa 8.0 119 CNS drugs
a n.a. = not analyzed
9In  addition  to  the  structure  of  the  drug,  the  passive  diffusion  across  the  BBB  is
dependent  on  the  cerebral  blood  flow  and  thus  on  the  number  of  brain  capillaries
(Hammarlund-Udenaes et al. 2008).  In  particular,  the  BBB  transport  of  a  drug  with  rapid
diffusion  across  the  BBB  is  dependent  on  the  cerebral  blood  flow.  The  blood  flow  in  the
human brain is approximately 0.6 mL/min/g; and in rat brain it is approximately 1.0
mL/min/g (Pardridge and Fierer 1985, Todd et al. 1993, Buijs et al. 1998). However, several
factors can influence the blood flow in the brain, e.g. cerebral metabolic rate of oxygen, the
presence of anesthetics, temperature and aging.
Carrier-mediated influx and efflux
In addition to simple passive diffusion, the BBB expresses several influx and efflux
transporters maintaining the optimal solute composition within the brain (Table 2).  These
transporters play a major role in transporting drugs in and out of the CNS (Tamai and Tsuji
2000, Ohtsuki and Terasaki 2007, Ueno et al. 2010). The influx transporters facilitate the
brain  entrance  of  essential  endogenous  molecules,  such  as  amino  acids,  glucose  and
nucleosides, which have unfavorable physicochemical properties for crossing the BBB via
passive diffusion, whereas the efflux transporters remove many structurally diverse
compounds out of the brain. The expression levels of an influx and efflux transporter can be
different to those in other membranes in the body (Pardridge 2005b). Due to the
asymmetric expression of transporters between the abluminal and luminal cell membranes
of the BBB, the steady state situation where the drug concentration is equal on both sides of
the BBB is not often true (Hammarlund-Udenaes et al. 1997). In addition, drug metabolism
occurs in the CNS, which may lead to different drug concentrations on each side of the BBB
(Minn et al. 1991).
Transporters  ferrying  solutes  without  being  coupled  to  ATP  hydrolysis  belong  to  a
superfamily of solute carriers (SLC) (Ohtsuki and Terasaki 2007). The transporters at the
BBB are categorized according to their substrate specificity and energy source. SLCs
includes facilitated transporters, ion-coupled transporters and exchangers that do not
require ATP, i.e. transporters ferrying glucose, amino acids, monocarboxylic acids,
vitamins, nucleosides, purine and pyrimidin bases, ions and organic anions and cations
(Tsuji 2005, Ueno et al. 2010, Abbott et al. 2010) (Table 2). Another transporter superfamily
consists  of  ATP-binding  cassette  (ABC)  proteins  that  directly  couple  efflux  transport  of
different  molecules  from  the  brain  to  blood  against  concentration  gradients  to  ATP
hydrolysis (Ohtsuki and Terasaki 2007). Both SLC- and ABC-transporters are temperature
dependent, and they can be saturated according to the Michaelis-Menten kinetics (Tsuji
2005).
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Table 2. Influx and efflux transporters expressed at the BBB (De Boer et al. 2003, Hawkins et
al. 2006, Ohtsuki and Terasaki 2007, Abbott et al. 2010, Ueno et al. 2010)
a A=abluminal membrane, L= luminal membrane (Table continues to the following page)
Amino acid transporters
Trivial
name
(gene
name)
Influx/
efflux
Predominant endogenous
substrates
Examples of
exogenous
substrates
Domaina
at the BBB
Sodium
dependent
EAAT1-3
(SLC1A1-3)
Efflux
Glutamic acid , aspartic
acid, taurine
DL-threo--
benzyloxy-
aspartate
A++
y+LNAA
(SLC7A7)
Efflux
Neutral and cationic amino
acids
3-amino-
bicyclo-
(2,2,1)-
heptane-2-
carboxylic acid
(BCH)
A++, L-
SNAT2
(SLC38A2)
Efflux Alanine, proline, glutamine,
serine, glycine
Methylamino-
isobutyric acid
A+++, L-
ASCT1-2
(SLC1A4-5) Efflux Alanine, serine, cysteine Unknown A+++, L-
B0AT2
(SLC6A15) Efflux
Neutral and cationic amino
acids (e.g. phenylalanine,
proline, glutamine, arginine)
BCH A+++, L-
SNAT3-4
(SLC38A3,
SLC38A5)
Efflux Glutamine, serine Unknown A++, L+
Sodium
independent
LAT1
(SLC7A5) Influx
Large, branched and neutral
amino acids
(e.g. tyrosine,
phenylalanine, leucine)
BCH, baclofen,
gabapentin,
levodopa,
melphalan,
phenylalanine
mustard
A+, L+++
CAT1
(SLC7A1)
CAT3
(SLC7A3)
Influx
Basic amino acids
(lysine, arginine)
N-ethyl-
maleimide
L++
xCT/4F2hc
(SLC7A11)
Influx Glutamic acid Unknown L+
Glucose transporters
Trivial
name
(gene
name)
Influx/
efflux
Predominant endogenous
substrates
Examples of
exogenous
substrates
Domaina
at the BBB
Sodium
independent
GLUT1
(SLC2A1)
Influx
Glucose, galactose,
mannose, glucosamine,
L-dehydroascorbic acid
Glucosides,
glucose
prodrugs
A++, L++
Sodium
dependent
SGLT1
(SLC5A1)
Efflux Glucose, galactose Glucosides A++
Nucleoside transporters
Trivial
name
(gene
name)
Influx/
efflux
Predominant endogenous
substrates
Examples of
exogenous
substrates
Domaina
at the BBB
Hydrogen
dependent
ENT1-2
(SLC29A1-2) Efflux
Nucleosides, nucleotides
and nucleobases
Cytarabine,
gemcitabine,
fluradabine
L++
CNT1-3
(SLC28A1-3) Influx
Nucleosides, nucleotides
and nucleobases
Cytarabine,
gemcitabine,
fluradabine
A+
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a A=abluminal membrane, L= luminal membrane
(Table continues to the following page)
Transporters for organic cations
Trivial
name
(gene
name)
Influx/
efflux
Predominant endogenous
substrates
Examples of
exogenous
substrates
Domaina
at the BBB
OCT2-3
(SLC22A2-3) Influx
Organic cations,
multispecific
1-methyl-4-
phenyl-
pyridinium,
cimetidine,
imipramine
L++
OCTN3
(SLC22A5)
Both Carnitine Quinidine L++, A++
Transporters for organic anions
Trivial
name
(gene
name)
Influx/
efflux
Predominant endogenous
substrates
Examples of
exogenous
substrates
Domaina
at the BBB
OAT3
(SLC22A8)
Efflux Organic anions, multispecific
Amino
hippuric acid,
homovanillic
acid, indoxyl
sulphate
A
OATP2B1
(SLCO2B1)
Influx Bile acids, estrogen
conjugates
Digoxin,
ouabain
L++
OATP1A2
(SLCO1A2)
Efflux Bile salts, organic anions,
organic cations
Rocuronium,
opioid
peptides
A++
OATP1C1
(SLCO1C1) Efflux Bile salts, organic anions Digoxin A++
Monocarboxylate transporters
Trivial
name
(gene
name)
Influx/
efflux
Predominant endogenous
substrates
Examples of
exogenous
substrates
Domaina
at the BBB
Hydrogen
dependent
MCT1
(SLC16A1)
Influx Lactate, monocarboxylates
Salicylic acid,
nicotinic acid,
some -
lactam
antibiotics,
valproic acid,
XP13512
A ++, L+++
MCT2
(SLC16A7)
Effflux Lactate, pyruvate
-Cyano-4-
hydroxy-
cinnamate,
phloretin,
quercetin
A+
Sodium
independent
MCT8
(SLC16A2)
Influx T3 thyroid hormone
Bromo-
sulfophthalein
A++, L++
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a A=abluminal membrane, L= luminal membrane
Large amino acid transporter 1
Large amino acid transporter 1 (LAT1) (SLC7A5), which is the transporter utilized in this
thesis, is widely expressed on the luminal and abluminal membrane of the brain capillary
endothelial cells where it has a prime role in transporting large, branched and neutral
amino acids from the circulation to the brain (Hawkins et al. 2006). LAT1 is also expressed
at some other blood-tissue barriers, i.e. in placenta, testis and tumor cells (Kanai et al. 1998,
Yanagida et al. 2001). Rapid transporter-mediated supply of amino acids into such tissues is
essential as there is an enhanced demand for amino acids for protein synthesis. It has been
shown that the expression levels of LAT1 mRNA at the bovine brain capillary endothelial
cells are 100-fold greater than the corresponding levels in other tissues, e.g. heart, spleen
and lung (Kanai et al. 1998). The endogenous substrates, such as leucine, isoleucine,
tyrosine, tryptophan and phenylalanine, bind to the LAT1 at the BBB with a Michaelis-
Menten constant (Km-value) of 10-100 μM (Boado et al. 1999). As a comparison, the Km-value
of those amino acids for the peripheral amino acid transporters of L-system is 1-10 mM.
LAT1 forms a functional heterodimeric transporter complex with another cell surface
glycoprotein, 4F2hc, which is required to allow LAT1 to become expressed on the cell
surface  (Figure  4A).  Because  the  crystal  structure  of  LAT1 is  not  known yet,  very little  is
known about the substrate binding site of LAT1 protein. The known structural features
ABC efflux transporters
Trivial
name
(gene
name)
Influx/
efflux
Predominant endogenous
substrates
Examples of
exogenous
substrates
Domaina
at the BBB
P-gp, MDR1 E Cholesterol
Amperenavir,
clarithomycin,
cyclosporin A,
dexa-
methasone,
docetaxol,
indinavir,
loperamide,
lovastatin,
morphine,
quinidine,
verapamil,
vincristine,
etc.
A+, L+++
MRP1 E Glucuronide Unknown L+++
MRP4 E
cAMP, cGMP, prostaglandin
E1-E2, glucuronided and
sulphated metabolites of
various compounds
Methotrexate,
6-mercapto-
purine,
topotecan
L+++
BCRP E
Folate, glucuronided
metabolites
Cerivastatin,
estrone-3-
sulfate,
methotrexate,
mitoxantron,
pantoprazole,
topotecan,
etc.
L+++
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required for efficient LAT1 binding are free -amino and -carboxyl groups and a
hydrophobic center (Figure 4B) (Uchino et  al. 2002). It has been shown that a compound
substituted either from the amino or the carboxyl groups cannot bind to LAT1. However,
the hydrophobic site can be modified. Non-natural LAT1 substrates substituted from the
meta-position of phenylalanine are shown to bind to LAT1 with much higher affinity than
corresponding analogues substituted from the para-position (Takada et  al. 1992). As the
transport of amino acids via LAT1 is Na+-independent, another Na+-dependent amino acid
transporter co-expressed in the same cell is required as the counterpart to transport an
amino acid against the concentration gradient (Figure 4A). The utilization of LAT1 in drug
delivery to the brain will be discussed in more detail in Chapter 2.3.
Figure 4. The  function  of  LAT1  as  a  counterpart  transporter  at  the  BBB  (A) and a simplified
illustration of LAT1 binding site (B) (Takada et al. 1992, Uchino et al. 2002).
Efflux transporters
The ABC efflux transporter family is divided into three superfamilies, i.e. P-glycoprotein (P-
gp), multidrug resistance-related proteins (MRP) and breast cancer resistance protein
(BCRP) (Ohtsuki and Terasaki 2007) (Table 2). They have very large substrate specificity,
ranging from small ions to large peptides. Thus, many drugs are not taken up into the brain
due to the extensive efflux activity at the BBB although they are able to cross the BBB (Ueno
et al. 2010). The energy of the ABC transporters to transfer molecules against a steep
concentration gradient is provided by ATP hydrolysis. The best-known and quantitatively
most important ABC-transporter at the BBB is P-gp, which is also called multidrug
resistance protein 1 (MDR1) (De Boer et al. 2003). The P-gp is expressed at the luminal
membrane  of  the  brain  capillary  endothelial  cells  where  it  prevents  the  entry  of  many
cationic drugs with diverse structural features. For example, many chemotherapeutics,
antibiotics, antivirals and immunosuppressants are known to be transported out of the
brain by P-gp (Ohtsuki and Terasaki 2007). A good example of clinically relevant influence
of P-gp in drug brain transport is loperamide, an opiate which is used as an antidiarrheal
agent (Schinkel et al. 1996). Loperamide does not cause any opiate-like CNS effect because it
is effectively removed from the brain via P-gp. In addition to the ABC-transporters, some
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SLC  transporters,  such  as  transporters  of  organic  cations  and  anions,  nucleosides  and
amino acids, take part in ferrying solutes from brain to the circulation (Ohtsuki and
Terasaki 2007).
Receptor- and adsorptive-mediated transport
The transporter utilization is mainly suitable for small molecules (Pardridge 2001). Instead,
larger endogenous macromolecules such as growth factors, enzymes and proteins are
transported across the BBB either by selective receptor-mediated (RME) or adsorptive-
mediated (AME) endocytosis (Begley and Brightman 2003, Abbott et  al. 2010). RME and
AME mean that a ligand is bound to a specific receptor located in a clathrin-coated pit
(RME) (Broadwell et al. 1988) or to the anionic charges (i.e. heparin sulphate proteoglycans)
of a clathrin-coated pit (AME) (Hervé et al. 2008). When the ligand binds to the receptor or
the  charged  pit,  the  pit  pinches  off  to  form  a  clathrin-coated  vesicle.  The  vesicles  are
immediately formed into uncoated vesicles because they lose their clathrin coat inside the
cell. The uncoated vesicles may fuse with a transcytotic endosome. The receptor is released
from  the  vesicle  inside  the  cell  but  its  ligand  can  remain  inside  the  vesicle  as  long  as  the
vesicle is adhering to the plasma membrane and the ligand will be released from the cell
(De Boer et al. 2003, Pardridge 2012). However, the ligand can also be released inside the
endothelial  cell  as  the  vesicle  can  be  a  subject  to  degradation  within  the  cell  by  the
endosomal enzymes even though they are intended to remain stable while crossing the
cytoplasm. The transcytosis process across the BBB is an energy-requiring, temperature-
sensitive transport mechanism. It is also evident that both RME and AME are time- and
concentration-dependent processes. The endocytosis at the BBB is not a very rapid process;
it can take even minutes (Mellman 1996). The brain uptake of molecules by RME is
saturable because the process is dependent on the number of receptors at the BBB available
for binding. The transport capacity of AME is dependent on the number of anionic binding
sites at the BBB. However, RME becomes saturated with lower concentrations (pmol/mg of
membrane protein) as compared to AME (nmol/mg of membrane protein).
In  the  RME,  essential  peripheral  macromolecules,  such  as  insulin,  transferrin  and  LDL
(low density lipoprotein), bind to the receptors which cause the endocytosis cascade (Rip et
al. 2009). The best recognized RME receptors at the BBB are human insulin receptor (HIR),
transferrin  receptor  (TfR),  leptin  receptor  and  LDL  receptors.  In  the  AME,  positively
charged polycationic compounds, mainly peptides or proteins such as albumin, histone,
immunoglobulin G and protamine bind initially non-specifically to the negatively charged
clathrin-coated pits of the luminal plasma membrane (Hervé et al. 2008). The anionic feature
of  the  luminal  surface  of  the  BBB  is  formed  by  the  sialic  acid  residues  of  glycoproteins
(Vorbrodt 1989). The clathrin-coated pits are more abundant at the luminal than at the
abluminal side (Simionescu et al. 1988). There may also be some interaction between the
polycationic molecules and the RME receptors which may contribute to the endocytosis of
polycationic molecules in addition to AME. RME and AME can be utilized in BBB-targeting
and drug delivery to the brain by vector-based prodrug technology. The applications of
RME and AME in drug delivery to the brain will be discussed in Chapter 2.3.
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The effect of CNS pharmacokinetics on drug delivery to the brain
In addition to the primary systemic pharmacokinetic parameters of a drug, i.e. volume of
distribution and clearance, there are pharmacokinetic factors within the CNS that affect the
ability of the drug to achieve an adequate free drug concentration at the site of action in the
brain (Neuwelt et  al. 2011). The important pharmacokinetic factors include BBB transport
rate, drug concentration in the brain (extent), intracranial distribution and drug elimination
from the CNS.
The BBB transport rate determines the ability of the drug to penetrate across the BBB
which is the result of many processes, i.e. passive diffusion, facilitated diffusion, active
uptake or efflux transport processes (Sugano et al. 2010). The rapid permeation of the BBB is
an important step towards reaching the brain parenchyma (Neuwelt et al. 2011). The
transport rate of a drug across the BBB is estimated by measuring the influx clearance (Clin,
Kin)  (Equation  1).  Kin is commonly converted to permeability-surface area (PA) product
using a rearranged form of the Crone-Renkin equation (Equation 2), which is in the units of
µL/min/g.  The PA product  is  a  net  effect  of  all  transport  mechanisms into  and out  of  the
brain. The different transport mechanisms cannot be distinguished, and the role of efflux
and influx transporters as well as the role of metabolism within the brain is included into
the net influx rate.
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In  equation  1,  qtot represents  the  amount  of  the  solute  in  the  brain,  Cpf represents the
concentration of the solute in the perfusion fluid or in plasma, Vv refers to the vascular
volume of the brain, and t is the perfusion time of the study. In equation 2, F demonstrates
the maximum allowable flow rate of the solute from the brain capillaries to the parenchyma
as determined by a lipophilic solute. The influx clearance can be estimated by using the in
situ brain perfusion technique, the intravenous injection technique or brain microdialysis,
which will be discussed in more detail in Chapter 2.2.
In  addition to  the  ability  to  cross  the  BBB,  the  extent  of  the  drug in  the  brain  is  crucial
(Hammarlund-Udenaes et al. 2008). Conventionally, as the brain has been thought to be one
compartment, the brain exposure of a drug has been evaluated as Kp or log BB, which
describes the ratio of total drug concentration in the brain to that in plasma (Equation 3),
and does not differentiate the intracranial distribution of the drug (Liu et  al. 2008). On its
own,  Kp is a misleading parameter in most cases because it depends greatly on the
partitioning of a drug into lipids. In fact, the nonspecific binding of the drug to the brain
parenchyma may be so high that there is not enough free fraction of the drug to achieve any
pharmacological effect (Jeffrey and Summerfield 2007, Summerfield et al. 2007). Since only
the unbound fraction of a drug is able to have its desired pharmacological action, the free
fraction of a drug both in plasma and in the brain should be evaluated in order to estimate
the CNS effect of a drug. As a consequence, the Kp,uu-value, which describes the ratio of the
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areas under the curves (AUCs) of free drug concentrations in the brain ECF to those in
plasma, is more relevant than the Kp-value for predicting potential activity of CNS drugs
(Hammarlund-Udenaes et al. 1997). In an attempt to clarify and demonstrate this
phenomena, Liu et. al. (Liu et  al. 2008) re-analyzed the earlier data of Kp-values of the 32
most prescribed CNS drugs collected by Doran et al. (Doran et al. 2005) and Maurer et al.
(Maurer et al. 2005) and showed that there was a 240-fold difference for Kp-values among
the  selected  drugs  but  only  a  34-fold  difference  for  Kp,uu-values. This reduction was
proposed to indicate the significant impact of nonspecific binding on the determinations of
the  Kp-values in the previous studies. The brain microdialysis technique, which will be
described in more detail in Chapter 2.2., is the only method currently available to directly
determine the unbound drug concentrations in the brain. Alternatively, Kp,uu can  also  be
evaluated by combining intravenous infusion and in vitro protein binding and non-specific
binding to brain tissue. With these combined in vitro methods, fu,brain (free fraction in brain)
and fu,plasma (free fraction in plasma) can be determined. In addition to measuring only the
extent of the drug brain uptake, Kp,uu can separate the role of passive diffusion (Kp,uu = 1) and
transporters (Kp,uu higher/lower than 1) in the brain uptake (Hammarlund-Udenaes et al.
2008). However, no specific transporters can be identified and in some cases, the net effect
of all transport mechanisms can obscure certain mechanisms.
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The intracranial drug distribution is another crucial parameter that should be considered
when addressing drug penetration into the brain (Hammarlund-Udenaes et al. 1997). This
can be evaluated by measuring the intracranial volume of distribution of unbound drug
fraction (Vu,brain) (Equation 5) which describes the relationship between the total and the
unbound drug concentrations in the brain (Figure 5). Vu,brain can be measured in vivo by the
brain microdialysis combined to the in vivo injection method. Vu,brain can also be estimated
using the in vitro brain slice uptake technique. One crude estimation is that if Vu,brain is
approximately 0.2 mL/g brain, the compound is merely found in the extracellular fluid of
the brain, if Vu,brain is approximately 0.8 mL/g brain, the drug is found in both extracellular
and intracellular fluids, and if Vu,brain is more than 0.8 mL/g the drug has a tendency to bind
nonspecifically to brain parenchyma (Hammarlund-Udenaes et al. 2008).
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Figure 5. A simplified illustration of the intracranial compartments.
As a consequence, all aspects determining the effective drug concentration at the site of
action within the brain cannot be evaluated from one parameter or by one method. If  one
wishes to evaluate the CNS pharmacokinetics of a drug, then the influx rate, the extent of
unbound drug in brain and the intracranial distribution of the drug need to be determined.
However, the CNS cannot be viewed as an isolated compartment of the body from the
pharmacokinetic point of view (Figure 5). As the most desired route for drug
administration to the brain is the transvascular pathway, the plasma concentration of the
drug  will  be  dependent  on  the  peripheral  pharmacokinetics  such  as  the  peripheral
distribution volume, clearance, extent of metabolism, plasma protein binding and
physiological variables between individuals, which can also have major effects on the drug
delivery to the CNS (Pardridge 1995). As an example, S-cetirizine has been shown to have
5.5-fold greater Kp-value (0.22) than that of R-cetirizine (0.04) in guinea pigs (Gupta et  al.
2006a) pointing to the stereoselective brain uptake of cetirizine. However, when the free
fractions of the S- and R-stereoisomers were determined in the brain extracellular fluid,
their Kp,uu-values were similar, i.e. 0.17 and 0.14, respectively. In addition, their Vu,brain were
also similar (2.5 mL/g). The stereoselective differences in the Kp-values were attributed to
differences  in  plasma protein  binding (Gupta et  al. 2006a, Gupta et  al. 2006b). In addition,
knowledge of the pharmacodynamics of the drug is essential as good pharmacokinetic
properties alone do not ensure drug efficacy (de Lange et al. 2005).
BBB characteristics and functionality in diseases
The function of the BBB is influenced by several diseases, which may change dramatically
the effect of drug therapies. For example, these diseases are inflammation,
neurodegeneration (Desai et al. 2007a, Zlokovic 2008), epilepsy (Heinemann et al. 2006),
cancer (Rosenberg 2012), stroke and trauma (Kaur and Ling 2008, Hermann and ElAli 2012,
Rosenberg 2012). In inflammation, stroke and trauma, the transient opening of the
endothelial  tight  junctions  is  caused  by  the  increased  activation  of  enzymes  which  can
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disrupt the BBB (e.g. serine proteases, cyclooxygenases and matrix metalloproteinases) and
increased concentration of the BBB disrupting humoral agents (e.g. bradykinin, histamine,
substance  P,  interleukins)  (Rosell  and Lo 2008,  Liu et al. 2012, Stanimirovic and Friedman
2012). In addition, the loss of oxygen can disrupt the structure of the proteins forming the
BBB (Koto et al. 2007), and the expression levels of the influx and efflux transporters at the
BBB can be affected by diseases such as epilepsy, which can hinder drug treatment against
these diseases (Heinemann et al. 2006). The protein levels can also be downregulated by
neurodegeneration such as Alzheimer’s disease which leads to leakage at the BBB (Desai et
al. 2007b, Algotsson and Winblad 2007). A leaky BBB is a severe dysfunction as it can lead
to severe CNS problems such as vascular brain edema, ischemia, impaired clearance of
toxic molecule and increased protein levels in the brain (Stanimirovic and Friedman 2012).
These  can  cause  impaired  neuronal  signaling  and  cognitive  functions  and  even  a  fatal
situation. On the other hand, in some situations, a leaky BBB can be beneficial in terms of
drug treatment. For example, a stroke may cause BBB disruption, and then drug delivery to
the brain may be possible due to the leaky BBB and more permeable vessels because of
angiogenesis (Habgood et al. 2007). Consequently, it could be beneficial to conduct brain
transport evaluation studies not only in a healthy one but also in a diseased brain.
2.2 METHODS TO STUDY DRUG BRAIN UPTAKE
A variety of computer-aided drug design programs and in vitro and in vivo methods for
evaluating brain transport of drugs have been developed (Figure 6 and Tables 3 and 4). As
discussed in Chapter 2.1.2, the parameters describing the drug brain uptake are extent (Kp,
Kp,uu) and rate (Kin, Clin, PA product). In addition, the brain cannot be considered as a single
homogenous compartment, and thus the intracranial distribution of the studied compound
(Vu,brain) should also be determined. These complex characteristics of drug transport to the
brain imply that no single physicochemical property, no computer-aided drug design
method, no in vitro assay or even no in vivo study can predict all of the CNS
pharmacokinetic  aspects.  Thus,  it  has  been  recommended  to  combine  several  methods  to
evaluate separate BBB transport mechanisms and intracranial drug distribution. However,
a single assay is often used to help the decision-making during different stages of drug
discovery and development (Figure 6) because it is less time-consuming and less labor-
intensive  as  compared  with  the  full  range  of  studies  to  determine  the  detailed  CNS
pharmacokinetics of a compound.
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Figure 6. Methods for evaluating the drug delivery to the brain during the different stages of
drug discovery and development (Goodwin and Clark 2005, Cecchelli et al. 2007).
2.2.1 Computer-aided drug design methods
Computer-aided drug design methods offer inexpensive, low resource-intensive and fast
prospective and predictive tools to evaluate the brain uptake of large sets of compounds in
the early phases of drug discovery (Mensch et al. 2009). Thus, significant efforts have been
made to develop computational models with which to evaluate the CNS permeation of
drugs,  mainly  predicting the  ability  of  a  compound to  cross  the  BBB by passive  diffusion
(Bickel 2005). An ideal computer-aided drug design method should take into account the
mechanistic BBB permeability including passive and carrier-mediated transport, and the
model should be based on a large number and diverse set of data validated by in vitro or in
vivo studies (Mensch et al. 2009). The outcome of the computer-aided drug design modeling
should  be  an  accurate  prediction  of  those  compounds  which  should  then  be  subjected  to
more resource-intensive in vitro and in vivo measurements.  However,  the  quantity  and
quality  of  experimental  data  has  to  be  carefully  considered  as  the  outcome  of  computer-
aided drug design models is only as reliable as the data fed into them (Goodwin and Clark
2005).
Most of the computer-aided drug design methods predict blood-brain partitioning (log
BB) of drugs via their physicochemical properties (Bickel 2005, Goodwin and Clark 2005),
and  they  are  widely  used  in  the  pharmaceutical  industry  where  rapid  screening  of  large
sets  of  compounds  is  required.  The  most  commonly  used  physicochemical  properties  are
log P, log D, MW, tendency to form hydrogen bonds, PSA and nitrogen and oxygen counts
(see also Table 1 at page 8). Conventionally, the computer-aided drug design methods have
20
focused on small molecules and the linear relationships between the BBB permeability and
partition coefficients measured in various solvent systems (Levin 1980, Young et al. 1988).
Recently, more sophisticated models taking a variety of physicochemical and
biopharmaceutical properties into consideration have been generated (Österberg and
Norinder 2000, Winkler and Burden 2004, Wager et al. 2010a).
The methods mentioned so far have focused on optimizing the log BB of the compounds,
and thus the only total concentrations of the compound in the brain are determined, not the
unbound concentration at the targeted site of CNS action, i.e. the concentration in the
extracellular or intracellular space in the CNS. As a consequence, the reliability of log BB
has been criticized (Hammarlund-Udenaes et al. 1997, Martin 2004), and more biological
based modeling methods have been considered to be more reliable (Pardridge 2004). For
example, models for log PS have been reported (Gratton et al. 1997, Liu et al. 2004), which
represent the permeability of a given solute across the brain capillary endothelium as an
anatomical representation of the BBB. However, those methods have not shown any
obvious major differences in the evaluation of the extent of passive diffusion across the BBB
when compared with the results obtained from the log BB methods based on in vitro data
(Liu et al. 2004, Summerfield et al. 2007). These methods do not address specific issues like
intracranial solute tissue distribution, and they simply represent the potential combination
of passive and carrier-mediated transport mechanisms. More recently, some effort has been
expanded on developing methods based on unbound brain concentrations of solutes.
Fridén et al. (2009) have found that log P has a negative effect on log (CSF:plasma) but a
positive  effect  on  log  BB  emphasizing  the  fact  that  lipophilicity  does  not  describe  the
partitioning of a solute to aqueous media, i.e. CSF. Thus, many compounds have the
likelihood to  be  non-specifically  bound to  brain  tissue when optimizing only  log BB,  and
the results of the log BB models have to be interpreted carefully.
The advances in our understanding of the properties of transporters have highlighted
that models based on passive diffusion alone are not a suitable way to predict the BBB
permeation as such. Therefore, computational screening approaches combining the passive
diffusion and the influence of influx or efflux transporters may represent more suitable
strategies to predict the BBB permeability of drugs (Chang and Swaan 2006, Allen and
Geldenhuys 2006). In addition, the transporters can be modeled with a transporter-based
design, when a suitable template of the transporter is available, or by substrate-based
design, when appropriate knowledge of substrates for the transporter is available (Chang
and Swaan 2006, Mehdipour and Hamidi 2009) although the information about the 3D
structure of BBB transporters is limited. For example, the ABC efflux transport has been
modeled by both homology techniques based on E.Coli -based protein (Seigneuret and
Garnier-Suillerot 2003) and by pharmacophore-based modeling identifying the substrate
recognition site (Yates et  al. 2003). In addition, the binding site of choline transporter has
been defined by substrate-based design (Geldenhuys et al. 2004). However, these models
that include some of the transporters do not still account for the role of cell metabolism in
the overall BBB permeability.
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2.2.2 In vitro methods
Several in vitro methods have been developed during recent years to evaluate both the BBB
permeation and intracranial distribution of drugs rapidly and less resource-intensively
(Table 3 at page 24) (Mangas-Sanjuan et al. 2010, Naik and Cucullo 2012). The in vitro
methods in general have been developed to complement and to some extent to replace
animal studies, and thus to increase the effectiveness of early-stage drug discovery.
However, the in vitro setting is not identical to the in situ or in vivo situation, and the in vitro
methods are usually a compromise of capacity, time, cost, reliability and predictability.
Because  of  the  unique  features  of  the  BBB  in  addition  to  the  complex  intracranial
distribution of drugs, novel in vitro methods have to be carefully validated and compared
with in vivo studies  before  making any definite  conclusions  based on these  techniques.  In
particular, imperfect formation of the tight junctions in the in vitro cell models, non-
physiological communication between the different cells of the neurovascular unit,
downregulation in expression levels and an asymmetric distribution of the transporters,
enzymes and receptors can lead to misleading conclusions (Abbott et al. 2008). If they are to
predict the in vivo BBB permeation, in vitro models need to closely mimic the in vivo
properties of the brain (Liu et al. 2008, Naik and Cucullo 2012). However, a feasible, rapid,
easy-to-use, reliable and low cost in vitro model mimicking the BBB in the in vivo situation
is still beyond the current ability of scientists. Nevertheless, a well-characterized in vitro
BBB model can offer a useful tool for studying the mechanism of BBB transport.
The in vitro BBB models can be divided into non-biological and biological models
(Mensch et al. 2009, Naik and Cucullo 2012). The non-biological models include parallel
artificial membranes permeability assays (PAMPAs) and immobilized artificial membranes
(IAMs) whereas the biological models include isolated brain capillaries and cell culture
models, originating from either cerebral or peripheral endothelial cells. The non-biological
models are generally simple, cheap and more suitable for high-throughput screening as
compared to the biological models. However, the non-biological models can be applied to
estimate only passive diffusion of drugs across the BBB because they are only formed from
physical lipid barriers. Instead, modern biological in vitro models of the BBB are usually
composed of living cells and they express active membrane transporters and metabolic
enzymes forming a more realistic model to estimate drug transport across the BBB.
Non-biological in vitro models
PAMPA is a suitable model to demonstrate passive diffusion of a drug across the BBB, and
it  has  a  good  correlation  with  Caco-2  cell  lines  (human  colon  adenoma  derived  cell  line)
and in vivo studies if the compound crosses biological membranes by passive diffusion
alone (Mensch et al. 2009, Naik and Cucullo 2012). The lipid composition of the membranes
can be modified to mimic better passive diffusion across the BBB, and several BBB-PAMPA
models have been generated (Mensch et al. 2010). Since PAMPA demonstrates only the
compartment of passive diffusion, and not the role of transporters and other transport
mechanisms, it can be used only as an early screen study tool as a complement to studies
conducted by computer-aided drug design, in vitro and in vivo methods.
IAM is another non-biological in vitro method used to evaluate the passive diffusion
across  the  BBB  (Mensch et  al. 2009,  Naik  and  Cucullo  2012).  IAM  consist  of  a
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phosphatidylcholine stationary phase which is bound into an inert silica support. The
stationary IAM phase mimics the lipid phase of biological membranes and the drug
interacts with IAM when it is driven across the membrane. The retention time of the solute
on  IAM  column  is  used  to  calculate  its  membrane  partition  coefficient.  The  IAM  method
has very limited applications for studying the BBB permeation of drugs because it does not
resemble the morphology of the BBB and thus the diffusion across the BBB. In addition, the
role of active transport and metabolism cannot be determined by this method.
Biological in vitro models
The origin of the biological cell models used for prediction of brain uptake of drugs is from
either mammalian brain or non-cerebral tissue cells (Mensch et al. 2009, Naik and Cucullo
2012). The biological in vitro models which originate from cerebral tissues include isolated
brain capillaries, brain capillary endothelial cell cultures (primary, immortalized),
transfected cells and co-cultured endothelial cells with astrocytes, whereas the non-cerebral
models include Caco-2, MDCK (Madin-Darby canine kidney) and ECV304/C6
(immortalized human umbilical vein endothelial cells co-cultured with rat C6 glioma cells)
cell lines.
Isolated brain capillaries
Functionally intact mammalian brain capillaries have been purified and isolated from
animal or human brain for decades and been used for the identification of the mechanisms
and biochemical signals that play a role in regulating BBB functions in health and diseased
conditions (Joo 1985). The isolated brain capillaries reflect rather well the in vivo situation as
the capillaries include endothelial structures, such as transporters, receptors and tight
junctions.  Thus,  this  method  has  been  recently  utilized  in  characterizing  the  role  of  some
transporters in the BBB transport of drugs (Miller et al. 2000, Mahringer and Fricker 2010).
The main limitation in the determination of the brain uptake with isolated brain capillaries
is that it is difficult to access the luminal surface (blood side) of the brain capillaries, and
therefore this method is not well suited for routine BBB permeability screening (Mensch et
al. 2009). In addition, the setup and the maintenance of the method are resource-intensive.
Brain endothelial cell cultures
To circumvent the drawbacks and limitations of capillary isolation, cultured cells are
widely used as in vitro models for BBB permeability. These models include primary and
low passage brain endothelial cell cultures or co-cultures with astrocytes and immortalized
brain endothelial cells (Mensch et al. 2009, Naik and Cucullo 2012). Those cells most
commonly are from bovine and porcine origins due to the high yield of the cells in the brain
of those species, but some cell lines have been based on rats or mice, even humans. Once
the endothelial cells have been isolated, the cells are cultured in flasks alone or in
combination with astrocytes or astrocytes-conditioned medium. In particular, the co-
cultured endothelial cell lines are known to mimic closely the in vivo BBB  as  the  barrier
tightness and the expression of BBB specific genes are better displayed (Li et al. 2010).
However, there is no brain endothelial cell based model with tight junction properties and
transporter expression levels similar to the in vivo situation. Therefore, the models
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commonly overestimate the BBB permeability of lipid-mediated transport and
underestimate that of carrier-mediated transport across the BBB. At the present time, even
the brain endothelial cell co-cultures have often TEER values up to one order of magnitude
lower than those found in vivo (Nicolazzo et al. 2006). In addition, the time and resources
required in isolating, seeding and incubating these cell cultures or co-cultures weakens
their popularity. These methods can also have poor batch-to-batch reproducibility.
However,  of  all  of  the in vitro methods  to  evaluate  the  BBB  transport  of  drug,  it  is  brain
endothelial cell  cultures or co-cultures with astrocytes which are most commonly used, as
the cultures are functional in terms of transporter and enzyme activity.
Immortalized brain cell cultures from different origins have been established to
circumvent the resource-intensive primary cell culture systems (Mangas-Sanjuan et  al.
2010). The most extensively characterized cell line consisting of immortalized rat brain
endothelial cells is RBE4 (rat brain endothelial cell line 4). However, immortalized brain
capillary endothelial cell lines are not suitable for studying the BBB permeability because
they do not generate completely the barrier function with the interendothelial tight
junctions. Instead, they are very suitable for studying the influence of BBB transporters on
the brain transport of a drug (Mensch et al. 2009). In fact, RBE4 cells have been considered
to be a model in vitro system to address the mechanistic aspects in carrier-mediated
transport  of  a  drug  across  the  BBB  as  they  functionally  express  a  wide  range  of  BBB
transporters (Terasaki and Hosoya 2001).
Non-cerebral in vitro cell models of the BBB
As the appropriate tightness of the endothelial cell lines of the BBB has not been achieved in
any in vitro system mentioned above, MDCK cells have been used to mimic the passive
CNS penetration of compounds in the early drug discovery (Lundquist et al. 2002, Mensch
et al. 2009). The MDCK cell line is a promising model because it achieves a reproducible
TEER,  exhibits  low  permeability  for  sucrose  and  is  easy  to  grow.  In  addition,  the  MDCK
cell line can be transfected with MDR-transporters which is a great advantage over
PAMPA.  The  MDCK-MDR1  cell  line  had  been  considered  to  give  a  more  predictive
correlation of in vivo BBB  permeability  of  passive  diffusion  and  efflux  of  drugs  than,  for
example, primary brain endothelial cell lines (Garberg et  al. 2005) most likely due to the
intercellular  tightness  of  the  endothelial  cells.  However,  the  influence  of  the  other  BBB
transporters has not yet been evaluated. Furthermore, the lipid composition of the MDCK
cell line is significantly different to that of primary brain microvessel endothelial cell line
(Di et al. 2009). In addition, the MDCK cell membrane is more polar and hydrophilic than
the BBB which can lead to an underestimation of the BBB permeability of lipid soluble
compounds  and  an  overestimation  of  that  of  water  soluble  compounds.  Another  non-
cerebral in vitro method to evaluate the BBB permeability is Caco-2 cell line (Garberg et al.
2005). It estimates especially the role of passive diffusion and also the efflux transporters to
some extent (Hunter et al. 1993, Hirohashi et al. 2000, Xia et al. 2005). However, the cell line
originates  from  human  colorectal  adenocarcinoma  and  does  not  have  similar
morphological features and transporter expression than at the BBB (Pardridge 1988). Thus,
the other in vitro models  have replaced Caco-2  as  tools  with  which to  determine the  BBB
permeability.
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In vitro models to estimate the intracranial drug distribution
Two in vitro assays exist today to evaluate the intracerebral distribution of a drug, i.e. brain
slice method and brain homogenate method (Fridén et al. 2007). These methods can be used
to evaluate the unspecific binding of a drug to brain tissues after the drug has crossed the
BBB. These methods are inexpensive and easy to perform. The difference between these
two methods is that the brain slice method maintains the cellular structure of the brain
tissue whereas in the homogenate method, the integrity of the tissue is disrupted before
dialysis. The validity of using the homogenized brain tissues has been criticized because the
tissue components are destroyed during the homogenization procedure which may have an
influence on the tissue binding sites (Becker and Liu 2006) and could lead to misleading
conclusions. In addition, intracellular accumulation of the drug cannot be demonstrated
properly with the brain homogenate method (Fridén et al. 2007). However, comparable
results of the unbound drug fraction based on the brain homogenate method and the brain
slice method have been used as a surrogate of the free drug concentration in the brain
extracellular fluid (Becker and Liu 2006, Liu et al. 2009).
Table 3. Summary of available computer-aided drug design and in vitro methods for evaluating
the  drug  transport  to  the  brain  (Foster  and  Roberts  2000,  Bickel  2005,  Cecchelli et al. 2007,
Hammarlund-Udenaes et al. 2009, Mangas-Sanjuan et al. 2010)
Method Estimated
parameters
Advantages Disadvantages
Computer-
aided drug
design to
model BBB
permeation
 log BB  Screening of large virtual
libraries
 Fast
 Low resource-intensive
 Limited databases based on
in vivo/in situ
measurements (log PS
models)
 Limited correlation to in
vivo conditions
Transporter
modeling
 Potentiality to
bind to a
specific
transporter
 Fast transparent
information to medicinal
chemists
 Low resource-intensive
 Not modeling multiple
transporters simultaneously
 Limited information about
predictive power for in vivo
situation
PAMPA  Passive
diffusion across
the BBB
 Inexpensive
 Low resource-intensive
 Fast
 Limited only to passive
diffusion
Isolated brain
microvessels
 Binding to a
specific
transporter
 Representing the in vivo
expression of transporters
and efflux systems at the
BBB
 Transcellular passage
cannot be measured
Endothelial cell
culture
 Rate
 Apparent
permeability
 Effect of culture conditions
on BBB transport
properties can be studied
(e.g.  astroglial factors,
serum effects,
inflammatory stimuli,
hypoxia/aglycemia)
 Limited tightness to mimic
in vivo situation
 Unreliable transporter
expression in mimicking in
vivo situation
 High batch-to-batch
variability
 Multitude of models
MDCK cell
culture
 Rate
 Apparent
permeability
 Tight cell membrane
 Possibility to transfect
specific transporters
 Not brain origin
 Expression of non-BBB
transporters and enzymes
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2.2.3 In situ brain perfusion technique
The in situ rat brain perfusion technique was originally established in rats by Takasato et al.
(Takasato et al. 1984) but several variations have been reported (Smith and Allen 2003). The
method  has  also  been  adopted  in  mice  (Smith  and  Allen  2003)  and  guinea  pigs  (Thomas
Née Williams and Segal 1996). In this technique, a known amount of the solute is perfused
into the animal’s catheterized common carotid artery (CCA) directly to the right brain
hemisphere with a constant fluid flow via the internal carotid artery (ICA), while the other
arteries are ligated (Figure 7). After the 20-180 s perfusion time, the brain is harvested and
the amount of the perfused solute in the brain is analyzed.
Figure 7. An illustration of the in situ rat brain perfusion technique.
The in situ brain perfusion technique is a widely used and rather suitable method to
determine brain uptake mechanisms and the rate of brain penetration of drugs. The in situ
method complements the in vivo and in vitro analyses and in addition has some unique
advantages (Bonate 1995, Foster and Roberts 2000, Smith and Allen 2003). First, the in situ
method demonstrates the solute transit from the circulation to the brain while the intact
and functional BBB is located at its normal physiological state.  This is the most important
advantage over the in vitro methods. Second, the composition of the perfusion fluid can be
controlled, and this can enable the study of saturable processes and toxic compounds. The
PA product (or Kin/Clin) determined by the in situ method describes the net influx clearance,
and the influence of transporters in the brain uptake can be determined. Third, the
concentration of the solute in the perfusion fluid is known and constant. Furthermore,
peripheral effects, e.g. metabolism, plasma protein binding and clearance, are avoided, and
only the BBB permeability is evaluated. The perfusate is not metabolized in or distributed
into  other  tissues,  only  to  the  brain.  In  addition,  the in situ brain perfusion technique
mimics the in vivo situation but the competition by endogenous compounds is minimized
when using physiologic saline as the perfusion solution.
However, the in situ method has some overall drawbacks and assumptions (Takasato et
al. 1984, Smith and Allen 2003, Hammarlund-Udenaes et  al. 2008). Firstly, the whole brain
tissue has to be analyzed instead of the extracellular fluid leading to a need to develop
extraction methods and extensive analytical assays. The in situ technique does not
determine the intracranial distribution of the drug nor its free fraction in the brain as the
drug concentrations are measured from a whole brain hemisphere (Hammarlund-Udenaes
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et al. 2008). Additionally, disruption in the physiological function of the BBB may occur
during the experiment e.g. by analgesics, air bubbles, particulate matter or hypoxia. One
assumption of the in situ rat brain perfusion technique is that efflux of the perfusate from
the brain back to the blood during the perfusion is not taken into account. Another
assumption related to this method is that the rate limiting step in brain penetration is the
permeation of the BBB. Furthermore, the short perfusion time (20–180 sec) means that it is
possible to study only well or modestly penetrating drugs with this technique. To reduce
the effects of these assumptions and limitations, the in situ data can be complemented in
some cases with the data of certain in vitro studies or other animal studies, such as in vivo
bolus injection or infusion or microdialysis (Gynther et al. 2010). The results obtained by the
in situ method cannot be used alone to determine the extent of clinically relevant drug brain
uptake.
2.2.4 In vivo methods
The in vivo evaluation of a CNS-acting drug is necessary in order to determine its brain
transport under physiological conditions (Bickel 2005). There are several in vivo models
available with which to evaluate the drug transport into the brain (Table 4). These methods
include brain uptake index, intravenous injection and infusion, microdialysis, CSF
sampling, external imaging methods and behavior tests. Most of the techniques are
performed in rats or mice. The in vivo transport  methods can be  distinguished from each
other by the following aspects:
- Whether the data can be collected from an individual subject or from various
subjects.
- Whether extensive, sensitive and selective analytics are required to determine the
drug levels from harvested tissues.
- Whether the drugs with slow or rapid uptake rates can be determined.
- Whether local or total drug concentrations can be determined.
Brain uptake index
The relative uptake of a drug compared to a reference compound can be determined by
measuring the brain uptake index (BUI) (Oldendorf 1970). In the BUI method, the reference
compound is radio-labeled and freely diffusible across the BBB (e.g. 14C-labeled butanol). In
that case, the test compound may also be radio-labeled, but this time with tritium (3H). If
the butanol is tritiated then a 14C-label can be used in the test compound. An injection
containing both the test and reference compounds is made into the common carotid artery
of an anesthetized animal without closing the other arteries. The animal is decapitated 5–15
s after the injection, the brain is harvested, and the radioactivity in brain tissue and injected
buffer is determined. The BUI represents the net uptake of the drug normalized against the
net uptake of the reference compound.
The main advantage of the BUI technique is that it is fast and relatively easy to perform
(Foster and Roberts 2000). However, the method is insensitive and somewhat inaccurate as
the whole fraction of the injected solutes does not reach the brain (Bonate 1995). This
method does not give any exact parameter because the results are correlated to the
reference as percentages (%) (Pardridge 1995). In addition, drugs that are taken up to the
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brain slowly (i.e. PA product  less  than 10  μL/min/g)  cannot  be  studied with this  method.
Because of these limitations, the in situ perfusion technique has replaced the BUI method as
it is more sensitive and precise.
Intravenous administration method
The most conventional, golden standard in vivo technique to study the brain uptake of
drugs is an intravenous method (Jeffrey and Summerfield 2007). The drug is injected or
infused intravenously, blood samples are withdrawn at various time points and the brain
tissue sample is harvested at the planned terminal time point. Finally, the intact drug
concentrations  from  the  blood  and  the  brain  samples  are  analyzed  with  a  sensitive  and
specific analytical method and the results are presented as the brain:plasma-ratio at a
certain time point. Alternatively, a comparison of the AUCs of the drug in the blood and
the  brain  over  a  certain  time  period  (usually  2  min  –  24  h)  can  be  used.  The  intravenous
administration has some advantages over the in situ method  as  it  involves  fully
physiological conditions, and one can obtain information of systemic pharmacokinetics at
the same time, this resembles most closely the human situation (Bickel 2005). This method
is also technically simple to conduct and it provides very high sensitivity as the tissue
uptake is measured over long periods of time. However, only the net effect of the brain
transport can be obtained and the role of the transporters in the brain uptake cannot be
easily studied. As the administered drug is distributed to the whole body of the animal, the
determination  of  certain  processes  involving  in  the  brain  transport  of  a  drug  may  be
challenging. In addition, the method provides only the total amount of the drug reaching
the brain and the intracranial distribution cannot be evaluated by this data without
additional in vitro studies (Hammarlund-Udenaes et al. 2008). The analysis of the drug
concentration from the whole brain tends also to be labor-intensive.
Intracerebral microdialysis
One important method to evaluate the brain transport of drugs is the intracerebral
microdialysis technique, which is the only method where information about the unbound
drug concentration in the brain extracellular fluid of an individual animal can be collected
in a time-dependent manner (Hammarlund-Udenaes et  al. 1997, de Lange et  al. 2005). The
information about the free concentration of the drug in the brain helps to determine the
target site concentration, which is crucial if one wishes to estimate the clinical usefulness of
a CNS-acting drug. The brain microdialysis method determines also the influence of the
transporters at the BBB on the brain transport of the drug (Dai and Elmquist 2003). Since
multiple samples at different time points can be collected from one individual animal, the
method is animal saving as compared to the tissue harvesting methods. In this method, a
semipermeable microdialysis probe is implanted to a selected brain area, and the drug
concentration in a local brain region can be determined. However, since it is an invasive
method, the probe implantation may lead to disruption of the BBB. After recovery, the test
compound is administered to the animal via a desired route. Drugs reaching the ECF can
pass through the semipermeable membrane of the probe into the dialysate consisting of a
physiological buffer. Brain microdialysis provides samples that are readily available for
chromatographic analysis. However, the sample size is small and the drug concentration in
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the dialysate can be low which means that sensitive analytic methods are required.
Furthermore, the intracerebral microdialysis determines the brain uptake only from the
brain area where the probe is implanted, and the drug distribution in other brain areas and
the total  amount  of  the  drug taken up into  the  brain  cannot  be  determined by one probe
(Mangas-Sanjuan et al. 2010). In addition, the extraction of the drug from the probe can be
inefficient (Hammarlund-Udenaes et al. 1997). In particular, highly lipophilic compounds
can  give  no  or  very  slight  recovery  from  the  probe.  Thus,  the  vast  majority  of  highly
lipophilic compounds found in current CNS compound libraries cannot be evaluated by the
intracerebral microdialysis. Moreover, the probe has to be validated to every studied
compound by measuring the drug extraction across the probe. The validation is commonly
an in vitro calibration, which is not always comparable to the in vivo situation, leading to
one possible weakness in the calculation of the results. In such cases, the intracranial
distribution of a drug should be evaluated by either the brain slice or a brain homogenate
method. Even though the cerebral microdialysis is a powerful method to evaluate the
clinically relevant brain uptake ability of a drug, the associated resource-intensiveness and
technical difficulty limits its usefulness, and this approach is not practical for routine
screening.
Cerebrospinal fluid sampling
Cerebrospinal  fluid  (CSF)  drug  concentration  has  been  used  as  a  surrogate  of  drug  brain
interstitial fluid concentration especially in human pharmacokinetic studies but also in
rodents and marmosets (Shen et al. 2004). CSF sampling can be conducted as serial
samplings from an individual subject after the drug has been administered via the desired
route. However, only limited information can be obtained from the CSF samples with
regard to drug delivery to the brain because the BBB and BCSFB are distinct from each
other, for example, in terms of transporter expression levels, resulting in unequal
concentrations in CSF and brain after systemic drug administration (De Lange and Danhof
2002, Shen et al. 2004). In addition, the drug may reach equilibrium between CSF and ECF
relatively slowly. Moreover, this sampling method does not necessarily reflect the regional
concentration differences of the drug within the brain.
External imaging methods (PET and SPECT)
The external imaging methods provide non-invasive techniques for measuring brain
concentrations of radio-labeled drugs in an individual living subject over a time course
together with plasma pharmacokinetics (Mensch et  al. 2009). Thus, some of them are also
suitable for clinical studies. The most commonly used external imaging methods include
single photon emission computed topography (SPECT) and positron emission tomography
(PET). Their applications differ according to the isotopes being used as well as the spatial
resolution achieved. The resolution of SPECT is in centimeter range, whereas that of PET is
as low as a few millimeters (Rahmim and Zaidi 2008). SPECT and PET have been used in
general to study brain metabolism and receptor/transporter binding of drugs as well as
characterizing inflammation and tumors of the brain, but the technique has not been used
extensively for the brain uptake studies of drugs.
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The  SPECT  imaging  method  can  be  used  to  study  the  BBB  permeability  of  drugs.  A
gamma-emitting molecule is imaged by a gamma camera, and the distribution of the drug
throughout the body can be examined (Nicolazzo et al. 2006). For example, in a comparison
of P-gp knock-out mice with their wild-type counterparts, the difference in brain transport
could be determined (Dyszlewski et al. 2002). However, this method has a limited role in
evaluating potential transport of a drug to the brain (Nicolazzo et al. 2006).
 PET in the other hand, has been used to determine the PA (permeability-surface area)
product of radioisotope emitting positrons also in clinical studies (Nicolazzo et  al. 2006).
PET imaging enables sensitive and high-resolution real-time quantitative determination of
drug distribution to the brain simultaneously from a specific brain region and from the
entire brain especially if the equipment is integrated with simultaneous analysis by
magnetic resonance imaging (MRI), which collects the anatomic data in real time. Thus,
other biochemical information, e.g. glucose metabolism, cerebral blood flow or whole
pharmacokinetic  time  course,  in  physiological  conditions  can  be  obtained  in  the  same
subject (Cunningham et  al. 2004). The results from PET studies are obtained as a sum of
bound and unbound drug concentration which limits its usefulness (Hammarlund-
Udenaes et al. 2008). In addition, no signal discriminating the intact tracer and its
metabolite(s) is obtained, and thus a short half-life and the metabolic instability of the tracer
limit  the  use  of  this  method.  The  correlation  for  the  decay  of  the  isotope  is  essential  for
obtaining reliable results. Recently, tracers of P-gp substrates, such as 11C-verapamil, 11C-
carvedilol and 11C-lorepamide have been introduced as tools to screen the MDR-
pharmacokinetics  of  other  P-gp  substrates  at  the  BBB  in  inhibition  studies  or  even  in
functional imaging of the P-gp kinetics (Syvänen et al. 2009). However, the imaging
methods have high costs as the radioisotopes and high-resolution equipment are expensive,
and therefore their applicability for routine studies in drug discovery is limited (Nicolazzo
et al. 2006). The personnel and the patients are also exposed to radiation which has to be
taken into account when using these imaging methods.
Knock-out animals
The influence of transporters on the distribution of drugs over the BBB can be estimated by
comparing the brain concentrations in transporter knock-out (KO) and wild-type mice. For
example three P-gp KO mice strains have been established. These are MDR1a () KO mice
(Schinkel et al. 1994), the MDR1b () KO mice (Schinkel et  al. 1997) and the
MDR1a/MDR1b () double KO mice (Schinkel et  al. 1997). The influence of P-gp on the
brain transport of a drug can be readily studied in these strains. However, many vital BBB
transporters cannot be knocked out because the knock-out strain is either not viable or
fertile. In addition, it is worth keeping in mind that other transporters might take over the
function of the knocked-out transporter as several transporters can have overlapping
functional (Löscher 2002), which limits the usefulness of KO mice. KO animals have been
successfully utilized with the intravenous administration technique (e.g. Meijer et al. 1998,
Desrayaud et al. 1998), the in situ brain perfusion technique (e.g. Dagenais et  al. 2000,
Cisternino et  al. 2001) and the cerebral microdialysis (e.g. De Lange et al. 1998, Xie et  al.
1999).
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Table 4. Summary of available in situ and in vivo methods for evaluating the drug transport to
the brain (Foster and Roberts 2000, Bickel 2005, Cecchelli et al. 2007, Hammarlund-Udenaes et
al. 2009, Mangas-Sanjuan et al. 2010)
Method Estimated
parameters
Advantages Disadvantages
In situ
perfusion
 Rate (PA
product)
 High sensitivity
 Permits modification of
both perfusate
composition and flow rate
 Artifacts by peripheral
metabolism excluded
 Rapid
 Technically more difficult
than intravenous
experiments and BUI
 Demand for valid analytical
tools and extensive sample
preparation
Brain uptake
index
(BUI)
 % brain uptake
in relation to
reference
 Fast
 Moderate technical
difficulty
 Permits wide range of
modifications of injectable
composition
 Artifacts by metabolism
largely excluded
 Relatively insensitive
 Neither rate or extent
measured
 Not suitable for poorly brain
penetrable drugs
 Radio-labeled compounds
needed
Intravenous
injection/
brain sampling
 Rate (Kin)
 Extent (Kp)
 Most physiological
approach
 Highest sensitivity
 Low technical difficulty
 Poorly permeating
compound can be studied
 Many animals has to be
used to gather sufficient
data
 Demand for valid analytical
tools and massive sample
preparation
 No data on unbound
concentrations
Microdialysis  Rate
(Clin)
 Extent (Kp,uu)
 Vu,brain
 Time course
measurements in
individual subjects
 Samples well suited for
subsequent analytical
procedures
 Data on all aspects of drug
brain exposure
 Technically involved and
time-consuming
 Possible adsorption to the
probes
 Local damage to BBB
integrity
 Only a specific site
measured
CSF sampling  Extent
(CSF:
unbound
plasma -ratio)
 Simple experiment
 Readily accessible for
sampling
 Applicable to humans
 Reflects permeability of B-
CSF-B and CSF fluid
dynamics rather than BBB
External
imaging
methods
 Rate (PA
product)
 Extent (Kp)
 Applicable to humans
(PET)
 Noninvasive and safe
 Spatial resolution
 Allows time course
measurements in
individual subjects
 Expensive equipment and
tracers
 Limited sensitivity (MRI)
and availability of labeled
tracers
 Poor spatial resolution for
small animals (SPECT)
 Total drug measured
 Resource intensive
 Short half-life of the some
isotopes
Knock-out mice  Extent (Kp)
 Rate (Kin)
 P-gp -effect
 Relationship with the BBB
transporters
 Total concentrations
 Possible up-regulation of
other transporters
In summary, there are various computer-aided drug design methods as well as in vitro
and in vivo assays available for assessing the brain transport of drugs (Tables 3 and 4). The
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in vivo techniques are the most reliable techniques as they use living tissue. In vivo
techniques have also an important role when creating more reliable computer-aided drug
design and in vitro methods. However, most of the in vivo techniques require large numbers
of animals and expensive equipment in addition to experimental expertise leading to
demand for resources. In that sense, computer-aided drug design and in vitro methods are
widely used in early-stage drug discovery especially as a complement to the in vivo
methods to clarify the mechanism of CNS penetration, including passive and active
transport.  Such  mechanistic  clarity  is  critical  for  the  development  and  application  of
predictive models of CNS penetration in the discovery decision making process. The main
drawback of computer-aided drug design, in vitro and most of the in vivo methods is their
limited  application  in  humans.  Thus,  it  can  be  difficult  to  extrapolate  the  results  from in
vitro or animal studies to humans. For example, the expression levels of various influx and
efflux transporters differ between species and this can exert a major influence on the drug
transport across the BBB (Ohtsuki and Terasaki 2007). In addition, many disease conditions
may induce changes in drug transport across the BBB (Liu et al. 2012).
The  parameters  which  are  to  be  determined  have  to  be  kept  in  mind  when  using  any
method to evaluate the BBB permeability, the BBB transport mechanisms or CNS
pharmacokinetics of a drug. Conventionally, those properties have been evaluated for most
CNS drugs in the early stage of drug discovery either by in vitro or computer-aided drug
design methods, or by in vivo measurement of the total brain to total plasma drug
concentration ratio (Hammarlund-Udenaes et al. 2008). These methods estimate mainly the
blood-brain  partitioning  of  a  drug  (log  BB  or  Kp,brain). Although these methods are
experimentally quite straightforward to carry out, as a single study they cannot predict the
pharmacological efficacy of CNS drugs. Most of these methods evaluate only the rate of
drug BBB permeation in addition to the total brain uptake; they do not evaluate the
unbound fraction of  the  drug in  the  brain.  Thus,  the  further  distribution of  the  drug into
different brain compartments is not taken into account. However, it is only free, unbound
fraction of a drug in the target site that can achieve the desired pharmacological activity
with most CNS drug targets. As a consequence, the free drug concentration in the brain is
the most reliable PK parameter for evaluating the drug efficacy.
2.3 STRATEGIES TO IMPROVE DRUG DELIVERY TO THE BRAIN
Since the BBB can be an insurmountable barrier restricting drug delivery to the brain,
various strategies have been developed to enhance the brain uptake of drugs (De Boer and
Gaillard 2007). The ultimate goal for these strategies is to deliver a CNS-acting drug to its
site of action at therapeutically effective concentrations and to maintain the drug at its site
of action for a required period of time. The focus of the strategies is to circumvent the BBB
either locally through direct injections or via intranasal delivery or transvascularly via
systemic administration. The systemic administration includes the chemical or mechanical
opening of the BBB and the utilization of the classic BBB transport mechanisms, i.e. passive
diffusion and carrier- or receptor-mediated transport. Conventionally, drug delivery to the
brain has been enhanced by increasing the passive diffusion across the BBB (Jeffrey and
Summerfield 2007). Thus, most of the marketed drugs against CNS-disorders are small and
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lipophilic, and they are supposed to cross the BBB mainly via passive diffusion (Pardridge
2012). Furthermore, strategies utilizing the brain specific carrier-mediated transport
mechanisms, i.e. transporter- and receptor-mediated transport, have been widely studied
during recent decades (De Boer and Gaillard 2007). In addition, colloidal carriers have been
widely applied to CNS drug delivery during recent years. In this thesis, only applications of
transvascular brain delivery have been discussed even though the local administration
routes, such as transcranial and intranasal delivery, have been successfully utilized in some
studies. The discussed strategies are summarized in Table 5.
Criteria for an ideal strategy to optimize drug delivery to the brain
Because  of  the  complexity  of  CNS  pharmacokinetics  of  drugs,  a  successful  strategy  to
optimize the drug delivery to the brain is dependent on several factors (Malakoutikhah et
al. 2011, Gaillard et al. 2012). The criteria for strategies enhancing drug delivery to the brain
are:
 Brain specificity
 Human applicability
 Safe interference with endogenous compounds
 Non-toxic and non-immunogenic in clinical use
 Safe in chronic use and in disease stage
 Adequate first-pass and plasma stability
 Optimal time in plasma in order to be able to reach the brain
 Only low binding to plasma proteins or brain tissue
 Not require structural modification of the parent drug
 Versatility to different class of molecules
 Low cost and straightforward manufacturing
 Scalability from laboratory to factory
 Patentability from industrial perspective
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Table 5. Advantages and limitations of the strategies enhancing drug delivery to the brain (De
Boer and Gaillard 2007, Gabathuler 2010, Vlieghe and Khrestchatisky 2012)
Strategy
Small (S)
or
large (L)
molecules
Advantages Limitations
BBB
disruption
S/L  No need for structural
modification of the drug
 For small and large
molecules
 Risk of toxicity
 Requirement of surgical
interventions
Lipophilization S  Increased membrane
permeability
 Straightforward
manufacturing
 Not brain specific targeting
 Increased plasma protein binding
 Intracellular accumulation
 Increased size of the molecule
 Interference with receptor-binding
 Only for small molecules
Receptor-
mediated
brain delivery
L/S  Brain specificity
 For small and large
molecules
 Possibly no need for any
chemical modification of the
drug
 Risk of immunogenicity
 High costs
 Need of carriers
 Difficult manufacturing
 Interference with the endogenous
ligands
 Slow uptake rate
 Low capacity
Adsorption-
mediated
brain delivery
L/S  For large molecules
 High capacity
 Possible toxicity or
immunogenicity
 Not brain specific targeting
 Slow uptake rate
Transporter
utilization
S  Brain specificity
 Less lipid soluble derivatives
 May increase the intra-
cellular levels of the drug
 Interference with the endogenous
substrates
 Only for small molecules
2.3.1 BBB disruption
One  strategy  to  increase  drug  delivery  to  the  brain  is  the  temporary  disruption  of  the
endothelial  tight  junctions  at  the  BBB.  The  disruption  of  the  BBB  can  be  achieved
osmotically, biochemically or mechanically. The osmotic opening occurs when hypertonic
solution (e.g. mannitol or arabinose solution) is administered to the intracarotid artery
which induces shrinkage of celebrovascular endothelial cells and subsequently there occurs
disruption of the endothelial tight junctions. The tight junctions can also be temporarily
disrupted by intravenously administered vasoactive compounds, such as bradykinin
analogues, leukotriene C4 or histamine, or by intravenous injection of solvents, such as
high-dose dimethylsulfoxide, or detergents, such as polysorbate 80 or sodium dodecyl
sulfate (Deli 2009). A mechanical and more site-specific opening of the BBB tight junctions
can be achieved by ultrasound (Cho et al. 2002, Hynynen 2008). The BBB disruption must be
temporary, lasting only for a few hours, and reversible, because the strategy may be highly
toxic and may cause severe neuropathological consequences (Tomkins et  al. 2007). In
addition, these strategies require highly qualified personnel and surgical intervention to
access  the  carotid  artery  leading  to  high  costs  with  this  technique.  Due  to  the  drawbacks
concerning the BBB disruption, this approach is questionable even though it is clinically
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used especially in neuro-oncology. However, as discussed in Chapter 2.2, drug delivery can
also be enhanced by a disruption of the BBB in the injured and inflamed brain.
2.3.2 Enhancing the passive diffusion across the BBB
The majority of the drugs currently marketed for use against CNS-related disorders are
basically lipid soluble small molecules with molecular weight less than 400 Da (Pardridge
2012). Thus, most of these drugs are able to cross the BBB by passive diffusion due to their
favorable  physicochemical  properties.  However,  a  minority  of  compounds  in  drug
discovery programs have adequate physicochemical properties to cross the BBB. Thus,
many attempts to improve the physicochemical properties of drugs during the early-state
drug discovery with an aim to enhance their brain uptake have been reported.
Modifying the structure of the drug
Due to the conventional beliefs that drugs penetrate across the BBB via passive diffusion,
this mechanism is considered to be the most used approach to cross the BBB. As discussed
in Chapter 2.1, passive diffusion across the BBB is mainly dependent on the molecular
weight,  charge  and  lipophilicity  (log  P)  of  a  drug.  There  are  several  guidelines  that  have
been used to predict the passive brain uptake of drugs, e.g. Lipinski’s rule-of-five (Lipinski
1997), Abraham’s equation (Gratton et al. 1997) and Central Nervous System
Multiparameter Optimization (CNS MPO) approach by Wager et al. (Wager et al. 2010).
With an attempt to increase passive diffusion of drugs across the BBB, medicinal chemistry
has been used to increase the lipid solubility of water-soluble compounds which have poor
brain uptake properties. This has led to the development of more lipophilic (1.5 < log P <
2.7) and less flexible CNS drugs with fewer hydrogen-bond donors and acceptors (< 7),
fewer formal charges and lower polar surface area as compared to non-CNS drugs (Wager
et al. 2010a, Ghose et  al. 2012). However, this approach does not meet many of the criteria
for an ideal CNS drug delivery strategy, and in fact, there are three major limitations with
this approach. First, the structure of the drug is modified which may influence the receptor
binding and the pharmacokinetics of the drug. Second, the lipophilization of a drug
increases its non-specific binding to plasma proteins and brain tissues. For example, the
brain tissue contains 20-fold more lipids than plasma (Jeffrey and Summerfield 2007), and
thus, if a drug is optimized to cross the BBB by passive diffusion it is relatively lipid soluble
and favors nonspecific binding to brain lipids rather than increasing the free concentration
at the molecular target site. Third, the permeability of a more lipid soluble analogue across
any cell membranes is increased leading to the fact that this approach is not brain specific.
Finally,  increased lipophilicity may also result in a chemical structure that is poorly drug-
like due to unfavorable solubility and/or metabolic instability.
Lipophilization by prodrug technology
To overcome the limitations of the structure modification of the drug, prodrug technology
has been utilized in order to create more lipophilic derivatives of poorly brain penetrable
drugs. Prodrugs in general are bioreversible derivatives of drugs that undergo an
enzymatic and/or chemical transformation in vivo to release the active, unmodified parent
drug, which can then exert the desired pharmacological effect (Rautio et al. 2008a) (Figure
35
8). In order to enhance the brain uptake, the prodrug has to be able to cross the BBB and
release the active drug selectively within the brain leading to prolonged retention of the
active drug in the brain. There are basically two approaches to enhance the passive
diffusion across the BBB by the prodrug technology, i.e. simple esterification or amidation
of  hydroxyl-,  amino-,  or  carboxylic  acid containing drugs  and so  called chemical  delivery
system (CDS) (Rautio et al. 2008b).
Figure 8. A simplified illustration of the prodrug (drug-promoiety) concept.
Hydrophilic  and  the  polar  functional  groups  of  a  drug  can  be  conjugated  with  a  non-
polar promoiety by simple esterification which may increase the permeation of the prodrug
across the BBB by increased lipophilicity. This kind of prodrug strategy has been exploited
in a variety of drugs. A classic example of this strategy is heroin, the acylated form of
morphine. Morphine with two hydroxyl groups has relatively high polarity and low brain
uptake, whereas the acylation of the hydroxyl groups increases its BBB permeability rate by
100-fold (Oldendorf et al. 1972). Other examples of the lipidization are alkyl and benzyl
esters of chlorambucil (Greig et al. 1990).
The CDS concept (Figure 9) is a more rational prodrug approach than simple
esterification to improve the lipophilicity and simultaneously the brain selectivity of a drug
(Bodor and Buchwald 1997). When utilizing the CDS concept, a drug is most commonly
conjugated with a lipophilic 1,4-dihydro-N-methylnicotinic acid (1-4-dihydrotrigonelline)
promoiety, which can result in a more lipid soluble derivative that may readily penetrate
through  the  biological  membranes  including  the  intestinal  epithelium  and  the  BBB.  Once
the administered prodrug has reached the brain parenchyma, the promoiety is oxidized by
the nicotinamide adenine dinucleotide redox system forming the quaternary salt. The
ionized salt cannot diffuse out from the brain and therefore the prodrug is retained inside
the cerebral tissue. The prodrug is then slowly hydrolyzed to its active form at the site of
action. Many drugs have been conjugated with such a promoiety (Rautio et al. 2008b). For
example, Bodor et al. (Bodor et al. 1981, Bodor and Farag 1983) have studied ester and
carbamate CDS-prodrugs of dopamine, and reported that the prodrugs were able to
penetrate into rat brain after intravenous administration and to achieve sustained
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dopaminergic activation in behavior studies in rats. Another application of a CDS-prodrug
is an estradiol conjugated with 1-4-dihydrotrigonelline promoiety, EstredoxTM, which has
increased significantly the concentration of estradiol in rat brain compared with treatment
with free estradiol (Bodor and Buchwald 2002). The drawbacks of the CDS strategy are the
same as those with the classic esterification strategy, i.e. there is increased volume of
distribution (more drug is outside the brain), possibly increased binding to plasma proteins
and increased molecular weight, which all may decrease the free drug levels at the site of
action. In addition, usually esters are enzymatically rather unstable in plasma which limits
their usefulness as ways to enhance the brain uptake of the parent drug.
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Figure 9. Mechanism of CDS-prodrug approach in CNS drug delivery.
2.3.3 Receptor-mediated drug delivery to the brain
Receptors transferring larger peptides and proteins into the brain can also be utilized in
improving drug delivery to the brain (Pardridge 2010). This utilization is called the
molecular Trojan horse strategy. By conjugating a drug with a BBB transport vector, e.g.
with a modified protein or receptor-specific monoclonal antibody (mAb), the conjugate can
cross the BBB via receptor-mediated transcytosis. While the endogenous ligands bind to the
receptor binding site of endogenous substrates, the mAb binds to another binding site in
the  receptor  than the  normal  binding site  of  its  endogenous ligand (Pardridge et al. 1991,
Skarlatos et  al. 1995).  This  is  an  advantage  of  conjugating  a  drug  to  the  antibodies  as  the
interference with endogenous ligands is eliminated. The most widely studied receptors in
the area of drug delivery to the brain have been transferrin, insulin, low-density lipoprotein
and diphtheria toxin receptors (Gaillard et al. 2012), and only these will be briefly discussed
in this thesis.
37
RMT  (receptor-mediated  drug  transport)  provides  an  opportunity  for  drug  delivery  to
the brain as some of the receptors are overexpressed at the BBB (Rip et al. 2009, Gabathuler
2010). However, the receptor may be occupied by its endogenous ligands, and this may
restrict the utilization of this strategy in such cases. In addition, the capacity for transport
with this strategy is rather low and the transport rate rather slow because one vesicle can
transfer only one conjugate. Since some of the receptors at the BBB are species dependent,
the extrapolation of preclinical in vivo results to clinical studies in humans may be difficult.
The drug can be conjugated directly with the vector but usually this process is facilitated
by chemical linkers, such as avidin-biotin technology, polyethylene glycol linkers or
colloidal carriers like polymeric micelles, liposomes, dendrimers or nanoparticles (Yang
2010, Gaillard 2010, Craparo et al. 2011, Gaillard et al. 2011). The carriers are often needed to
increase the stability of the conjugate in plasma or to increase its solubility properties. In
addition, it is not always possible to conjugate a large molecule directly with the vector
without losing its activity. The whole conjugate or particle crosses the BBB by endocytosis
after receptor binding by forming a vesicle. The vesicle then moves across the endothelial
cytoplasm, and finally releases the drug to the abluminal side of the BBB by exocytosis. The
release of the drug can also occur inside the cell, and this has to be taken into account when
designing RMT-mediated systems.
Colloidal carriers in the receptor-mediated drug delivery
Polymeric micelles, liposomes and nanoparticles are self-assembling colloidal vesicles
which have been widely investigated as carriers for drug delivery to the brain (Craparo et
al. 2011). Colloidal carriers, per se,  cannot  cross  the  BBB  by  passive  diffusion  due  to  their
large size and high molecular weight. However, a poorly brain penetrable drug possessing
inadequate physicochemical characteristics and even high molecular weight can be targeted
to specific surface receptors of brain endothelial cell membrane with the assistance of a
coated colloidal carrier. The high molecular weight complex crosses the BBB by receptor-
mediated endocytosis, and finally the carrier releases the drug inside the brain. The carrier
can be loaded with a range of drugs, and the surface properties of the carrier can be
modified and this makes the strategy an attractive alternative for transporting drugs across
the BBB.
An ideal colloidal carrier for the receptor-targeted prodrugs should fulfill the following
criteria: 1) the carrier should be nontoxic, non-immunogenic, biodegradable and
biocompatible, 2) the particle size should be less than 100 nm, 3) the carrier should be stable
in blood, 4) the carrier should include a BBB-targeting moiety, 5) the stability of the parent
drug should be maintained and 6) the carrier should be applicable for small molecules,
proteins, peptides or nucleic acids (Gaillard et al. 2011). However, most colloidal systems in
general bind efficiently to plasma proteins as they often possess hydrophobic surface
properties. They are also taken up to macrophages by rapid liposomal uptake in the liver
and spleen, and are rapidly removed from the circulation. These problems can be overcome
either by adsorbing some surfactant molecules (such as copolymers of polyoxyethylene and
polyoxypropylene) at the surface of the carrier or by providing steric stability by a direct
chemical  link  of  polyethyleneglycol  (PEG)  to  the  surface  of  the  particles  (Peracchia et  al.
1998, Peracchia et al. 1999, Lee et al. 2003). For example, the half-life of pegylated liposomes
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in human can be as long as 90 hours (Gabizon et al. 2003). Even though a large variety of
nanocarriers have been developed, only liposomes and polymeric nanoparticles have been
extensively utilized for drug delivery to the brain (Craparo et al. 2011).
Liposomes were the first generation of colloidal carriers developed for drug delivery
(Bawarski et  al. 2008). Liposomes consist of unilamellar or multilamellar phospholipid
bilayers surrounding an aqueous compartment; they are usually 0.1-2 μm diameter in size.
Thus, liposomes are able to incorporate a wide variety of hydrophobic drugs into their
bilayers and encapsulate hydrophilic drugs in their core at high concentrations (Ricci et al.
2006). The structure of the liposomes resembles biological membranes. The biophysical
properties of the biodegradable lipids, e.g. size, surface charge, lipid composition and
cholesterol amount, can be modified to achieve controlled distribution, tissue uptake and
drug  delivery.  In  addition,  BBB-targeting  ligands,  such  as  substrates  for  the  receptors
expressed  at  the  BBB,  can  be  conjugated  to  the  surface  (Ricci et al. 2006) (Figure 10). The
liposomes utilized in drug delivery to the brain are often conjugated with PEG in order to
extend their half-life in blood. In addition, PEGylation reduces possible steric hindrance of
the liposome at the receptor-binding site (Maruyama et al. 1995).
Figure 10. Structure of a unilamellar PEGylated liposome with antibodies for receptor-targeted
drug delivery.
Polymeric nanoparticles are biodegradable carriers with diameters in the 50-400 nm
range. A drug may be dissolved into the nanoparticles or entrapped, encapsulated,
chemically attached or adsorbed to the constituent polymer matrix (Ricci et al. 2006). The
materials in the nanoparticles vary. The receptor targeted biodegradable nanoparticles can
be made from polymers such as polyalkylcyanoacrylates, polyacetates, polysaccharides, or
chitosan (Ricci et al. 2006, Wohlfart et  al. 2012). The nanoparticles possess higher chemical
and enzymatic stability in the body than liposomes as they undergo fewer interactions with
blood components, and this can allow sustained release of the drug at the site of action
(Ricci et  al. 2006). In addition, the preparation of nanoparticles is generally more
straightforward to scale up.
Transferrin receptor
Transferrin receptor (TfR) is the most widely characterized RMT system for drug delivery
to the brain (Pardridge 2010). The physiological function of the TfR is to mediate the brain
uptake of iron-bound transferrin, which has a very high affinity for the receptor. In
addition to the BBB, TfR is also expressed in hepatocytes, erythrocytes, intestinal cells,
placenta and monocytes (Jefferies et al. 1984). TfR can be utilized for drug transport into the
brain by using either endogenous transferrin or an antibody directed against the TfR (e.g.
39
OX26) as a targeting ligand (Jones and Shusta 2007). Transferrin as a vector may not be
advantageous in the in vivo situation as  there  is  a  very high concentration of  endogenous
transferrin in the circulation, and the receptors are mostly saturated. In addition, there is a
risk of the interference with iron tissue concentrations. To circumvent these limitations
concerning transferrin, antibodies which bind to a different binding site as the endogenous
ligands have been developed. OX26 (rat TfR monoclonal antibody) (Lee et al. 2000), RI7217
(mouse TfR monoclonal antibody) (Van Rooy et al. 2011) and 8D3 (mouse TfR monoclonal
antibody) (Zhang and Pardridge 2005) have all been examined with promising results in in
vivo studies. However, no clinical studies have been conducted with these vectors. Thus,
the possible immunogenicity of these vectors remains unclear (Jones and Shusta 2007). In
addition, the expression of TfR in tissues other than brain limits the use of this receptor in
brain specific drug delivery. The interference of the antibody conjugates with the
endogenous iron homeostasis is also unclear.
Insulin receptor
Insulin receptor is another widely characterized receptor at the BBB for transporting
macromolecular drugs to the brain via RME (Pardridge 2010). The endogenous ligand for
insulin receptor is insulin. However, insulin, like transferrin, cannot be used as a targeting
vector because this could cause insulin overdose and the risk of severe hypoglycemia.
Therefore, antibodies of the insulin receptor have been developed. The most extensively
studied antibodies are MAb83-14 (mouse origin) and HIRMAb (human insulin receptor
binding monoclonal antibody) (Jones and Shusta 2007). The former triggers extensive
immunogenic  reactions  in  humans,  and  thus,  chimeric  forms  of  the  antibody  have  been
developed. As HIRMAb is totally human-based, it has been considered to be a highly
potent vector for transporting macromolecules into the brain. However, the possible
interference of glucose homeostasis limits the usefulness of HIRMAb in humans, and no
clinical studies with HIRMAb have yet been conducted.
Low-density lipoprotein receptors
Low-density lipoprotein receptors (LDLR) 1 and 2 have been utilized in RME-related BBB-
targeting of drugs over the years (Gabathuler 2010). These are multifunctional and multi-
ligand receptors binding for example LDL, receptor associated protein, apolipoproteins,
plasminogen activators, amyloid precursor protein, lactoferrin, melanotransferrin, HIV-1
TAT protein and engineered angiopeps (De Boer and Gaillard 2007). Melonotransferrin
(Demeule et al. 2002), lactoferrin (Ji et al. 2006), apolipoprotein E (Hülsermann et al. 2009)
and angiopeps (Régina et al. 2008) could be useful carriers as BBB-targeting vectors. In fact,
the angiopep-2-paclitaxel conjugate is currently undergoing clinical trials for the treatment
of malignant glioma. Since LDLR1 and LDLR2 have many ligand binding sites, the binding
of one ligand to the receptor does not interfere with the binding of another ligand.
Diphtheria toxin receptor
Diphtheria toxin receptor (DTR) is expressed at the BBB but it has no endogenous ligands
(Gaillard et al. 2005). This is a major advantage over the receptors mentioned above in the
drug targeting point of view. However, diphtheria toxin can bind to DTR and it is also
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transported into the brain via endocytosis by this receptor. Diphtheria toxin is obviously
too toxic to be used as a vector in vivo. Instead, a mutated form of diphtheria toxin, cross-
reacting material (CRM197), has been used, and in this form it does not cause diphtheria
toxin -like toxicity making CRM197 an attractive alternative for RMT (Gaillard et al. 2005).
DTR is strongly up-regulated under inflammatory conditions (Tanaka et al. 1999, De Boer
and Gaillard 2007), and therefore it is an interesting BBB-targeting receptor to deliver drugs
against diseases evoking inflammatory response, e.g. Alzheimer’s disease, Parkinson’s
disease, ischemia, epilepsy, tumor and encephalitis.
2.3.4 Adsorptive-mediated drug delivery to the brain
Cationization of a water or lipid soluble drug or a colloidal carrier may result in increased
absorptive-mediated endocytosis across the BBB (Bickel et al. 2001). For example, cationized
human serum albumin, immunoglobulins and other positively charged cell-penetrating
peptides have been used as the vectors for adsorptive-mediated drug transport (Kumagai et
al. 1987, Bickel et al. 2001, Hervé et  al. 2008). The strategy utilizing adsorptive-mediated
drug transport possesses a high capacity since the transporting vesicles are not easily
saturated, and even weak interaction between the BBB and the peptide enables BBB
penetration. However, cationization has not been extensively used because the brain
specificity of this strategy is limited (Hervé et  al. 2008). In addition, this strategy is
associated  with  an  increased  risk  of  toxicity  and  immunogenicity  as  well  as  aggregate
formation in the circulation which are other challenges which will need to be overcome
before clinical applications of adsorptive-mediated drug delivery to human brain.
2.3.5 Circumventing the efflux transporter system
The efflux transporters present at the BBB can prevent the brain uptake of many drugs.
There are two strategies to avoid the efflux transporters from a medicinal chemistry point
of view: 1) structural modification of the drug or 2) temporal inhibition of the efflux
transporters (Begley 2004).
In the structural modification, the design of drugs is focused on reducing the affinity of a
drug for a specific efflux transporter (Begley 2004). The functional groups recognized by the
efflux system can be replaced or masked with another functional group. However, due to
the multifunctional binding sites and the lack of detailed knowledge of the SAR of the
efflux transporters, that kind of strategy may be challenging. In addition, the change of the
structure of the drug may alter also its pharmacological efficacy.
Inhibition of  the  drug efflux transporters  at  the  BBB is  another  strategy to  increase  the
drug concentration in the brain (Breedveld et al. 2006, Potschka 2012). This can be achieved
by decreasing the efflux transport rate of a drug by co-administration of a drug which has
the ability to inhibit efflux transport. For example, in one study a P-gp substrate, verapamil,
was taken up to the brain in significantly higher amounts when co-administered with a P-
gp inhibitor, cyclosporin A (Syvänen et al. 2008). An efflux inhibitor can also be covalently
conjugated with a drug to form a codrug (Rautio et al. 2008b). However, the use of efflux
inhibitors is limited to acute use, and thus this strategy cannot be used to treat chronic CNS
diseases  because  toxic  compounds,  which  are  normally  transported  out  of  the  brain  by
these efflux transporters, can accumulate into the brain and evoke neurotoxicity. In
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addition, efflux transporters are also expressed in the rest of the body and their inhibition
may alter drug distribution into several tissues, which may cause increased toxicity
elsewhere  in  the  body.  Furthermore,  a  lack  of  specific  inhibitors  for  many  of  the
transporters limits their usefulness.
2.3.6 Transporter-mediated drug delivery to the brain
The  BBB  expresses  a  number  of  specific  carrier-mediated  transport  mechanisms  ensuring
an adequate nutrient supply for the brain (Hediger et  al. 2013). Thus, they can also be
utilized in BBB-targeting of drugs. There are basically two approaches which can be
utilized: 1) modifying the structure of a drug itself  to mimic a substrate of a carrier at the
BBB, i.e. “pseudonutrient”  strategy,  and  2)  a  conjugation  of  a  drug  with  a  transporter
substrate in a bioreversible manner, i.e. prodrug strategy (Pavan and Dalpiaz 2011). There
are several advantages to utilizing the BBB specific transporters as drug carriers. First, this
strategy can be brain specific when transporters which have high expressions on the BBB
have been utilized. Second, the plasma protein binding and the unspecific binding to brain
tissues may be decreased because these kinds of molecules are usually less lipid soluble.
Decreased  lipophilicity  often  leads  to  decreased  binding  to  the  proteins  and  lipids  in
plasma and brain (Summerfield et al. 2006; Jeffrey and Summerfield 2007). In addition,
molecules utilizing transporters may be also taken up to the intracellular compartments of
the brain tissue in a transporter-mediated manner. However, there are also several
drawbacks concerning the utilization of the transporters at the BBB. First, the uptake rate
via a specific transporter depends on its degree of occupation, and the transporter
utilization may be limited by the saturation of the transporter with its endogenous
substrates  (del  Amo et  al. 2008). High binding affinity of the drug to the transporter is
required in  order  to  achieve adequate  transport  across  the  BBB.  Second,  the  selectivity  of
the drug for the transporter limits the utilization of the strategy because of steric hindrance
induced  by  either  the  chemical  modification  of  a  functional  group  of substrate for
transporter-mediated drug delivery or the conjugation of a drug with a substrate of the
transporter. Thus, the strategy is limited mainly to small molecules and is restricted to
drugs that closely mimic the endogenous substrates of the carrier. Third, many transporters
at the BBB are also expressed in the peripheral tissues decreasing the brain specific
distribution  of  the  drug.  Since  the  expression  levels  and  amino  acid  sequences  of  certain
transporters at the BBB are species dependent, the extrapolation of preclinical in vivo results
to clinical studies in humans may be difficult. However, the transporter systems displayed
at the luminal and abluminal membranes of the BBB, especially GluT1 and LAT1, have
been  shown  to  have  a  sufficiently  high  transport  capacity  to  hold  promise  for  significant
drug delivery to the brain (Pavan and Dalpiaz 2011).
GluT1 is the only transporter at the BBB that transports hexoses, such as glucose,
galactose and mannose, from blood to the brain having a vital role in the glucose brain
supply (Pardridge and Oldendorf 1975). The high transport capacity (Dwyer and Pardridge
1993) and the expression at the luminal and abluminal membranes of the BBB (Farrell and
Pardridge 1991) make GluT1 an attractive transporter also for drug delivery to the brain.
However, “pseudonutrient” drugs or “pseudonutrient” prodrugs for GluT1 have not been
studied since GluT1 appears to be very selective in the stereochemical requirements for its
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substrates (Pavan and Dalpiaz 2011). Nevertheless, several ester conjugates of glucose and
various drugs have been introduced with an aim to enhance the brain delivery of the drug
via GluT1. As examples, various opioid agonist peptides, which are non-glycosylated
compounds, have been shown to be transported across the BBB via GluT1 and to achieve
prolonged analgesia in mice (Negri et al. 1998). In addition, glucose conjugates with
levodopa and dopamine (Fernández et al. 2000, Fernández et al. 2003, Bonina et al. 2003), 7-
chlorokynurenic acid (Battaglia et al. 2000), nipecotic acid (Bonina et al. 2003), indomethacin
and ketoprofen (Gynther et al. 2009) have been studied.
In contrast to GluT1, there are several drugs in clinical use that act as “pseudonutrients”
as they mimic the endogenous substrates of LAT1, e.g. melphalan (Cornford et al. 1992),
baclofen (Deguchi et al. 1995) and gabapentin (Thurlow et al. 1996) (Figure 11). Levodopa, a
prodrug of dopamine, is the only prodrug in clinical use that is transported into the brain
through LAT1 (Gomes and Soares-Da-Silva 1999) (Figure 12). Once transported into the
brain, levodopa is decarboxylated into dopamine by L-amino acid decarboxylase (AADC).
In addition, the “pseudonutrient” prodrug analogue of 7-chlorokynurenic acid utilizing
LAT1 as a carrier to the brain have been reported (Figure 12) (Hokari et al. 1997). All the
mentioned LAT1 substrates fulfill the structural requirements for LAT1 binding, i.e. free -
amino and -carboxyl groups of the amino acids and a lipophilic center. However, in drug
discovery such structural requirements are in general difficult to fulfill while maintaining
the desired therapeutic activity, which limits the usefulness of the “pseudonutrient”
strategy.
Figure 11. Examples of drugs utilizing LAT1 in brain uptake.
Figure 12. The examples of “pseudonutrient” LAT1 prodrugs.
A drug which is not a LAT1 substrate can be conjugated with a LAT1 substrate by a
prodrug approach in order to enhance its brain uptake via LAT1. This can be used as an
alternative for the “pseudonutrient” strategy. This strategy does not include the structural
modification of the drug, i.e. it is reversibly conjugated with an endogenous substrate of the
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carrier. For example, L-tyrosine has been conjugated with nipecotic acid (Bonina et al. 1999),
phosphonoformate (Walker et al. 1994) and ketoprofen (Gynther et al. 2008) with ester
linkage, and L-cysteine has been conjugated with 6-mercaptopurine with a disulfide linkage
(Killian and Chikhale 2001) (Figure 13). These prodrugs have been shown to possess
affinity for LAT1 in cell lines or in in situ rat brain perfusion, and the L-tyrosine derivative
of  nipecotic  acid  has  also  been  shown  to  achieve  anticonvulsant  activity  in  an in vivo
epilepsy rat model. The translocation of the prodrug across the BBB has been demonstrated
only with the ketoprofen derivative. However, no plasma or brain pharmacokinetic data of
these prodrugs after peripheral administration in vivo has been published. This would be
important since it is possible that the ester prodrugs are degraded prematurely by systemic
bioconversion  before  their  distribution  to  the  brain.  The  only  study  where  the  free  drug
concentrations in brain intracellular fluid have been demonstrated was carried out with
ketoprofen-L-lysine (Gynther et al. 2010) (Figure 13). After intravenous administration of
ketoprofen-L-lysine to rats, the distribution of free ketoprofen in the brain intracellular fluid
compared to plasma levels was shown to be 363 times higher than those achieved with the
corresponding treatment with ketoprofen. This may be evidence of LAT1-mediated cellular
uptake within the brain. Cysteine and lysine themselves are small,  polar amino acids and
thus weak substrates for LAT1. However, significantly higher affinities for LAT1 have been
observed  when  they  are  conjugated  with  the  parent  drugs  (Killian  and  Chikhale  2001,
Gynther et al. 2010). Even though LAT1 has been utilized in several studies as a prodrug
carrier into the brain, limited information is available on the specific characteristics of the
LAT1 at the BBB, i.e. only rather lipophilic conjugates have been studied so far. In addition,
the maximum size of the conjugate that will still possess affinity for LAT1 and be
translocated across the BBB has not been determined yet. One drawback of using LAT1
prodrugs as a strategy to improve drug delivery to the brain is the rather selective
expression of LAT1 at the BBB and other blood-tissue barriers (Verrey 2003). Thus, the
intestinal absorption of the LAT1 prodrugs via LAT1 may be low, and the prodrug
approach may need to be restricted to parenteral administration.
Figure 13. Examples of prodrugs utilizing LAT1 in drug delivery to the brain.
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2.3.7 Conclusions and strategies for future
Several chemical and biological strategies have been found to enhance drug delivery to the
brain after systemic administration. Those strategies include disruption of the BBB,
enhancement of passive diffusion, inhibition of efflux transporter and utilization of the
endocytosis-mediated, adsorptive-mediated or transporter-mediated transport mechanisms
as discussed previously. These strategies can also be combined with other delivery systems,
such as incorporation of the drug into liposomes and nanoparticles. During the past
decade, both interest and effort have been focused on the development of novel strategies
to improve drug delivery to the brain, and many of them have shown their usefulness and
brain specificity in animal models. However, a rather low number of marketed drugs have
utilized these novel strategies, and unfortunately, the insights gained from academia have
not been effectively translated into new medicines in pharmaceutical industry (Gaillard
2010).
Conventionally, the strategy to enhance brain delivery of small molecular weight drugs
has been the lipophilization of the drug either by modifying the chemical structure of the
drug or by a prodrug approach with an aim to increase the passive diffusion across the
BBB. However, this strategy is rarely brain specific and the free fraction of more lipophilic
molecules in the brain is often low. Another strategy to enhance drug delivery to the brain
is the osmotic, biochemical or mechanic BBB disruption. The most promising strategy to
enhance the brain delivery of small molecular weight drugs is possibly the utilization of
transporters expressed at the BBB by conjugating a substrate of these transporters with a
poorly brain penetrable drug via a prodrug approach. The most attractive feature of the
transporter-mediated drug delivery to the brain is its ability to target drugs to the BBB
specific transporters. This strategy has the probability to enable specific intracellular uptake
in  addition  to  BBB  crossing,  hence  enhancing  the  drug  levels  site-specifically  which  may
reduce  its  side-effects  in  other  tissues.  This  may  be  beneficial,  especially  when  treating
brain tumors. Ideally, the active drug is released from the promoiety enzymatically by a
brain-specific enzyme. However, the prodrug is often altered by a premature cleavage.
After all, the enzymatic activity in the systemic circulation is much higher than in the brain
tissue.  Furthermore,  the  prodrug  may  be  too  stable  in  order  to  release  the  parent  drug
which limits the usefulness of this strategy.
Since almost all macromolecules are not taken up into the brain as such, there is a great
demand  for  strategies  to  improve  the  brain  delivery  of  high  molecular  weight  drugs.
Prodrug  delivery  to  the  brain  via  RME  would  be  the  most  promising  brain  delivery
strategy if the safety issues could be circumvented. In particular, the nanoparticles and
liposomes targeted to the receptors of the BBB have been considered as a great opportunity
to carry macromolecules into the brain. However, there are still some unresolved problems
concerning the safety, toxicity and immunogenicity of the novel vectors and carriers, which
limits their clinical use. Many of the prodrugs utilizing RME are too inefficient in terms of
brain uptake. It has been estimated that at least 2% of the injected dose of a macromolecule
following intravenous administration should reach the brain (Pardridge 2010). However,
the possible loss of dose (98%) to the peripheral tissues is significant from a cost and side-
effect point of view. Another challenge of the receptor-targeted prodrugs is their
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accessibility into the intracellular organelle (e.g. mitochondrial). In addition to permeation
of  the  BBB,  internalization  of  a  brain-targeted  drug  into  specific  cells  is  dependent  on  its
ability to cross the additional barriers. The goal of all of the strategies discussed above is to
deliver the drug to its site of action at therapeutically effective concentrations and to
maintain the action for a required period of time.
There  is  still  demand  for  further  research  to  develop  novel  strategies  to  enhance  drug
delivery to the brain even though some of the recently introduced strategies have shown to
hold promise compared with the conventional strategies. The strategies improving drug
delivery  to  the  brain  should  be  applied  to  the  early  preclinical  stage  of  CNS  drug
development which may lead to improved productivity and success in later development
stage and decreased attrition rates of CNS drugs. In addition, the brain uptake of known
drugs with poor brain penetration could be enhanced by these strategies to enlarge their
indications to treat also CNS diseases. It is not realistic to think that one could design one
universal strategy suitable for all drugs because the strategy for improving drug delivery to
the  brain  should  be  defined  for  a  given  drug  according  to  its  physicochemical  and
pharmacokinetic properties, its site of action within the brain and the possible influence of
the disease conditions. Therefore, a successful strategy for CNS delivery and targeting has
to be tailored for each active drug. However, recent and future advances in drug CNS
delivery strategies could provide new knowledge which will make it possible to achieve the
goal of safer and more efficient drug CNS delivery.
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3 Aims of the Study
The general objective of this doctoral thesis was to design novel LAT1-targeted prodrugs
for improved CNS permeation and evaluate their brain uptake using in situ and in vivo
methods. The premise of this is that a transporter in general, LAT1 in particular, provides
considerable promise to improve the drug delivery into the CNS without increasing the
non-specific tissue binding into the brain. LAT1-targeting may enable the CNS delivery of
poorly BBB penetrable drugs. In addition, more selective brain delivery of a prodrug by
LAT1-targeting may decrease the peripheral side-effects of its parent drug. The parent
drugs selected for this study were valproic acid, kynurenic acid and dopamine.
The more specific aims were:
 To determine whether LAT1 prodrugs with modified, unnatural amino acids as
promoieties can bind to LAT1 with high affinity in order to compete with its
endogenous substrates.
 To optimize the release of the parent drug from the amide prodrugs of LAT1 in
order to prevent premature bioconversion in the systemic circulation while
maintaining optimal bioconversion to the parent drug in the brain parenchyma.
 To evaluate whether different LAT1-targeted promoieties can be used for both
anionic and cationic drugs.
 To determine whether hydrophilic prodrugs can be transported across the BBB via
LAT1. Before this study, the studied LAT1 prodrugs have possessed log D >0.
 To create a computer-aided predictive 3D pharmacophore model of LAT1 to
discover the structure-activity relationships between the substrate and the
transporter and to find novel promoieties to improve the brain penetration of poorly
permeable CNS drugs.
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4 General Experimental Procedures
4.1 STUDIED PARENT DRUGS, PRODRUGS AND OTHER COMPOUNDS
Valproic acid prodrugs
Valproic acid, a clinically used antiepileptic drug, was selected as one of the parent drugs in
the present thesis with the goal to improve its CNS delivery. The best recognized
pharmacological effects of valproic acid include its ability to increase the brain levels of -
aminobutyric acid (GABA), its ability to act as a GABA-mimetic on postsynaptic receptors
and its ability to reduce conductance of sodium and potassium ions (Bolaños and Medina
1997). Valproic acid causes rare but severe off-target peripheral side-effects (i.e.
teratogenicity and hepatotoxicity), and these could possibly be decreased by improving the
selectivity of its brain uptake. Valproic acid was also applicable for this study because of its
appropriate properties for prodrug derivatization, analytics and pharmacological studies.
According to the in situ rat brain perfusion studies valproic acid is not a substrate for LAT1,
but it is a substrate for MCT-transporters at the BBB, most likely for MCT1, and the brain
uptake of valproic acid is believed to be mainly MCT-mediated (Adkison and Shen 1996).
However, the efflux clearance of valproic acid from brain to plasma is much higher than the
influx clearance because valproic acid is also a substrate for efflux transporters at the BBB
(Kakee et al. 2002).
Valproic acid prodrugs 1–6 (Table 6) are phenylalanine derivatives and they were
designed to show the potential of meta-substituted phenylalanine to be a novel promoiety
for LAT1-mediated drug transport. The meta-substitution had been previously shown to
improve the LAT1 binding of melphalan analogues (Takada et al. 1992). However, this was
the  first  time  to  adopt  this  knowledge  to  prodrug  design  as  a  way  of  enhancing  brain
delivery of poorly brain penetrable drugs which do not structurally resemble LAT1
substrates. This was also the first time when unnatural amino acid promoieties were used
in order  to  increase  the  LAT1 affinity  of  the  prodrug.  Most  of  the  valproic  acid prodrugs
were amide derivatives (3–7), and this novel design concept was based on the previous
studies with lysine-ketoprofen in our laboratory (Gynther et al. 2010). The lysine ketoprofen
prodrug showed sufficient rate of bioconversion and release of the parent drug in the rat
brain without suffering significant premature degradation in the plasma (Gynther et  al.
2010). The valproic acid prodrugs were synthesized and 1–4 were reported in the
publication I as a part of the doctoral thesis of Kalle Malmioja, M.Sc. The syntheses of
prodrugs 5–7 have not been published yet. The prodrugs were characterized with
combustion analysis to be at least 95% of purity.
Kynurenic acid prodrugs
Kynurenic acid, a broad-spectrum non-selective glutamate receptor (NMDA) antagonist,
was also used as a CNS-targeted parent drug. Kynurenic acid has been shown in preclinical
studies to inhibit epileptic seizures in animal models (Németh et  al. 2004, Demeter et  al.
2012), to act as neuroprotective agent in Huntington’s disease models (Guidetti et al. 2000,
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Zádori et al. 2011), and to mitigate characteristic histochemical alterations in an
experimental migraine models (Knyihár-Csillik et al. 2007, Vámos et al. 2009). There were
two reasons to choose kynurenic acid as the second investigated parent drug. First,
kynurenic acid as such has been shown to reach the brain only at low levels (Leeson and
Iversen 1994). Second, kynurenic acid was believed to be released from the promoiety more
rapidly than valproic acid as its structure contains more electrophilic features. Thus, the
amide bond at 8 and 9 should be more susceptible for hydrolysis. Kynurenic acid prodrugs
8 and 9 (Table 6) were synthesized (not reported data) as a part of the doctoral thesis of
Kalle Malmioja, M.Sc. The prodrugs were characterized with combustion analysis to be of
at least 95% of purity.
Dopamine prodrugs
Dopamine  was  also  used  as  the  third  set  of  investigated  parent  compounds  in  the
present thesis. Levodopa, a prodrug of dopamine, is currently clinically used as a
dopamine precursor for patients with Parkinson’s disease. Dopamine was chosen as it is a
poorly brain penetrable cationic and hydrophilic compound, and thus it enlarged the
spectrum of the parent drugs used to cationic molecules. In addition, dopamine is largely
ionized in the bloodstream and it is not able to cross the BBB via passive diffusion. Thus,
dopamine  cannot  be  supplied  to  the  brain  as  such.  Before  this  study,  the  studied  LAT1
prodrugs have been relatively lipophilic (log D >0). Instead, the designed dopamine
prodrugs are very hydrophilic, and the impact of the hydrophilicity on the BBB permeation
via LAT1 can be determined. The design of prodrug 10 (Table  6)  was  based  on  previous
studies with meta-substituted phenylalanine as a potential carrier of LAT1-mediated
prodrug uptake to the brain. The design of prodrugs 11 and 12 (Table 6) was based on
previous studies with lysine derivative of ketoprofen (Gynther et al. 2010). In addition, the
promoieties of 11 and 12 were selected to study the influence of the length of the alkyl side
chain between the amino terminal and the parent drug on the extent of LAT1 binding.
Dopamine prodrugs 10–12 were synthesized and reported in the publication II as a part of
the doctoral thesis of Kalle Malmioja, M.Sc. The prodrugs were characterized with
combustion analysis to be of at least 95% of purity.
Other studied compounds
The 3D pharmacophore model generated in the present thesis was based on in situ data
from both purchased and synthesized compounds. All the purchased compounds were at
least 98% purity. The structures of the selected compounds for generating the 3D
pharmacophore of LAT1 are presented in Table 18 on page 95. L-tryptophan (14), L-
phenylalanine (15), 3-cyano-L-phenylalanine (16), 5-methoxy-DL-tryptophan (18), levodopa
(19), gabapentin (20), 5-hydroxy-L-tryptophan (22), -methyl-L-tyrosine  (23), DL-
phenylalanine (24), L-alanyl-L-tyrosine  (25), 2-amino-3-phenyl-1-propanol (27), saclofen
(28), sulfanilamide (30) and 2,6-diaminopimelic acid (32) were purchased from Sigma-
Aldrich  Co  (St.  Louis,  MO,  USA).  N-phenyl-L-glutamine (21), L-alanyl-L-tyrosyl-L-alanine
(29) and N--benzoyl-L-lysine (31)  were  purchased  from  Bachem  AG  (Bubendorf,
Switzerland). 2-Amino-5-methoxybenzoic acid (26) was purchased from Lancaster
Synthetic Inc. (Windham, NH, USA). The characterization and purity of the synthetic
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products, i.e. the ketoprofen prodrugs 13, 17 and 33–36, have been reported earlier (Gynther
et al. 2008 and Gynther et al. 2010).
Table 6. The chemical structures of the studied prodrugs 1–12. The parent drugs are circled.
Nro. Structure Nro. Structure
1
NH2
O
OH
O
O
7
2 8
3 9
4 10
5 11
6 12
4.2 ANALYTICAL METHODS
4.2.1 High-performance liquid chromatography (HPLC)
The amounts of the valproic acid prodrugs 1–6 in analytical and biological samples were
analyzed by the Agilent 1100 HPLC system (Agilent Technologies, Waldbronn, Germany)
that consisted of a binary pump G1312A, a vacuum degasser G1379A, an automated
injector system autosampler Hewlett-Packard 1050, UV-detector Hewlett-Packard 1050
variable wavelength detector and an analyst software Agilent ChemStation for LC Systems
Rev. A.10.02. A RP-HPLC C-8 column (Agilent Technologies, Wilmington, DE, USA) was
used with a Zorbax C-8 guard column (Agilent Technologies, Wilmington, DE, USA). The
UV-detector was set at 254 nm. Injection volume was 15 μL. The mobile phase consisted of
a mixture of acetonitrile (12%) and a 0.05 M phosphate buffer solution of pH 3.0 (88%)
having the flow rate at 1.1 mL/min.
 The  amounts  of  the  kynurenic  acid  prodrugs 8 and 9 and  kynurenic  acid  in  analytical
and biological samples were analyzed by the Agilent 1100 HPLC system described above.
As an exception, the kynurenic acid samples were detected by a fluorescence detector
(Agilent Technologies, Wilmington, DE, USA) at an excitation wavelength of 340 nm and
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an emission wavelength of 389 nm. The RP-HPLC column was Zorbax-Aq (100 × 2.1 mm,
3.5 μm) with a Zorbax-Aq guard column (Agilent Technologies, Wilmington, DE, USA).
The injection volume was 25 μL. The mobile phase consisted of a mixture of acetonitrile
(13%, v/v) and 50 mM sodium acetate, 100 mM zinc acetate (87%, v/v). The pH of the
mobile phase was adjusted to 5.9 with hydrochloric acid (2 M). The zinc acetate was not
added to the mobile phase when measuring the analytical samples because zinc ions may
precipitate in the instrument in the presence of phosphates. The column temperature was
maintained at +30 °C with mobile phase flowing at 1.5 mL/min.
 The amounts of the dopamine prodrugs 10–12 and dopamine in analytical and biological
samples were analyzed by the Agilent HPLC 1100 Series system (Agilent Technologies,
Wilmington, DE, USA) that consisted of a binary gradient pump G1312A, a vacuum
degasser G1322A, an autosampler G1313A, a thermostatically controlled column
compartment G1316A and ChemStation software (Rev. B.04.03; Agilent Technologies, Palo
Alto, CA, USA). The prodrugs and dopamine were detected by an electrochemical (EC)
detector  ESA  CouloChem  III  detector  (ESA  Inc.,  Chelmsford,  MA,  USA)  with  an
amperometric analytical cell model 5041 with a glassy carbon-ceramic target and 0.0005		
gasket. The applied potential was +150 mV and the range 20 nA. Injection volume was 2.5
μL for  analyzing dopamine and 5  μL for  the  prodrugs.  The analytes  were  separated on a
reversed phase column (Zorbax SB-Aq, 100 × 2.1 mm, 3.5 μm, AgilentTechnologies,
Wilmington, DE, USA) with a Zorbax-Aq guard column (AgilentTechnologies, Wilmington,
DE, USA) with isocratic elution. The mobile phase consisted of acetonitrile (20%, v/v) and
150 mM monobasic sodium phosphate containing 4.8 mM citric acid monohydrate, 3 mM 1-
octanesulfonic  acid  sodium  salt  and  50  μM  disodium  EDTA  (80%,  v/v).  The  pH  of  the
mobile phase was adjusted to 5.6 with sodium hydroxide (10 M). The column temperature
was maintained at +30 °C with mobile phase flowing at 0.3 mL/min.
4.2.2 Gas chromatography mass spectrometry (GC-MS)
The  amount  of  valproic  acid  in  analytical  and  biological  samples  was  analyzed  by  the
Agilent GC system (6890 N gas chromatography, 7683 ALS autosampler and 5973 mass
selective detector, Agilent Technologies, Palo Alto, CA, USA). The data were processed by
the Agilent Enhanced Chemstation software (version 2.00). A cross-linked 5% phenyl
methyl siloxane capillary column (HP-5MS; 30 m x 0.25 mm x 0.25 μm, Agilent
Technologies, Wilmington, DE, USA) was used with helium as the carrier gas (0.9 mL/min).
A volume of 0.05 μL of the sample was injected into the system (1 μL split injection, ratio
1:20). The temperature program was as follows: at +90 °C, followed by an increase of 2
°C/min to +100 °C, and the by 40 °C/min to +300 °C. Selected monitoring at m/z 201 for
silylated  valproic  acid  and  octanoid  acid  (internal  standard)  was  used  to  quantify  the
compounds.
4.2.3 Brain sample preparations
 The prodrugs 1–5 and valproic acid were separated from the brain tissue (a whole brain
hemisphere) by protein precipitation followed by liquid-liquid extraction and solid-phase
extraction (SPE). The thawed brain hemisphere was first homogenized in 2.5 mL of 20%
(v/v) methanol in water. For precipitating the proteins, the samples were then acidified
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with 200 µL  of  5  M  hydrochloric  acid  and  vortexed  for  5  min.  When  separating 1–5 and
valproic acid from the brain tissue, methanol in water (2 mL of 20% v/v) was added and the
homogenates were vortexed for 2 min. After standing for 10 min, the samples were
centrifuged for 10 min (7500g at +7 °C) after which the supernatants were collected. This
was repeated three times and the supernatants were combined. When separating 8 and
kynurenic  acid  from  the  brain  tissue,  the  solvent  added  was  water,  and  the  liquid-liquid
extraction was repeated twice. When separating prodrugs 10–11 from the brain tissue, the
homogenated brain hemisphere was first extracted with 1.5 mL of methanol, and the
homogenates were vortexed for 2 min. After standing for 10 min, the samples were
centrifuged for 10 min (14000 g at +7 °C) after which the supernatants were collected. The
supernatant was evaporated to 3 mL under a stream of nitrogen at +40 °C. The washing of
the pellet was repeated two times with water (1.5 mL) and the supernatants were
combined. Water was added to the combined supernatants to give a final volume of 8 mL
after which they were centrifuged (14000g at +7 °C). The supernatants of 1–11, valproic acid
and kynurenic acid were loaded into preconditioned and equilibrated C18 SPE-columns
(Supelco Discovery DSC-18 3 mL, Bellefonte, PA, USA). The columns were first washed
with 2 mL of 5% (v/v) methanol in water and then with 2 mL of water. Finally, prodrugs 1–
5 were  eluted  from  the  columns  three  times  with  3  mL  of  methanol,  the  prodrug 8 and
kynurenic acid two times with 0.75 mL of methanol, the prodrugs 10–11 two times with 0.5
mL of 80% (v/v) methanol in water, and valproic acid and octanoic acid with 0.5 mL of 50%
(v/v) acetonitrile/acetone containing 4% (v/v) ammonium hydroxide. The eluents were
evaporated to dryness under nitrogen stream at +40 °C. Prior to analysis, the prodrugs of
valproic acid and dopamine were reconstituted in 150 μL or 200 μL of 20% (v/v) acetonitrile
in water, and kynurenic acid and prodrug 8 were reconstituted in 150 μL of methanol. The
samples of valproic acid were diluted in 50 μL of pyridine and derivatized with 50 μL of
N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) + trimethylchlorosilane (TMCS) (Sigma,
St. Louis, MO, USA) for 30 min at +40 °C. The samples were analyzed by the analytical
methods described above. External standards were used for the brain samples except for
the valproic acid samples in which octanoic acid was used as an internal standard. The
prodrugs were shown to remain intact during the whole sample preparation procedure.
The calibration curves of the brain methods were linear over a range of 0.4–16 nmol/brain
hemisphere for 1–5, 0.4–5 nmol/brain hemisphere for 8, 0.015–10 nmol/brain hemisphere for
kynurenic acid, 0.2–16 nmol/brain hemisphere for valproic acid, 0.01–2.0 nmol/brain
hemisphere for 10 and 0.4–2.0 nmol/brain hemisphere for 11. The methods were also shown
to be specific, precise and repeatable (Table 7). The criteria for these assay validation
parameters were set according to the FDA guideline for bioanalytical method validation
(FDA 2001), i.e. RSD%s of the peak areas to determine precision and repeatability less than
20% and 15%, respectively.
 Dopamine levels in rat striatal samples were assayed by homogenizing the tissue in 0.1
M perchloric acid (1:10, w/v) with MSE Soniprep 150 ultrasonic disintegrator (MSE
Scientific Instruments, Crawley, UK). The homogenates were centrifuged for 15 min at
16000g at +4 °C. The supernatants were then filtered through 0.45 μm GHP Acrodisc
Syringe Filters (Pall Gelman Laboratory, Ann Arbor, MI, USA) and diluted (1:1) with 0.1 M
perchloric acid. Dopamine concentrations in tissue homogenates of both striata were
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determined by the HPLC method described above. External standards were used for the
striatal samples. The calibration curve of this method was linear over a range of 0.05–10.0
pmol/injection.
Table 7. Specificity, precision and repeatability of the methods to determine prodrugs 1–5, 8,
10 and 11 and valproic acid and kynurenic acid in rat brain samples
Specificitya Precision (RSD%)b Repeatability (RSD%)b
1 + 7.8 (0.5) 5.2 (8)
2 + 6.4 (0.5) 9.1 (8)
3 + 4.6 (0.5) 11.8 (8)
4 + 7.2 (0.5) 2.1 (8)
5 + 5.2 (0.5) 11.3 (2)
8 + 18.2 (0.5)c 5.6 (5)c
10 + 9.7 (0.05) 13.2 (1)
11 + 10.3 (0.4)c 9.9 (2)c
Valproic acid + 7.3 (0.4) 3.9 (8)
Kynurenic acid + 10.4 (0.015) 11.7 (1.6)c
a + = no interference peaks at the same retention time
b Concentration (nmol/brain hemisphere) presented in parentheses
c n=3
4.2.4 Plasma sample preparations
The prodrugs 3–5, 8–10, valproic acid and kynurenic acid were separated from the thawed
plasma samples simply by protein precipitation. First, the plasma samples (100 μL) were
acidified with 20 µL of  5  M hydrochloric  acid and vortexed for  2  min.  Methanol  (200  μL)
was added and the plasma samples were vortexed for 2 min. After standing for 10 min, the
samples were centrifuged for 5 min (16000g at +7 °C). The supernatants as such were
analyzed by the analytical methods described above except for the supernatants of valproic
acid samples,  which were  diluted with 1200 μL of  water,  and loaded into  preconditioned
and equilibrated C18 SPE-columns (Supelco Discovery DSC-18 1 mL, Bellefonte, PA, USA).
The column was first washed with 1 mL of 5% (v/v) methanol in water and then with 1 mL
of methanol to wash out the intact prodrug. Finally,  valproic acid and octanoic acid were
eluted from the columns two times with 0.5 mL of 50% (v/v) acetonitrile/acetone with 4%
(v/v) ammonium hydroxide and the eluents were evaporated to dryness under a nitrogen
stream at +40 °C. Prior to analysis, the samples were diluted in 50 μL of pyridine and
derivatized with 50 μL of BSTFA + TMCS (Sigma, St. Louis, MO, USA) for 30 min at +40 °C.
The samples were analyzed by the GC-MS method described above. The prodrugs were
shown to remain intact during the whole sample preparation procedure. External standards
were used for the plasma samples except for the valproic acid samples in which octanoic
acid was used as an internal standard. The calibration curves of the plasma methods were
linear over a range of 0.2–15 nmol/100 μL of plasma. The methods were also shown to be
specific, precise and repeatable (Table 8). The criteria for these assay validation parameters
were set according to the FDA guideline for bioanalytical method validation (FDA 2001),
i.e. RSD%s of the peak areas to determine precision and repeatability less than 20% and
15%, respectively.
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Table 8. Specificity, precision and repeatability of the methods to determine prodrugs 3, 4, 5,
8, 9 and 10 and valproic acid and kynurenic acid in rat plasma samples
Specificitya Precision (RSD%)b Repeatability (RSD%)b
3 + 14.1 (5) 3.7 (100)
4 + 10.1 (5) 7.9 (100)c
5 + 15.3 (10) 13.1 (100)c
8 + 3.0 (4)c 11.6 (100)c
9 + 2.4 (4)c 4.3 (100)c
10 + 11.3 (2) 2.7 (100)
Valproic acid + 7.8 (2)c 4.0 (100)
Kynurenic acid + 5.7 (2) 5.9 (50)c
a + = no interference peaks at the same retention time
b Concentration (μM) presented in parentheses
c n=3
4.3 PHYSICOCHEMICAL PROPERTIES AND IN VITRO STABILITY OF THE
PRODRUGS
4.3.1 Apparent distribution coefficients
Apparent  distribution  coefficients  (log  D)  of  the  prodrugs  and  their  parent  drugs  were
determined in mutually saturated 1-octanol–phosphate buffer solution at pH 7.4 at room
temperature (+21 °C). The studied compound was first dissolved in the phosphate buffer,
combined with 1-octanol, and the octanol–phosphate buffer mixture was shaken for 180
min to reach an equilibrium distribution. The concentration of the studied compound in the
phosphate phase before and after the shaking was analyzed by the analytical method
described above, and the log D value was calculated. The determination of the log D values
was conducted by Kalle  Malmioja,  M.Sc.,  as  a  part  of  his  doctoral  thesis  (the  data  is  only
partly reported in this dissertation).
4.3.2 Aqueous solubility
The aqueous solubilities of the prodrugs and their parent drugs were determined at room
temperature (+21 °C) in 0.16 M phosphate buffer at pH 7.4, in acetate buffer at pH 4.0 and in
hydrochloride buffer at pH 1.2. An excess amount a prodrug was added to 0.5 mL of buffer,
the mixtures were shaken for 2 h, filtered (0.45 μm, Millipore, Billerica, MA, USA) and
analyzed by the methods described above. The pH of the mixtures was checked during the
shaking, and adjusted if needed. The determination of the aqueous solubilities was
conducted by Kalle Malmioja, M.Sc., as a part of his doctoral thesis (the data is only partly
reported in this dissertation).
4.3.3 Polar surface areas
Topological polar surface areas (Å2) of 10–12,  dopamine and L-dopa were calculated with
MOE-2011.10 [Molecular Operating Environment (MOE), 2011.10; Chemical Computing
Group Inc., Montreal, QC, Canada] using group contributions to approximate the polar
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surface area only from connection table information. The parameterization was that of Ertl
et al. (2000).
4.3.4 Calculated pKa-values
The calculated pKa-values  of  valproic  acid and kynurenic  acid were  obtained by the  java-
based online application MarvinSketch (ChemAxon Ltd, Budabest, Hungary), which is
available in website https://www.chemaxon.com/marvin/sketch/index.php. The pKa-
calculator is based mainly on empirically calculated partial charges. Hydrogen bonds are
also parameterized and taken into account within the calculation.
4.3.5 In vitro stability studies
To demonstrate the chemical and enzymatic stabilities of the prodrugs and their parent
drugs under physiological conditions, and to demonstrate the bioconversion of the
prodrugs to their parent drugs, the compounds were exposed to degradation in various
media, including phosphate buffer (pH 7.4, 0.16 M, μ=0.5), 75% (v/v in isotonic phosphate
buffer of pH 7.4) rat plasma, 50% (v/v in isotonic phosphate buffer of pH 7.4) rat liver
homogenate and 20% (v/v in isotonic phosphate buffer pH 7.4) rat brain homogenate. Each
studied compound was incubated in a thermostatically controlled water bath at +37 °C, and
100 μL aliquots were withdrawn at regular time intervals. The withdrawn biological
samples were subjected to protein precipitation with 200 μL of acetonitrile or methanol.
After mixing, the samples were centrifuged for 10 min (16000 g at +7 °C). The samples from
the phosphate buffer were analyzed immediately without protein precipitation. The
analysis was performed to determine the amounts of both the intact prodrug and the parent
drug in the supernatant. The determination of the in vitro stability in the publications I and
II was conducted by Kalle Malmioja, M.Sc., as a part of his doctoral thesis.
4.4 ANIMALS
Adult male Wistar rats were obtained from the Laboratory Animal Centre Kuopio, Finland
(originally from Harlan, the Netherlands). At the beginning of the studies, the rats were 7–9
weeks old and weighed 200–250 g. Pelleted food (Teklad 2016S, Harlan Laboratories, Inc.,
Indiapolis, IN, USA) and tap water were supplied ad libitum, and the rats were housed in
artificially light- and temperature-controlled environment (12 hours light/dark cycle, +22 ± 1
°C). All procedures with the animals were performed according to the appropriate
European Community Guidelines and reviewed by the Animal Ethics Committee at the
University  of  Eastern  Finland,  and  approved  by  the  local  provincial  government  (license
numbers ESHL-2008-11150/Ym-23, ESHL-2009-06954/Ym-23 and ESAVI/6317/
04.10.03/2011). The animal welfare 3R principles (replacement, refinement and reduction)
were followed. The rats were anesthetized by ketamine (90 mg/kg, i.p.) (Intervet
International B.V., Boxmeer, Netherlands) and xylazine (8 mg/kg, i.p.) (Intervet
International B.V., Boxmeer, Netherlands). The post-operative analgesic was
buprenorphine (0.12 mg/kg, s.c.) (Reckitt Benckiser Healthcare Ltd, Hull, UK).
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4.5 IN SITU RAT BRAIN PERFUSION STUDIES
One of the most precise methods for evaluation of the brain uptake mechanisms of drugs
and their translocation across the BBB is the in situ rat brain perfusion method (Takasato et
al. 1984). The in situ method  has  advantages  over  the in vivo and in vitro methods which
have been utilized to estimate the BBB transport of molecules as discussed in Chapter 2.2.
The in situ rat brain perfusion technique is versatile and sensitive for studying brain uptake
and its mechanism especially when utilizing the transporters at the BBB as the perfusion is
directed only to the brain and the peripheral effects, e.g. metabolism, plasma protein
binding and clearance, can be avoided. In addition, the composition of the perfusion fluid
can be controlled, which enables the determination of saturable transport mechanisms. In
this thesis, the modified in situ rat brain perfusion technique (Smith and Allen 2003,
Gynther et al. 2008) was used to determine the transport mechanisms, LAT1 affinity and the
brain uptake of the studied compounds.
The rats were anesthetized and their body temperature was maintained at +37 °C during
the operation. After exposure of the right common carotid artery system, the right external
carotid artery was ligated, and the right common carotid artery was cannulated with a PE-
50 catheter containing 100 IE/mL heparin. The right occipital and the right pterygopalatine
arteries were left open. Before perfusion, the perfusion buffer (composition in mM: 128
NaCl, 24 NaHCO3, 4.2 KCl, 2.4 NaH2PO4 x H2O, 1.5 CaCl2 x 2H2O, 0.9 MgCl2 x 6 H2O and 9
D-glucose) was gassed to pH 7.4 with 95% O2/ 5% CO2 to attain blood steady state gas
levels. The perfusate was then filtered through 0.45 μm Millex-HV filter and warmed to +37
°C. Just immediately before the perfusion, the blood flow from the systemic circulation was
stopped by severing the cardiac ventricles to eliminate the contralateral blood flow
contribution. Hypoxic brain damage, while the common carotid artery was cannulated, was
prevented via the crossover of blood from the contralateral carotid artery at the circle of
Willis (Smith and Allen 2003). During the perfusion, the perfusion flow rate in the common
carotid artery was kept constant at 10 mL/min using a Harvard PHD 22/2000 syringe pump
(Harvard Apparatus Inc., Holliston, MA, USA). The flow of the perfusion fluid was
controlled so that the perfusion was conducted only to the right brain hemisphere to
prevent pressure harming the BBB. After 30–60 s of perfusion, the animal was decapitated,
the skull was opened and the right brain hemisphere was immediately deep-frozen or
excised into six different regions (frontal, parietal, occipital, hippocampus, thalamus and
striatum).  The  brain  samples  from  the  regions  (10–25  mg)  were  digested  in  0.5  mL  of
Solvable (PerkinElmer, Boston, MA, USA) for 3 hours at +50 °C, 1.5 mL of scintillation
cocktail (Ultima Gold, PerkinElmer, Boston, MA, USA) was added, and the radioactivity
was analyzed on a liquid scintillation spectrometer (Wallac 1450 MicroBeta; Wallac Ltd.,
Finland). The frozen samples were stored at -70 °C until sample preparation.
4.5.1 Validation of the in situ rat brain perfusion technique
The in situ rat  brain  technique was validated by determining the  intravascular  volume of
the rat brain capillaries (Vv)  using  0.2  μCi/mL  [14C]-sucrose  (PerkinElmer,  Boston,  MA,
USA) as a marker as well as by determining the cerebral perfusion flow rate (F) of 0.2
μCi/mL  [3H]-diazepam (PerkinElmer, Boston, MA, USA) and the brain capillary
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permeability-surface area (PA) product of 0.3 μCi/mL [14C]-urea (PerkinElmer, Boston, MA,
USA). PA of 0.2 μCi/mL [14C]-L-leucine was also determined to validate the technique. The
results of the validation studies were compared with the results reported previously
(Rousselle et al. 1998, Killian et al. 2007, Gynther et al. 2008) (Table 9). The sucrose perfusion
demonstrates  the  integrity  of  the  BBB capillaries  and tight  junctions  during the  perfusion
and represents the vascular volume of the rat brain. The diazepam perfusion represents the
maximum allowable passive transition of the solute from brain capillaries to the
parenchyma under the particular test conditions. These two validation results were used in
all the brain uptake calculations. The PA product of a relatively low penetrable, polar 0.3
μCi/mL [14C]-urea was also determined and found to be consistent with the values reported
earlier (Table 9). Finally, the PA product of 0.2 μCi/mL [14C]-L-leucine,  a  known
endogenous substrate of LAT1, was observed to be similar to the values reported earlier
(Table 9). This is the value of the 100% L-leucine BBB uptake which has been used as a
control in competition studies.
Table 9. The validation results for the in situ rat brain perfusion technique (mean ± SD)
Parameter
The present
results
(n=4)
Killian et al. 2007 Gynther et al. 2008 Rouselle et al. 1998
Vv
(μL/g)
14.9 ± 2.0 - 11.6 ± 1.3 ~ 8
F
(μL/s/g) 73.6 ± 11.9 51.9 ± 2.2 28.5 ± 4.0 60–80
Urea PA
product
(μL/s/g)
0.24 ± 0.05 0.34 ± 0.3 0.18 ± 0.06 ~ 0.1–0.2
L-leucine PA
product
(μL/s/g)
19.0 ± 3.6 51.8 ± 3.2 20.6 ± 3.2 -
Vv (μL/g) was calculated from equation 6.
)(
)(
)(
sucrosepf
sucrosetot
sucrosev C
q
V  (6)
where  qtot represents  [14C]-sucrose (PerkinElmer, Boston, MA, USA) amount in the brain
(μCi/g) after a short perfusion, and Cpf represents [14C]-sucrose concentration in the
perfusion fluid (μCi/μL). F (μL/s/g), which demonstrates the maximum allowable transition
of the solute from the capillaries to the parenchyma, was calculated from equation 7.
)(
)(
diazepampf
x
diazepamtot
CT
q
F  (7)
where qtot represents [3H]-diazepam (PerkinElmer, Boston, MA, USA) amount in the brain
(μCi/g)  after  the  perfusion,  Cpf represents [3H]-diazepam concentration in the perfusion
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fluid  (μCi/μL),  and  T  (s)  represents  the  perfusion  time  minus  the  delay  time  for  the
perfusate to reach the brain once the perfusion pump has been started. The PA products
(μL/s/g) were calculated using Crone-Renkin equation (Smith and Allen 2003) and
equations 6, 7, 8 and 9.
)(
)()()(
leucinepf
sucrosevleucinepfleucinetot
in TxC
xVCq
K

   (8)
)1ln(*
F
K
FPA in (9)
In equation 8, qtot represents the amount of the radio-labeled solute (e.g. [14C]-L-leucine)
in the rat brain (μCi/g) after a perfusion, Cpf represents the concentration of the radio-
labeled solute  in  the  perfusion fluid (μCi/μL),  Vv is  calculated from equation 6,  and T (s)
represents the perfusion time minus the delay time for the perfusate to reach the brain once
the perfusion pump has been started. In equation 9, F is calculated from equation 7, and Kin
is calculated from equation 8.
4.5.2 Determination of brain uptake mechanism
To  determine  the  ability  of  the  studied  compounds  to  bind  to  LAT1  using  the in situ rat
brain perfusion, 0.2 μCi/mL of [14C]-L-leucine  (i.e. 0.64 μM) was added into the perfusion
fluid consisting of various concentrations (typically 100 μM) of the studied compound. The
studied compound and L-leucine  were  added  to  the  perfusion  fluid  immediatedly  before
the perfusion was started. The PA product of [14C]-L-leucine was determined after a 30
second co-perfusion,  and the  LAT1 binding of  the  LAT1 substrates  was demonstrated by
the reduction in the PA product of [14C]-L-leucine caused by competitive binding of the
substrate to LAT1. The PA product of 0.2 μCi/mL [14C]-L-leucine after the co-perfusion with
the studied compound was compared with the 100% permeability-surface area of 0.2
μCi/mL [14C]-L-leucine without any competitive substrates. The 100% permeability-surface
area  product  of  [14C]-L-leucine has been determined to be 19.0 ± 3.6 μL/s/g after 30 s
perfusion of 0.2 μCi/mL [14C]-L-leucine solution (Table 9). Alternatively, a saturable LAT1
binding was revealed by the decrease in PA product of [14C]-L-leucine  caused  by  the
competitive binding of the substrate to LAT1 when using 0.5-700 μM concentrations of the
studied compound. The inhibition value (Ki) was determined in these competition studies,
and this value indicates the concentration where the substrate inhibits the brain uptake of
the  [14C]-L-leucine half of the maximum. In fact, of the two other influx amino acid
transporters expressed at the BBB, i.e. system y+ and system X- transporters, the transporters
of the system y+ also  take  leucine  into  the  brain.  Leucine  is  not  a  substrate  for  system  X-
transporters. However, the uptake of leucine via the system y+ transporters  is  inefficient
with a millimolar Km-value and it is sodium-dependent, whereas the transport of its
principal substrates, i.e. L-lysine, L-arginine and L-ornithine, is efficient, sodium
independent and they exhibit Km-values between 70 and 200 μM (Palacín et  al. 1998). In
general, the affinity of the neutral amino acids for LAT1 expressed at the BBB can be more
than 10-fold higher than that of the other amino acid transporters at the BBB (Hawkins et al.
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2006). For the reasons mentioned above, leucine has been widely used as a LAT1 specific
substrate  while  studying  the  role  of  LAT1  as  the  BBB  transport  mechanism  (Bonina et al.
1999, Killian and Chikhale 2001, Reichel et al. 2002, Killian et al. 2007, Gynther et al. 2010).
To  determine  whether  the  binding  of  the  valproic  acid  prodrugs 1–4 to  LAT1  is
reversible or irreversible, the PA product of [14C]-L-leucine was studied after perfusing the
rat brain first with 1–4 at a 100% inhibitory concentration of [14C]-L-leucine for 30 s,
followed  by  washing  the  prodrug  from  the  brain  capillaries  with  30  s  of  perfusion  of
prodrug-free perfusion medium and finally perfusing the brain with 0.2 μCi/mL [14C]-L-
leucine for 30 s. The theory is that if the endogenous substrate is taken into the brain in an
amount that is comparable to that of the first perfusion, then the binding of the prodrug is
reversible.
The brain uptake of the valproic acid prodrugs 1–5 and the  dopamine prodrugs 10–11
was also performed using the in situ rat  brain  perfusion technique.  To quantify  the  brain
uptake of the prodrugs, the rat brain vasculature was perfused for 60 s with +37 °C
perfusion medium containing 600 μM concentration of prodrugs 1–5 and  100  μM
concentration of 10–11. After the perfusion, the brain vasculature was washed with cold
prodrug-free perfusion medium (+5 °C) for 30 s to wash out the remaining prodrug from
the brain vasculature and to decrease the efflux activity of the transporters.
 In addition to the uptake studies of the prodrugs at +37 °C, the brain uptake was also
determined by inhibiting the carrier-mediated uptake non-specifically at lowered
temperature (+5 °C). In an attempt to delineate the role of the non-saturable transport
mechanism, the rat brain capillaries were first washed for 30 s with cold prodrug-free
perfusion medium (+5 °C) to decrease the activity of the transporters. In order to maintain
the low activity of LAT1, the 60 s perfusion with the prodrug was performed at +5 °C.
Finally, the brain hemisphere was washed with the cold prodrug-free perfusion medium
(+5 °C) for 30 s to wash out the remaining prodrug from the brain vasculature and to
maintain the reduced efflux-activity of the transporter. In the determination of whether
LAT1 possesses some activity during the cold perfusion even at +5 °C, the cold perfusion
study of 10 was also performed in the presence of an endogenous competitor, 2 mM L-
phenylalanine. A competition study with 2 mM L-phenylalanine was also conducted at +5
°C to clarify whether 10 was being taken up into the brain in a carrier-mediated manner.
The role of the other amino acid transporters in the brain uptake of the prodrugs 3 and 4
was also studied at 600 μM concentration for 60 s by using 1 mM concentration of the
substrates of those transporters as inhibitors. L-Lysine (Sigma, St. Louis, MO, USA) for the
transporters of system y+ and L-glutamic  acid  (Sigma,  St.  Louis,  MO,  USA)  for  the
transporters of system X- were used since these amino acids acid are not substrates of LAT1
(Hawkins et al. 2006).
4.6 IN VIVO BOLUS INJECTION STUDIES IN RATS
4.6.1 Intravenous injections
The brain uptake of the valproic acid and its prodrugs 3–5, kynurenic acid and its prodrug
8 and the dopamine prodrug 10 from  blood  to  the  brain  as  well  as  the  basic  plasma
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pharmacokinetics of these compounds were determined after intravenous bolus injection in
rats. The rats were anesthetized and their right jugular vein was exposed and cannulated
with a PE-50 catheter. The rats were treated with buprenorphine (0.12 mg/kg, i.p.) as an
analgesic for 24 h after the cannulation, and the rats were allowed to recover until the
following day. The studied compounds were administered into the cannulated jugular
vein. Valproic acid, the prodrugs 3–5 and 10 were administered as a 0.5 mL bolus injection
dissolved in 0.9% NaCl-solution and kynurenic acid and its prodrug 8 as 0.25 mL bolus
injection dissolved in 50% (v/v) DMSO in 0.9% NaCl solution. Plasma samples and whole
brain hemispheres were collected 2–360 min after the administration of the studied
compound. The collected samples were immediately frozen, and stored at -70 °C. Rat brain
and plasma levels of the samples were analyzed after the sample preparation by the
methods described in Chapter 4.5. The brain levels were corrected by the measured brain
sample concentration at the cerebral vascular space component, which was previously
determined to be 14.9 μL/g (Table 9). To study the efficacy of the dopamine prodrug 10, the
rats were pretreated with an intraperitoneal injection of carbidopa (30 mg/kg) (Orion
Pharma, Espoo, Finland) and entacapone (10 mg/kg) (Orion Pharma, Espoo, Finland) 30
min before the administration of 10 in  order  to  compare 10 to the standard L-dopa
treatment of Parkinson’s disease.
4.6.2 Intraperitoneal injections
The  ability  of  prodrug 10 and levodopa to release dopamine in the rat striatum after
intraperitoneal administration was investigated by treating the rats with 50.71 μmol/kg of
10 or levodopa. Before the intraperitoneal administration, the rats were allowed to adapt to
the handling and animal room environment for five days. The dopamine levels after the
intraperitoneal administration of 10 plus  carbidopa  and  entacapone  were  compared  to
those achieved after an equivalent intraperitoneal dose of L-dopa (free base) combined with
carbidopa and entacapone. Both L-dopa and prodrug 10 were administered as a suspension
containing a few drops of Tween 80 (Sigma-Aldrich Chemie GmbH, Steinheim, Germany)
in 0.9% NaCl solution. Carbidopa (30 mg/kg) and entacapone (10 mg/kg) were
administered intraperitoneally in the same formulation 30 min before the administration of
L-dopa or 10. The rats were sacrificed at 10, 30, 60 and 180 min after administration of L-
dopa or 10, and their dissected striata were frozen immediately in liquid nitrogen and
stored at -70 °C until sample preparation and HPLC-EC analyses.
4.7 MOLECULAR MODELING STUDIES
4.7.1 2D similarity search
In Chapter 8, 2D similarity searches were performed on ZINC2008 database (Irwin and
Shoichet  2005)  to  discover  previously  unreported  LAT1-binding  compounds  which  could
be applied in generating a 3D pharmacophore model. Compounds 1, 3 and 13 (Table 18 on
page 95) which possess a very high affinity for LAT1 (>90% L-leucine brain uptake
inhibition) were used as template molecules. The search was performed on subsets of
Sigma-Aldrich, Acros and Bachem compounds selected from the ZINC2008 database. The
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resulting hit molecules with a Tanimoto coefficient value of 60 were visually inspected, and
the most promising compounds were selected for further analysis. Only L-enantiomers of
the hit compounds were considered. The selected hit compounds (n=8) were further
compared with previously reported inactive prodrugs of ketoprofen (33–36) (0% L-leucine
uptake inhibition) (Gynther et  al. 2008) to exclude structures having properties similar to
the inactive compounds. Connolly surfaces for the compounds were calculated with Sybyl-
X  1.2  (Tripos  Intl,  St.  Louis,  MO,  USA)  and  their  shape  and  lipophilic  potential  were
compared to the ketoprofen prodrugs 33–36. Six amino acid derived structures 18, 21, 23,
25, 29 and 31 (Table 18 on page 95) were selected for the in situ rat brain perfusion tests to
analyze their  ability  to  bind to  LAT1.  The 2D search was conducted by Henna Ylikangas,
M.Sc., and reported in the publication III as a part of her doctoral thesis.
4.7.2 3D pharmacophore
The ligands for the 3D pharmacophore were preprocessed using the LigPrep package of
Schrodinger Suite 2010.6 (Schrödinger LLC, Portland, OR, USA). The tautomers and
stereoisomers were considered by generating different tautomers at pH 7±1 using Epik
(Schrödinger LLC, Portland, OR, USA) (Shelley et al. 2007). All chirality combinations were
generated  but  the  amount  of  molecular  structures  was  narrowed  down  by  selecting  only
stereoisomers of compounds with >50% L-leucine uptake inhibition, in which their terminal
amino acid function was in the S-configuration. S, R- and S, S-configurations for compounds
13 and 17 (Table 18 on page 95) were selected as they contain two chiral centers. Instead, all
chirality combinations of the inactive compounds 33–36 (0% L-leucine uptake inhibition)
were included. Partial atomic charge calculation and minimization of the molecular
structures in 500 steps was performed using OPLS_2005 force field (Jorgensen and Tirado-
Rives 1988). The pharmacophore model was generated using Phase 3.3 (Schrödinger LLC,
Portland, OR, USA) (Dixon et al. 2006a, Dixon et al. 2006b, Watts et al. 2010), which identifies
the common spatial arrangement of chemical features common to the active ligands. The
activity of each ligand was assigned manually as the natural logarithm of L-leucine uptake
inhibition percentage multiplied by two. Compounds with L-leucine uptake inhibition of
>50% (Table 18 on page 95) were assigned as active whereas compounds with L-leucine
uptake inhibition of 0% were considered to be inactive (Table 18 on page 95). Multiple
conformers were generated for the compounds using ConfGen method (Schrödinger LLC,
Portland, OR, USA) (Watts et  al. 2010) with 500 minimization steps. The ligands were
superimposed with each other and aligned with respect to alternative feature mappings.
The following features were selected for creating the pharmacophore sites: Hydrogen bond
acceptor (HBA), hydrogen bond donor (HBD), hydrophobic, negative charge, positive
charge and aromatic ring. Different alignments were scored and the resulting feature
mappings were ranked to identify the pharmacophore hypothesis which yields the best
alignment for the compounds with high affinity for LAT1 (>50% L-leucine uptake
inhibition). The resulting ensemble of pharmacophore hypotheses was ranked using the
default scoring procedures of Phase 3.3. After selecting the best pharmacophore, the
hypotheses were rescored with a special emphasis placed on the selectivity of the
pharmacophore weighing the selectivity score by 1. The resulting 4-point pharmacophore
with the best overall survival score (4.671) consisting of features HBA, HBD, negative
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charge and aromatic ring was selected for further analysis. The 3D pharmacophore was
created by Henna Ylikangas, M.Sc., and reported in the publication III as a part of her
doctoral thesis.
4.8 DATA ANALYSIS AND STATISTICS
The figures were created and all statistical analyses were performed using nonlinear
regression by GraphPad Prism 5.0 for Windows (GraphPad Software Inc., La Jolla, CA,
USA). Statistical significance of differences between various groups was analyzed using
one-way ANOVA followed by a two-tailed Dunnett’s test. The significance is reported as
***p < 0.001 or as *p < 0.05 for all tests. The pharmacokinetic data analysis after intravenous
administration was carried out by WinNonlin® Professional 5.3 (Pharsight Corparation, St.
Louis, MO, USA) by using non-compartmental model for the intravenous bolus injections,
and with 1/Yhat weighting.
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5 Meta-substituted Phenylalanine: A New Prodrug
Design Idea for Drug Delivery to the Brain via LAT1
Abstract. LAT1 transports amino acids and drugs mimicking amino acids across the BBB.
LAT1 has been shown to possess very high affinity for substrates substituted from the
meta-position of the aromatic ring in phenylalanine. In the present study, this information
was  for  the  first  time  exploited  in  the  design  of  LAT1  prodrugs  to  improve  the  brain
delivery of poorly brain penetrable drugs. Four phenylalanine derivatives of valproic acid
were designed and their ability to utilize LAT1 in CNS delivery was studied with an aim to
show that the meta-substituted phenylalanine prodrugs bind to LAT1 with higher affinity
than the para-substituted derivatives in the in situ rat  brain  perfusion.  All  the  prodrugs
crossed the rat BBB in a carrier-mediated manner via LAT1. For the first time, a novel meta-
substituted phenylalanine analogue promoiety was introduced, and it improved the LAT1
affinity by 10-fold, and more importantly, the rat brain uptake of the prodrug by 2-fold
compared with those of the para-substituted derivatives. Unnatural amino acid analogues
have not been studied previously as LAT1-targeted promoieties. Therefore, the results
indicate  that  a  new  prodrug  design  idea  for  CNS  drug  delivery  utilizing  transporter-
mediated prodrug approach has been generated.
Adapted  from:  Peura  L.†, Malmioja K.†, Laine K., Leppänen J., Gynther M., Isotalo A.,
Rautio J.:  Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: New prodrug
design ideas for central nervous system delivery. Molecular Pharmaceutics 8:1857–1866,
2011. © 2011 The American Chemical Society. All rights reserved.
† Authors equally contributed to this work.
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5.1 INTRODUCTION
One of the most significant challenges in pharmaceutical research is the development of
strategies to improve the CNS delivery of drugs, as discussed previously in this thesis.
Despite recent advances in brain research, adequate efficient drug therapies against many
CNS disorders such as Alzheimer's disease, Parkinson's disease and brain tumors have not
been discovered. A successful treatment of CNS diseases requires not only the
identification of appropriate targets within the CNS but also strategies to improve the
passage of therapeutics across the relatively insurmountable BBB into the CNS at sufficient
levels to achieve the desired effect. One strategy to improve the BBB permeation of drugs is
to utilize the specific carrier-mediated transport mechanisms present at the BBB. GluT1 and
LAT1 have been found to have a sufficiently high transport capacity to also hold promise
for significant drug delivery to the brain (Pavan and Dalpiaz 2011). As discussed in Chapter
2.3.6, LAT1-mediated prodrug design has been proven to be suitable for drugs structurally
resembling amino acids (e.g. 7-chlorokynurenic acid and dopamine) but importantly, LAT1-
mediated  prodrug  design  has  also  been  shown  to  be  suitable  for  drugs  having  other
chemical structures than amino acids.
The promoieties of the published prodrugs utilizing LAT1 have so far been natural
amino acids, i.e. tyrosine, lysine and cysteine. The present study developed further this
strategy to achieve carrier-mediated drug transport into the rat brain via LAT1 by
conjugating a model compound not only to L-phenylalanine but also to its analogues which
are not natural amino acids. It is known that the LAT1 binding of a phenylalanine analogue
substituted at the meta-position is a more potent transporter substrate than the analogue
substituted at the para-position (Takada et al. 1992). Thus, prodrugs substituted at the meta-
position of phenylalanine could possess high affinity for LAT1, which may be beneficial for
the prodrugs to compete with the endogenous amino acid in the circulation when being
translocated across the BBB via LAT1. Prior to this study, aromatic amino acid analogues
have not been utilized as prodrug promoieties in drug delivery to the brain. To show the
potential of the aromatic amino acid analogues as carriers for improving the brain uptake of
drugs via LAT1, both ester (1 and 2) and amide (3 and 4) prodrugs of valproic acid (Figure
14) were synthesized and evaluated. Their mechanism of BBB transport and the amount of
1–4 transported into the brain were investigated by using the sophisticated in situ rat brain
perfusion technique (Takasato et al. 1984; Smith and Allen 2003; Gynther et al. 2008). Both
ester and amide analogues were studied to optimize the release of valproic acid from the
promoiety within the brain. The purpose of the present study was to show that meta-
substituted phenylalanine prodrugs are more potent LAT1 substrates than those
substituted at para-position of phenylalanine using valproic acid as a model drug.
Figure 14. Chemical structures of the valproic acid prodrugs 1–4.
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5.2 RESULTS AND DISCUSSION
5.2.1 In vitro stability studies of the valproic acid prodrugs
The stability of the prodrugs 1–4 in aqueous buffer (pH 7.4) and their bioconversion to
valproic acid were determined in 20% rat brain homogenate, 50% rat liver homogenate as
well as in 75% human plasma (Table 10). All the four prodrugs demonstrated adequate
chemical stability in aqueous solutions for further evaluation. The ester derivatives 1 and 2
hydrolyzed rapidly to valproic acid in the tissue homogenates and in plasma. On the other
hand, the enzymatic bioconversion studies of the amides 3 and 4 in both the brain and the
liver homogenates and in plasma resulted in only very slight degradation of the prodrugs
in vitro. Therefore, the half-lives of 3 and 4 remain unidentified. Although the
biodegradation of 3 and 4 was determined to be quite slow, it is reasonable to determine
their transporter binding mechanism and the brain uptake. In some earlier cases, amide
prodrugs have been reported to release the active drug only in vivo (Song et  al. 2002,
Gynther et al. 2010). In fact, the slow release of an active drug in the CNS might provide
sustained therapeutic effect for a prodrug (Elia et al. 2007). In addition, a prodrug designed
to release the parent drug in a desired tissue should stay intact in the systemic circulation
before reaching the tissue.
Table 10. Degradation rates of the prodrugs 1–4 in phosphate buffer (pH 7.4), in rat brain and
liver homogenates and in human plasma (+37 °C) (t1/2 , mean, n=2)
Prodrug
Buffer (pH 7.4)
(degraded in 3
weeks)
20% Rat brain
homogenate
t1/2 (min)
50% Rat liver
homogenate
t1/2 (min)
75% Human
plasma
t1/2 (min)
1 < 20% 75 1.00 708
2 < 15% 86 1.38 696
3 0% < 4%a < 7%a 0%a
4 0% < 6%a < 10%a < 3%a
a degraded in 24 hours
5.2.2 Transporter-mediated brain uptake of the valproic acid prodrugs
To identify the BBB uptake mechanism and the structure-activity relationships between
LAT1 and the prodrugs 1–4, the in  situ perfusion technique described above was used.
LAT1 is one of the most interesting transporters for improving the CNS delivery of small
drugs by the prodrug approach because it is expressed to a greater extent at the BBB than at
the  other  tissues,  and  the  binding  affinities  for  LAT1  at  the  cerebrovasculature  can  be  as
much as 1000-fold higher than those for other LAT-members at the peripheral cells
(Pardridge 1983, Pavan et  al. 2008). Moreover, LAT1 has a relatively broad substrate
specificity that is useful for prodrug design (Ohtsuki and Terasaki 2007, Pavan and Dalpiaz
2011). The other two amino acid transporters at the BBB ferrying amino acids into the brain
are transporters of system y+ (CAT1) and X- (EAAT1–3) (Hawkins et al. 2006), and prodrugs
mimicking amino acids can also have affinity for those transporters. Thus, the role of these
other transporters has to be ruled out while studying LAT1-mediated brain uptake of a
drug.
Strong inhibition of the PA product of [14C]-L-leucine was found when perfusing 0.2
μCi/mL  [14C]-L-leucine in the presence of the prodrug 1, 2, 3, or 4 (Figure  15).  All  of  the
prodrugs  were  able  to  inhibit  the  brain  uptake  of  [14C]-L-leucine in a concentration
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dependent and saturable manner indicating that the prodrugs were able to bind to the
LAT1 at the BBB. In addition to LAT1 binding, there were substantial differences between
Ki-values of the prodrugs 1–4, which were 2.7, 32.4, 3.2 and 34.1 μM (mean, n = 2),
respectively (Figure 15). This observation illustrates clearly that the region selective
positioning of valproate in the L-phenylalanine structure significantly affects the binding of
a prodrug to LAT1. There were no significant differences between the affinities for LAT1
whether  valproic  acid  was  linked  to  the  promoiety  by  amide  or  ester  bond.  However,  a
clearly significant difference between the affinities of the prodrugs for LAT1 was observed
when valproic acid was linked to the para- or meta-position of the phenylalanine
promoiety. The affinities of 1 and 3 are more than 10-fold higher compared with those of 2
and 4. The results confirm the LAT1 substrate binding properties reported by Takada et al.
(1992) who have shown that meta-isomer of melphalan is taken up more efficiently into the
rat brain than its para-isomer in the in situ rat brain perfusion studies. These results confirm
that the earlier findings of Takada et al. could also be exploited in this prodrug approach to
improve the brain uptake of polar and hydrophilic compounds. Because the prodrugs were
racemic mixtures, and LAT1 prefers L-isomers (Smith 2000), the affinity of the prodrugs
having a pure L-amino acid promoiety will be even stronger.
The  reversibility  of  the  binding  of  the  prodrugs  to  rat  LAT1  was  also  examined  to
confirm that the prodrugs 1–4 do not inhibit the LAT1-mediated transport as irreversible
inhibitors. The reversibility studies were organized by determining the PA product of [14C]-
L-leucine after perfusing the rat brain first with a prodrug at 93 μM (1 and 3) or 400 μM (2
and 4)  concentration for 30 s,  followed by washing the prodrug from the brain capillaries
with 30 s perfusion of prodrug-free perfusion medium, and finally perfusing the rat brain
with 0.2 μCi/mL [14C]-L-leucine for 30 s. The rat brain PA product of the [14C]-L-leucine after
the prodrug perfusion and wash resulted in 80–90% of the original PA product of the
control demonstrating that the binding of the prodrugs was reversible (Figure 16). The
reversibility is an essential requirement, obviously, for the brain uptake of prodrugs via
specific transporters.
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Figure 15. Inhibition of 0.2 Ci/mL [14C]-L-leucine uptake across the BBB by valproate prodrugs
1–4. The Ki-values are 2.7, 32.4, 3.2 and 34.1 M (mean, n = 2), respectively.
Figure 16. Reversibility  of  the  LAT1  binding  of  the  prodrugs 1–4.  The  brain  uptake  of  0.2
μCi/mL [14C]-L-leucine was inhibited in presence of the prodrugs at 93 μM (1 and 3) or 400 M
(2 and 4) to 5–20% of the 0.2 μCi/mL [14C]-L-leucine (n=3–4). When the brain vasculature was
washed after perfusing the vasculature with the prodrug, the uptake of leucine was not inhibited
more than 10%. 200 μM phenylalanine (Phe) was used as a positive control. The reversibility of
the binding of phenylalanine to LAT1 was similar to that of the prodrugs. An asterisk denotes a
statistically significant difference from the respective control (***P < 0.01, one-way ANOVA,
followed by Dunnett t-test).
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5.2.3 Brain uptake studies of the valproic acid prodrugs
The total amounts of the translocated prodrugs 1–4 in  the  brain  after  the in situ rat brain
perfusion were studied to confirm that the prodrugs 1–4 not only bind to LAT1 but are also
translocated across the BBB into the brain tissue. The translocation of a substrate across the
BBB into the brain does not necessarily occur even if the substrate binds very tightly to the
transporter (Krupka 1990). As illustrated in Figure 17, the valproate prodrugs 1–4 are able
to cross the rat BBB and gain entry into the brain tissue. The amides (3 and 4) were shown
to be translocated across the rat BBB more efficiently than the esters. However, the
difference between these two groups of compounds may be due to the exposure of the
esters  to  the  degrading  enzymes  at  the  BBB  during  the  perfusion.  This  result  provides
encouragement to perform more comprehensive in vivo brain uptake studies for the amide
prodrugs. The improvement in the brain uptake of meta- compared to para-substituted
phenylalanine derivatives is also clearly shown in Figure 17. The PA product of prodrug 3
at 600 μM is almost 29 pmol/mg/min, which is more than 2-fold higher than that of prodrug
4. Thus, 3 both  binds  to  LAT1  and  is  translocated  across  the  BBB  significantly  more
efficiently than 4. The difference between the rate of the brain uptake of 3 and 4 is not as
great as one would expect according to their binding affinities as 3 possesses 10-fold higher
affinity for LAT1 compared to that of 4 and the brain uptake of 3 is only 2-fold greater than
that of 4. The reason for the lower than expected uptake capacity of the prodrug 3 may be
steric restrictions. In other words, the prodrug 3 may bind to LAT1 so tightly that it  does
not leave the transporter relatively as easily as prodrug 4.
Figure 17. The in situ rat brain uptake of 1–4. The brain uptakes of the ester prodrugs 1 and 2
at concentration 600 μM are 4.7 ± 0.5 and 3.1 ± 0.2 pmol/mg/min (mean ± SD, n=3),
respectively. The uptakes of the amide prodrugs 3 and 4 at concentration 600 μM are 28.9 ±
1.3  and  12.2  ±  2.0  pmol/mg/min  (mean  ±  SD,  n=3),  respectively.  An  asterisk  denotes  a
statistically significant difference from the respective control (***P < 0.01, one-way ANOVA,
followed by Dunnett t-test). Column 600 M 1 was used as a control in Dunnett t-test. There is
also  ***  significant  difference  if  column  600  μM 4 is  used  as  a  control  in  Dunnett  t-test  for
column 600 μM 3.
The role of the other influx amino acid transporters at the BBB (i.e. system y+ and X-) in
the brain uptake of the prodrugs 3 and 4 was studied by perfusing the rat brain with 3 and
4 at 600 μM concentration for 60 s with 1 mM L-lysine (a substrate of the system y+) and L-
glutamic acid (a substrate of the system X-) as competitors for the other amino acid
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transporters. There were no statistically significant differences in the translocations of the
prodrugs across the BBB while co-perfused with the substrates of the other amino acid
transporters at the BBB. Therefore, the role of the other influx amino acid transporters at the
BBB  in  the  brain  uptake  of  these  prodrugs  was  ruled  out.  Hence,  in  addition  to  the
concentration dependent inhibition of the brain uptake of L-leucine (Figure 15), this is
another clear confirmation that it is LAT1 which ferries these prodrugs across the BBB.
The role of LAT1 in the rat brain uptake of 3 and 4 at a 50 μM concentration was also
confirmed by using cold perfusion (+5 °C). The lower temperature decreased the brain
uptake of the prodrugs from about 1 pmol/mg/min (4) and 2 pmol/mg/min (3) to
concentrations either below or near to the limit of detection (Figure 18). This is clear
evidence  of  the  carrier-mediated  passage  of  the  prodrugs  across  the  BBB.  In  previous
studies, a lower perfusion medium temperature did not have any effect on the passive
diffusion of [3H]-diazepam across the BBB (Gynther et al. 2008).
Figure 18. Rat brain uptake of the prodrugs 3 and 4 during cold perfusion. Perfusion medium at
+5  °C  decreased  significantly  the  uptake  of  50  μM 3 and 4 from 2.0 ± 0.1 and 0.9 ± 0.03
pmol/mg/min  to  almost  zero  (mean  ±  SD,  n  =  3),  respectively.  An  asterisk  denotes  a
statistically significant difference from the respective control (***P < 0.01, one-way ANOVA,
followed by Dunnett t-test). Columns 50 M 3 and 50 M 4 were used as controls in Dunnett t-
test.  The  cold  perfusion  was  not  performed  for  the  ester  prodrugs  because  of  their  high
exposure for enzymatic degradation.
In summary, these results show that both para- and especially meta-substituted
phenylalanine derivatives can be efficient promoieties for improving the brain uptake of
drugs  that  cannot  cross  the  BBB  passively.  The  valproate  prodrugs  conjugated  with  the
phenylalanine derivative were taken up into the rat brain carrier-mediatedly, rapidly and
in significant amounts via LAT1.
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5.3 CONCLUSIONS
The present study demonstrated that the phenylalanine derivative prodrugs 1–4 of valproic
acid have affinity for LAT1 at the rat BBB, their binding to LAT1 is reversible, and they are
translocated across the BBB into the brain parenchyma in a carrier-mediated manner. In
addition, the role of the other influx amino acid transporters at the BBB in the brain uptake
of the LAT1 prodrugs was ruled out. Consequently, the prodrugs 1–4 satisfy the
requirements of LAT1-targeted prodrugs. The ester derivatives are able to release the active
drug in the brain in vitro. The amide derivatives were relatively stable in the in vitro studies.
The most important finding of the study is the identification of a new potential
promoiety for drug delivery to the brain. This is the first time that amino acid derivatives,
different from natural amino acids, have been investigated as promoieties in the LAT1-
mediated prodrug approach. Moreover, phenylalanine derivative substituted in the meta-
position is bound to LAT1 and translocated across the BBB significantly more efficiently
than the corresponding para-substitued analogue. Thus, phenylalanine derivatives
substituted  in  the  meta-position  could  be  highly  usable  in  prodrug  design  for  the  LAT1-
mediated CNS delivery of small molecular weight drugs with poor brain penetration
properties.
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6 In Vivo Characterization of Promoieties for Improving
the Release Properties of LAT1-targeted Amino Acid
Amide Prodrugs*
Abstract. Systemically administered tissue-targeted prodrugs should stay sufficiently intact
in the systemic circulation but they should achieve the release of an active drug within the
targeted tissue. In the present study, LAT1-targeted amide prodrugs of valproic acid were
synthesized, their ability to release valproic acid was studied in vitro, and their ability to
bind  to  LAT1  was  studied  with  the in situ rat brain perfusion technique. In addition, the
most promising prodrugs were studied in vivo in  rats  after  intravenous bolus  injection to
determine their brain uptake and ability to release the parent drug in the rat plasma and
brain. The results demonstrated that after intravenous administration the brain uptake of
the prodrugs with meta-substituted phenylalanine as a promoiety is almost 1.6–1.9-fold
greater than that of their para-substituted counterpart. However, all of the valproic acid
prodrugs were too stable both in in vitro and in vivo studies, and therefore the parent drug
was changed to kynurenic acid to examine whether the release rate of the valproic acid
prodrugs would be dependent on the properties of the parent drug. The ability of the
kynurenic acid prodrugs to release the parent drug was studied in vitro, and their ability to
bind to LAT1 was evaluated with the in situ rat  brain  perfusion  technique.  Finally,  their
ability to release kynurenic acid was investigated in vivo in rats after intravenous bolus
injection. The amide prodrug of kynurenic acid attached to the meta-substituted
phenylalanine showed high affinity for LAT1 in the in situ studies. However, it was not
able  to  cross  the  BBB in vivo in as high concentration as the corresponding valproic acid
analogues, and the release of kynurenic acid was not detected in either rat plasma or brain.
The results of the present study indicate that the attachment of phenylalanine to the parent
drug via an amide bond from the meta-position of its aromatic ring increases the brain
uptake  of  the  prodrugs  by  LAT1 in vivo where  the  LAT1  prodrugs  compete  with  the
endogenous amino acids for their brain uptake. However, more effort needs to be done to
optimize the release of the active model drug from the promoiety.
* Unpublished results
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6.1 INTRODUCTION
LAT1, which is a transmembrane protein highly expressed specifically at the BBB, has a
principal  role  in  transporting  large,  branched  and  neutral  amino  acids  from  the  systemic
circulation to the brain (Hawkins 2006). LAT1 has been utilized to enhance the brain uptake
of poorly brain penetrable drugs via prodrug technology by conjugating natural amino
acids to a drug (Rautio et al. 2008). However, this approach has been criticized as LAT1 has
been assumed to be saturated under physiological circumstances by its endogenous
substrates (del Amo et al. 2008). In this thesis, high-affinity promoieties have been designed
in order  to  enhance the  brain  uptake of  LAT1 prodrugs in  the  presence  of  the  competing
LAT1 substrates. As shown in Chapter 5, meta-substituted phenylalanine holds promises as
a high-affinity LAT1 promoiety, and the prodrugs attached to that promoiety could be able
to compete with the endogenous LAT1 substrates in brain uptake via LAT1.
In addition to the enhanced uptake to the desired tissue, the optimization of the
bioconversion of a tissue-targeted prodrug to the parent drug is also a great challenge.
Ideally, a systemically administered prodrug which has its site of action in a peripheral
tissue should remain sufficiently intact in the systemic circulation and achieve a site-
specific release of the parent drug within the desired tissue (Kearney 1996). This
requirement for the optimum stability of a prodrug in the systemic circulation needs also to
be considered when designing LAT1-targeted prodrugs. In general, the most commonly
used derivatives in prodrug approaches are esters (Ettmayer et al. 2004). The ester prodrugs
are mostly converted to the parent drugs by esterases which are expressed in almost all
body compartments and tissues, e.g. gastro-intestinal  tract,  blood,  liver,  kidney  and  brain
(Liederer and Borchardt 2006). Thus, ester prodrugs are suitable for enhancing the oral
bioavailability of drugs when rapid conversion to the parent drug after absorption is
required. However, the ester bonds have been considered as being too unstable in the
systemic  circulation  as  they  are  usually  subjected  to  rapid  premature  degradation  by  the
esterases in the bloodstream and liver before reaching their desired site of action. Instead,
amide derivatives, which are hydrolyzed mostly by esterases and amidases, have been
considered as more stable in plasma and liver (Simplício et al. 2008, Mahato et al. 2011), and
amide derivation has been shown recently to hold promise as a valuable alternative for
esterification to achieve the stability in the prodrugs in the systemic circulation (e.g. Gong et
al. 2004, Elia et al. 2007, Bender et al. 2009, Gynther et al. 2010).
The  aim  of  the  present  study  was  to  determine  the  brain  uptake  of  the  previously
published amide prodrugs of valproic acid (3 and 4) (Figure 19) in rats after an intravenous
bolus injection and to evaluate their ability to release valproic acid after the intravenous
bolus injection in rat systemic circulation and in rat brain. In addition to 3 and 4, three other
novel amide prodrugs of valproic acid, 5–7 (Figure  19),  were  designed  to  optimize  the
release properties of amide promoieties of LAT1. These three prodrugs were synthesized,
and their abilities to bind to LAT1 were studied with the in situ rat brain perfusion
technique. Their brain uptake and ability to release valproic acid was evaluated in rat
plasma  and  brain  after  intravenous  bolus  injection.  Kynurenic  acid  was  also  used  as  an
alternative parent drug in this study, and two amide prodrugs of kynurenic acid (8 and 9)
(Figure 19) were prepared to allow a comparison between the releasing properties of these
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two parent drugs. The ability of the kynurenic acid prodrugs to release the parent drug was
studied in vitro in  aqueous solution (pH 7.4),  in  rat  plasma and in  the  rat  brain  and liver
homogenates,  and  their  ability  to  bind  to  LAT1  was  studied  with  the in situ rat brain
perfusion technique. Finally, the ability of 8 to cross the BBB and to release kynurenic acid
was studied in vivo after an intravenous bolus injection. The brain uptake of the prodrugs
and the concentrations of the released parent drugs were compared to the brain uptake of
the parent drug after intravenous bolus injection with an equivalent dose.
Figure 19. Chemical structures of the prodrugs 3–9.
6.2 RESULTS AND DISCUSSION
6.2.1 In vitro stability studies
The stability of the valproic acid prodrugs 5 and the  kynurenic  acid prodrugs 8 and 9 in
aqueous  buffer  (pH  7.4)  and  their  enzymatic  bioconversion  to  valproic  acid  or  kynurenic
acid, respectively, were determined in 20% rat brain homogenate, 50% rat liver homogenate
as well as in 75% human plasma (Table 11). The in vitro studies of the valproic acid
prodrugs 3 and 4 had been previously conducted (see Chapter 5.2.1). Prodrugs 5–9 were
designed with the aim to enhance the release of the parent drug from the amide prodrugs
as 3 and 4 were shown to be too stable. The valproic acid prodrugs 5 and 7 were anticipated
to release valproic acid more easily compared to 3 and 4 because the structure of those
prodrugs  is  more  flexible.  By  increasing  the  flexibility  of  the  structure  around  the  amide
bond, the possible steric restrictions for amide hydrolysis caused by the phenylalanine
promoiety could to be studied. Although the valproic acid prodrug 6 includes an additional
methoxyl group at the para-position of the aromatic ring of phenylalanine, which is likely
to influence negatively on its susceptibility towards hydrolysis, it was examined to evaluate
whether the additional substituent in the aromatic ring would have any influence on LAT1
binding. Kynurenic acid itself includes electrophilic atoms, and thus the calculated pKa-
value of its carboxylic acid is 0.96. In comparison, the corresponding pKa-value of the
carboxylic acid of valproic acid is 5.14.  Thus, the amide bonds at the kynurenic acid
derivatives were expected to be chemically more unstable than those at the valproic acid
prodrugs, and prodrugs 8 and 9 were expected to release of the parent drug more easily
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than the corresponding valproic acid prodrugs 3 and 4. Prodrugs 5, 8 and 9 demonstrated
adequate chemical stability in aqueous solutions to encourage further in situ or in vivo
evaluation. However, the enzymatic degradation of the studied prodrugs in the biological
samples resulted in only slight or non-existent degradation of the prodrugs in vitro. No in
vitro stability studies of prodrug 7 were  conducted as  it  did not  exhibit  affinity  for  LAT1
(see Chapter 6.2.2).
Table 11. Degradation rates of the prodrugs 5, 6, 8 and 9 in phosphate buffer (pH 7.4), in rat
brain and liver homogenates and in human plasma (+37 °C) (t1/2 , mean, n=2–3)
Prodrug
Buffer (pH 7.4)
(degraded in 3
weeks)
20% Rat brain
homogenate
(degraded in 24
hours)
50% Rat liver
homogenate
(degraded in 24
hours)
75% Human
plasma
(degraded in 24
hours)
5 0% < 6% < 7% 0%
6 n.a.a n.a.a 0% n.a.a
8 0% 0% 0% 0%
9 0% 0% 0% 0%
a not analyzed
Despite the slight in vitro biodegradation of the prodrugs, it was decided to determine
their LAT1 binding and brain uptake as well as their ability to release the parent drug in
vivo, as amide prodrugs have been previously shown to release the active drug in a living
animal even though the in vitro degradation had not been demonstrated (Song et al. 2002,
Gynther et al. 2010). In general, the amide prodrug design has been recently applied
successfully to optimize the stability of prodrugs in the systemic circulation. For example,
the bioavailability of gemcitabine has been enhanced by using valproic acid as a promoiety
(Bender et al. 2009). The gemcitabine prodrug has been shown to be cleaved by human
carboxylesterase 2 (CES2) (Pratt et  al. 2013a), and it has displayed significant antitumor
activity in human colon and lung tumor xenograft models in mice (Pratt et al. 2013b), and it
has been demonstrated to be well tolerated in phase I clinical studies (Koolen et al. 2011).
There are other successful examples of the recent amide prodrugs for improving the drug
delivery to the brain, e.g. the LAT1 prodrug lysine-ketoprofen (Gynther et al. 2010) and the
tacrine prodrug, 9-[P-(N,N-dipropylsulfamide)] benzoylamino-1,2,3,4-4H-acridine (Gong et
al. 2004). In addition, an example of a recent amide prodrug in clinical use is
lisdextroamphetamine (Vyvanse, New River Pharmaceuticals/Shire) (Elia et al. 2007).
Vyvanse has been designed to have less abuse potential than other amphetamines because
amphetamine is released from the prodrug in a sustained manner and the plasma levels of
amphetamine remain that low that the euphoric effects of amphetamine are not achieved
easily.
6.2.2  Affinity  of  the  valproic  acid  and  kynurenic  acid  prodrugs  for  LAT1  in in situ rat
brain perfusion
A substantial decrease in the permeability-surface area (PA) product of [14C]-L-leucine was
detected when perfusing 0.2 μCi/mL [14C]-L-leucine (i.e. 0.64 μM) in the presence of 100 μM
valproic acid prodrug 5 (Figure 20). The PA product of [14C]-L-leucine was inhibited by 92 ±
2% (mean ± SD, n=3) when the rat brain was co-perfused with L-leucine and 5. This
inhibition of the L-leucine brain uptake was similar to that seen with the valproic acid
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prodrug 3, i.e. 93 ± 2% (mean ± SD, n=3). Therefore, the modification in the prodrug
structure  in  the  vicinity  of  the  amide bond did not  have any effect  on the  LAT1 binding.
The high LAT1 affinity of the meta-substituted phenylalanine was also confirmed with the
kynurenic acid prodrug 8, as it inhibited the brain uptake of L-leucine by 85 ± 4% (mean ±
SD, n=3) (Figure 20). Thus, the additional rigidity in the structure of LAT1 substrate
structure  did  not  seem  to  have  any  dramatic  influence  on  LAT1  binding.  In  contrast,  the
valproic acid prodrugs 6 and 7 and  the  kynurenic  acid  prodrug 9 did  not  possess  high
affinity for LAT1 (Figure 20). 6 was able to inhibit the brain uptake of L-leucine by 33 ± 6%,
7 by 2.6 ± 3% and 9 by 25 ± 3% (mean ± SD, n=3), respectively.
Figure 20. LAT1 binding data of 100 μM prodrugs 3–9. The PA product of 0.2 μCi/mL [14C]-L-
leucine, 19.0 ± 3.6 μL/s/g, was inhibited by 93 ± 2% in the presence of 3, by 64 ± 4% in the
presence of 4, by 92 ± 2% in the presence of 5, by 33 ± 6% in the presence of 6, by 2.6 ± 3%
in the presence of 7, by 85 ± 4% in the presence of 8 and by 25 ± 3% in the presence of 9
(means  ±  SD,  n=3–5).  The  asterisks  denote  a  statistically  significant  difference  from  the
respective control (***P < 0.001 and **P < 0.01, one-way ANOVA, followed by Dunnett t-test).
The in situ binding studies confirmed the earlier finding that phenylalanine substituted
in the meta-position of its aromatic ring is a highly potent LAT1 promoiety. However,
binding  of  the  prodrugs  to  LAT1  was  shown  to  be  dependent  on  the  parent  drug  as  the
valproic acid derivatives 3 and 4 exhibited more efficient LAT1 binding than the
corresponding  derivatives  of  kynurenic  acid  (8 and 9). This indicates that the prodrug
structures of 8 and 9 have structural features that are probably unfavorable for fitting well
into the binding pocket of LAT1. The kynurenic acid prodrugs are structurally more rigid
which may weaken their possibility to bind to LAT1. However, in order to compare their
ability  to  release  the  parent  drug,  structurally  similar  prodrugs of  valproic  acid (3 and 4)
and kynurenic acid (8 and 9) were chosen for further in vivo analyses. In addition, the novel
valproic acid prodrug 5 was selected for further in vivo analyses to determine whether it
had an improved ability to release valproic acid compared to 3. The affinity of the valproic
acid prodrug 6 was significantly lower than that of 3 indicating that the additional
methoxyl group in the aromatic ring of the promoiety was unfavorable for efficient LAT1
binding causing most probably sterical restrictions in the binding pocket of LAT1. It is also
possible that 6 may  form  a  hydrogen  bond  between  the  methoxy  group  and  the  amide
bond, which could weaken its ability to bind to LAT1. The poor affinity of the valproic acid
prodrug 7 indicates that an aromatic ring in the prodrug structure is essential for efficient
LAT1  binding.  As  the  LAT1  affinities  of  the  valproic  acid  prodrugs 6 and 7 were
significantly lower than those of the valproic acid prodrugs 3 and 4, no additional in vivo
studies with 6 and 7 were conducted.
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6.2.3 Plasma pharmacokinetics and brain uptake of the selected prodrugs after
intravenous administration
The plasma pharmacokinetics of the valproic acid prodrugs 3–5 and the kynurenic acid
prodrugs 8–9 were studied in rats after an intravenous bolus injection. A total of 40.0
μmol/kg solution of the studied compound was administered into the right jugular vein of
the rats, and plasma samples were withdrawn at 5, 10, 60, 180 and 360 minutes after the
injection. Two of the valproic acid prodrugs, 3 and 4, showed similar plasma
pharmacokinetics to valproic acid (Table 12). In contrast, 5 was cleared more rapidly than
valproic acid itself, and therefore the peak plasma concentration of 5 was lower than those
of the corresponding levels of valproic acid and its other derivatives (Table 12). Kynurenic
acid was rapidly eliminated from the rat plasma whereas its prodrugs 8 and 9 remained in
the rat plasma for a longer period of time (Table 12). The kynurenic acid prodrugs 8 and 9
are  most  probably  bound  to  plasma  proteins  such  that  the  total  concentrations  of  the
prodrugs in plasma are sustained for a longer period of time.
Table 12. The plasma concentrations of valproic acid (VA), kynurenic acid (KYNA) and prodrugs
3–5 and 8–9 in rat plasma after intravenous bolus injection (40 μmol/kg). The concentrations
are presented as mean ± SD (n=2–3).
a mean (n=2), range of the concentrations in the parentheses
In addition to the plasma pharmacokinetics, the brain uptake of the valproic acid
prodrugs 3–5 and the kynurenic acid prodrug 8 were determined and their brain
concentrations after an intravenous bolus injection in rats were compared to those of
valproic acid or kynurenic acid. A total of 40.0 μmol/kg solution of the studied compound
was administered into the right jugular vein of rats, and the brain samples were collected at
5, 10, 60, 180 and 360 minutes after the injection. The results indicate that prodrugs 3–5
were also able to cross the BBB in vivo (Table  13).  Valproic  acid and kynurenic  acid were
rapidly removed out of the brain, whereas the valproic acid prodrugs remained in the brain
for  a  longer  period of  time.  The AUCs of 3 and 5,  the  valproic  acid prodrugs with meta-
substituted phenylalanine as the promoiety, in the rat brain were respectively 1.55-fold and
1.88-fold greater than that of 4, the corresponding para-substituted analogue. Furthermore,
the brain:plasma-ratios after the systemic administration of 3 (0.08) and 5 (0.19) were
significantly higher than the corresponding ratio for 4 (0.04). These findings indicate that
Sampling
time
VA
(µM)
3
(µM)
4
(µM)
5
(µM)
KYNA
(µM)
8
(µM)
9
(µM)
5 min
146.5
(145.5-147.4)a
134.2 ±
13.6
141.9 ±
23.1
66.0 ±
3.1
154.3 ±
19.9
247.9 ±
36.7
234.1 ±
20.9
10 min 80.9 ± 5.2
55.9 ±
2.1
96.5 ±
25.8
45.6 ±
4.7
97.5 ±
11.0
193.0 ±
18.8
175.4 ±
44.7
60 min
18.3
(17.5-19.2)a
30.7 ±
11.5
34.4 ±
10.1
8.8 ±
1.3
8.2 ±
7.0
58.2 ±
1.1
54.9 ±
22.5
180 min
14.8
(14.2-15.4)a
11.4 ±
8.7
10.1 ± 3.0 0 0
25.1 ±
2.6
27.3 ± 5.3
360 min 1.4
(0.6-2.2)a
0 0 0 0 18.4
± 0.5
18.5 ±
16.3
AUC5-360 min
(µmol/min/L)
6495 6186 7447 3037 3840 16288 15833
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the meta-substituted phenylalanine derivatives of valproic acid, 3 and 5,  are  able  to  cross
the BBB at higher amounts than the para-substituted derivative 4. This observation
demonstrates for the first time that LAT1-targeted prodrugs are able to utilize LAT1 as a
carrier to pass from the systemic circulation to the brain, and the prodrugs are able to
compete with the endogenous amino acids being transported to the brain via the same
transporter. The results also indicate that the brain uptake of the LAT1 prodrugs from the
systemic circulation is dependent on their affinity for LAT1. Interestingly, the
corresponding meta-substituted phenylalanine prodrug of kynurenic acid (8) was not able
to  cross  the  BBB  at  high  levels,  and  the  brain  uptake  of 8 after  intravenous  injection  was
poor (Table 13). Compound 8 was detected from the brain samples only 5 minutes after its
intravenous administration into rats. As mentioned above, since 8 is a lipid soluble
compound,  it  is  most  probably  highly  bound  to  plasma  proteins,  and  then  its  low  free
fraction in plasma would not be high enough to allow it  to compete with the endogenous
amino acids for LAT1 binding.
Table 13. The brain concentrations of valproic acid (VA), kynurenic acid (KYNA) and prodrugs
3–5 and 8 in rat brain tissue after intravenous bolus injection (40 μmol/kg). The concentrations
are presented as mean ± SD (n=2–3).
Sampling
time
VA
(nmol/g)
3
(nmol/g)
4
(nmol/g)
5
(nmol/g)
KYNA
(nmol/g)
8
(nmol/g)
5 min 10.7 ± 1.4 1.3 ± 0.1 1.4 ± 0.3 2.9 ± 1.8 1.4 ± 0.6 0.4 ± 0.2
10 min
4.8
(3.8-5.8)a 1.9 ± 0.3 1.4 ± 0.1 3.7 ± 0.3 0.3 ± 0.2 0
60 min
0.9
(0.6-1.2)a
2.1 ± 0.1 0.9 ± 0.04 1.8 ± 0.3 0 0
180 min
0.7
(0.6-0.8)a
1.3 ± 0.1 0.9 ± 0.04 1.9 ± 0.6 0 0
360 min 0 a 0.9 ± 0.4 0.8 ± 0.2 0.6 ± 0.1 0 0
AUC5-360 min
 (nmol*min/g)
338.7 496.8 319.0 592.2 11.08 0
a mean (n=2), range of the concentrations in the parentheses
6.2.4 Release of the parent drug from the selected prodrugs in rat systemic circulation
and brain after intravenous administration
The ability of valproic acid prodrugs 3–5 and  the  kynurenic  acid  prodrugs 8–9 to release
either valproic acid or kynurenic acid, respectively, in the rat systemic circulation was also
studied from the samples collected from the rats treated with 3–5 or 8–9. Prodrugs 3 and 5
exhibited  only  slight  bioconversion  to  valproic  acid  in  the  rat  plasma  after  intravenous
administration (Table 14), whereas prodrug 4 remained totally intact in the rat systemic
circulation for 360 minutes after administration. The kynurenic acid prodrugs 8 and 9 did
not elevate the endogenous kynurenic acid levels in the rat plasma for 360 minutes after
their intravenous administration, and thus, the change of the parent drug did not achieve
any improvement on the release properties of the prodrugs being studied in the present
study.
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Table 14. The  concentrations  of  valproic  acid  (VA)  and  its  concentrations  released  from
prodrugs 3–5 in rat plasma after intravenous bolus injection (40 μmol/kg). The concentrations
are presented as mean ± SD (n=2–3).
Sampling time VA
(µM)
VA from 3
(µM)
VA from 4
(µM)
VA from 5
(µM)
5 min
146.5
(145.5-147.4)a
7.3
(6.8-7.8)a
0 3.6 ± 0.1
10 min 80.9 ± 5.2
6.2
(5.5-6.9)a
0
2.6
(1.9-3.3)a
60 min
18.3
(17.5-19.2)a
3.4b 0 0.9 ± 0.03
180 min 14.8
(14.2-15.4)a
0 0 0
360 min 1.4
(0.6-2.2)a
0 0 0
AUC5-360 min
(µmol/min/L)
6495 274 0 94.1
a mean (n=2), range of the concentrations in the parentheses, b n=1
In  addition  to  the  plasma  studies,  the  ability  of  prodrugs 3–5 and 8 to release either
valproic acid or kynurenic acid, respectively, in the rat brain was also studied from the
same brain hemispheres collected from the rats treated with 3–5 or 8. Only the valproic acid
prodrugs 3–5 showed a slight bioconversion to valproic acid in the rat brain (Table 15).
Prodrug 8 did not increase the endogenous brain concentrations of kynurenic acid (data not
shown). This observation was not unexpected as 8 did not reach the brain after the
intravenous administration. The release of valproic acid from prodrug 5 was slightly
superior to that from prodrug 3; this was thought to be mainly due to the additional carbon
of the prodrug 5 between the parent drug and the promoiety, which increases the flexibility
of the prodrug structure. Thus, the release of the parent drug from the prodrug can be
optimized by modifying the structure of the promoiety. However, in the present study, the
amount of released valproic acid either from 3 or 5, i.e. 5% and 8% of the concentration of
the intact prodrug in the brain, respectively, was not comparable to the brain
concentrations of valproic acid itself achieved after an equivalent dose (Table 15). This was
an unexpected finding as the design of these amide prodrugs was based on the previous
findings of the ketoprofen-lysine derivative, which showed almost ideal biotransformation
to ketoprofen in rats in vivo even though it had been found to be stable in the in vitro studies
(Gynther et al. 2010). This may suggest that LAT1 promoieties have to be tailor-made for
each parent drug, and it will be difficult, if not impossible, to design a functional and
universal LAT1 promoiety especially in terms of its ability to release the parent drug.
However, an amide prodrug utilizing LAT1 may be a potential alternative way to enhance
the brain uptake of drugs with extremely poor brain uptake, since only a 5–10% release of
an active drug would nonetheless result in a significant enhancement in the brain levels of
certain drugs.
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Table 15. The  concentrations  of  valproic  acid  (VA)  and  its  concentrations  released  from
prodrugs 3–5 in  rat  brain  tissue  after  intravenous  bolus  injection  (40  μmol/kg).  The
concentrations are presented as mean ± SD (n=2–3).
Sampling time VA
(nmol/g)
VA from 3
(nmol/g)
VA from 4
(nmol/g)
VA from 5
(nmol/g)
5 min 10.7 ± 1.4 0.3 ± 0.05 0.03 ± 0.01 0.6 ± 0.2
10 min
4.8
(3.8-5.8)a
0.2
(0.1-0.26)a
0.04
(0.03-0.05)a
0.5 ± 0.1
60 min
0.9
(0.6-1.2)a
0.3 ± 0.2 0 0.4 ± 0.02
180 min 0.7
(0.6-0.8)a
0 0 0
360 min 0 a 0 0 0
AUC5-360 min
(nmol*min/g)
338.7 24.81 1.24 48.3
a mean (n=2), range of the concentrations in the parentheses
 Studies to optimize the release properties of the valproic acid prodrugs are still ongoing
in our laboratory. For example, substituents unstabilizing the amide bond between the
meta-substituted phenylalanine promoiety and valproic acid have been designed in order
to improve the degradation rate of the amide prodrugs of LAT1. In contrast, substituents
stabilizing the ester bond between the promoiety and valproic acid have been designed in
order  to  slow  down  the  hydrolysis  rate  of  ester  prodrugs  of  LAT1.  However,  as  the
bioconversion of the studied prodrugs via esterases and amidases seems to be either too
rapid or too slow for tissue-targeted prodrugs, alternative biotransformation routes need
also to be considered. Another limitation is that brain-specific enzymes degrading prodrugs
within  the  brain  have  not  yet  been  established.  On  the  other  hand,  acid-  (e.g. acetal, acyl
hydrazone and imine) and reductive-sensitive (e.g. disulfide) bonds between the promoiety
and  the  parent  drug  could  be  used  to  deliver  therapeutic  agents  to  gliomas  as  the  pH  of
tumor  cells  is  often  lower  (pH  4.5–6)  than  that  in  blood  or  normal  tissues  (Tannock  and
Rotin 1989) and the tumor tissue represents a hypoxic environment (Denny 2010). In fact,
the LAT1-mediated prodrug design could be extended to enhance the transport of
chemotherapeutics into tumor cells, as LAT1 is over-expressed in several tumor cells (e.g.
Kim et al. 2008, Sakata et al. 2009, Fan et al. 2010, Liang et al. 2011). An example of a LAT1-
utilizing chemotherapeutic in clinical use is melphalan (Goldenberg et al. 1979, Cornford et
al. 1992).
Furthermore, despite the poor ability of 3–5 to release valproic acid, the valproic acid
prodrugs  may  act  as  effective  anticonvulsants  as  such  possessing  improved  and  more
sustained brain uptake compared to valproic acid itself. Similar examples have been
previously shown with other amide derivatives of valproic acid (Bialer and Yagen 2007,
Shekh-Ahmad et al. 2012). In addition, 3–5 as  such,  may  inhibit  the  activity  of  histone
deacetylases (HDACs) similar to valproic acid. HDACs are enzymes that remove the acetyl
groups  from  the  amino  acids  of  histones  and  they  play  a  major  role  in  regulating  the
structure of DNA (Kazantsev and Thompson 2008). HDACs have been shown to induce
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gene silencing via aberrant chromatin remodeling, and inhibitors for HDACs have been
found to upregulate gene transcription. Consequently, HDAC inhibitors have been
considered as potential therapeutics for a broad range of human disorders, e.g. cancers and
neurodegenerative diseases.
6.3 CONCLUSIONS
In  the  present  study,  amide prodrugs of  valproic  acid (3–7)  and kynurenic  acid (8 and 9)
targeted to LAT1 were examined with the aim to determine their plasma pharmacokinetics
and brain uptake after systemic administration and to optimize the release of the parent
drug from the promoiety. Prodrugs 3, 5 and 8, which have the meta-substituted
phenylalanine as their promoiety, were shown to possess high affinity for LAT1 at the rat
BBB during the in situ rat brain perfusion. Moreover, the valproic acid prodrugs with a
meta-substituted phenylalanine as the promoiety (3 and 5) were shown to be translocated
across the BBB in significantly greater amounts than the corresponding para-substituted
prodrug  (4) after their intravenous administration to rats. This is the first study where
LAT1 prodrugs have been clearly shown to be translocated across the BBB via LAT1 after
their systemic administration. However, the release of valproic acid or kynurenic acid from
all of the studied amide prodrugs was inadequate even though the amide hydrolysis was
tried to be optimized by decreasing the sterical restrictions or changing the parent drug to
the more easily leaving kynurenic acid. As a consequence, more effort will be needed to
optimize the release of the active parent drug from its promoiety.
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7 LAT1-targeted Prodrugs of Dopamine
Abstract. The utilization of LAT1 in prodrug design has been widely applied to anionic and
lipophilic  parent  drugs.  The interest  of  this  study was to  enhance the  brain  uptake of  the
cationic and water soluble compound, dopamine, by utilizing LAT1 at the BBB in a prodrug
approach.  Three  amino  acid  prodrugs  of  dopamine  were  synthesized  and  their  prodrug
properties were examined in vitro.  Their LAT1 binding and BBB permeation were studied
using the in situ rat  brain  perfusion  technique.  The  brain  uptake  after  intravenous
administration and the dopamine-releasing ability in the rat striatum after intraperitoneal
administration were also determined for the most promising prodrug. All the prodrugs
underwent adequate cleavage in rat tissue homogenates. The prodrug with the
phenylalanine  derivative  as  the  promoiety  had  both  higher  affinity  for  LAT1  and  better
brain uptake properties than those with an alkyl amino acid mimicking promoiety. The
phenylalanine  prodrug  was  taken  up  into  the  brain  after  intravenous  injection,  but  after
intraperitoneal injection the prodrug did not elevate striatal dopamine concentrations
above those achieved by the corresponding L-dopa treatment. These results indicate that
the attachment of phenylalanine to the parent drug via an amide bond from the meta-
position of  its  aromatic  ring could also  be  highly  applicable  in  prodrug design for  LAT1-
mediated CNS delivery of cationic and hydrophilic small molecular weight drugs.
Adapted from:  Peura L†,  Malmioja  K†,  Huttunen K,  Leppänen J,  Hämäläinen M,  Forsberg
M,  Rautio  J† and  Laine  K†.  Design,  Synthesis  and  Brain  Uptake  of  LAT1-targeted  Amino
Acid Prodrugs of Dopamine. Pharmaceutical Research 30:2523-2537, 2013. © 2013 Springer
Science + Business Media. All rights reserved.
† Authors equally contributed to this work.
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7.1 INTRODUCTION
The  need  for  efficient  drug  delivery  strategies  to  enhance  the  extent  of  brain  permeation
seems worthwhile while the general population is aging and the physicochemical
properties of many novel drugs tend to be less favorable for brain uptake (Wager et al.
2010b). As discussed previously in this thesis, one promising strategy for improving the
poor brain uptake of drugs is to adopt the prodrug approach which utilizes specific
transporters expressed at the BBB of which LAT1 is a widely utilized transporter in the
drug delivery to the brain. However, the variety of the LAT1 promoieties has been rather
narrow as the LAT1 promoieties have been previously applied only to anionic drugs
(Bonina et al. 1999, Killian and Chikhale 2001, Gynther et al. 2008, Gynther et al. 2010). In
addition, the previously published prodrugs have been relatively lipophilic especially after
conjugation  with  the  promoiety.  It  was  attempted  here  to  diversify  the  LAT1  prodrug
approach  to  a  cationic  parent  drug,  dopamine,  by  studying  LAT1  binding  and  by
determining the translocation across the BBB of its relatively hydrophilic prodrugs.
Several prodrugs of dopamine providing better structural features for intestinal
absorption, protection from premature metabolism and improved brain distribution have
been  investigated  (Chemuturi  and  Donovan  2007).  The  prodrugs  with  improved  brain
delivery consist mainly of more lipophilic derivatives of dopamine intended to enhance the
passive delivery of dopamine especially across intestinal endothelial cells and the BBB
(Borgman et al. 1973, Bodor et al. 1981, Bodor and Farag 1983, Simpkins et al. 1985, Carelli et
al. 1996, Denora et  al. 2007). However, a few transporter-utilizing prodrugs of dopamine
have  been  described  previously  (Fernández et  al. 2000, Fernández et al. 2003, More and
Vince 2008); unfortunately the in vivo pharmacokinetic properties of those GluT1 or
glutathione transporter utilizing derivatives of dopamine have not been studied with all of
these prodrugs. In addition, none of the pharmacokinetic studies has compared the
prodrugs against the standard L-dopa therapy, i.e. L-dopa combined with the peripheral
inhibitors of aromatic L-amino acid decarboxylase (AADC) and catechol-O-methyl
transferase (COMT).
L-dopa, the only clinically used prodrug of dopamine, is transported into the brain via
LAT1 transporters as a “pseudonutrient” (Gomes and Soares-Da-Silva 1999). The
“pseudonutrient” structure of L-dopa is metabolically transformed into dopamine in the
brain while its metabolic transformation in peripheral tissues is prevented by simultaneous
administration of peripheral inhibitors of L-dopa metabolizing enzymes, i.e. AADC  and
COMT. The need for these inhibitors complicates L-dopa treatment. Furthermore, chronic L-
dopa treatment is confronted by many problematic pharmacokinetic obstacles, e.g.
extensive metabolism, plasma fluctuations, erratic oral absorption and variability in the
extent of the first-pass metabolism (Nutt 2008). In advanced Parkinson’s disease, an
extensive loss of nigrostriatal dopaminergic neurons leads to a significant decrease in
striatal AADC activity (Olanow et al. 2006)  that  is  essential  to  convert L-dopa into
dopamine. Nonetheless, L-dopa  with  AADC-  and  COMT-inhibitors  still  remains  the
cornerstone of the drug treatment of Parkinson’s disease.
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The present study examines three amino acid promoieties, meta-substituted carboxylic
acid analogue of phenylalanine (10), 2-amino-apidic acid (11) and aspartic acid (12) (Figure
21), as LAT1-targeted promoieties of a cationic dopamine with the aim to enhance its brain
uptake. The prodrugs 10–12 were synthesized and their physicochemical properties were
first determined in in vitro assays. Then their abilities to bind to LAT1 and to cross the BBB
were studied by using the in situ rat brain perfusion technique. Finally, the brain uptake of
the selected prodrug 10 after intravenous administration in rats and its ability to release
dopamine in the rat brain after intraperitoneal administration were determined. The ability
of 10 to release dopamine was compared to that of the standard L-dopa treatment with the
inhibitors of AADC and COMT.
Figure 21. Chemical structures of the dopamine prodrugs 10–12
7.2 RESULTS AND DISCUSSION
7.2.1 In vitro studies of the dopamine prodrugs
The aqueous solubilities of 10 and 11 at pH 7.4 were determined to be higher than
10 mg/mL. The maximum solubilities of 10 and 11,  and the  aqueous solubility  of 12 were
not determined because of the small amount of the prodrugs available. The apparent
partition coefficients of 10–12 at pH 7.4 (log D) were determined to be negative; -1.57 ± 0.16
for 10, -1.54 ± 0.16 for 11 and -2.25 ± 0.12 for 12 (mean ± SD, n=3), respectively, indicating
that  the  prodrugs  are  extremely  hydrophilic  at  pH  7.4.  As  a  comparison,  the  log  D  of
dopamine at pH 7.40 was determined to be 0.20 ± 0.11 (mean ± SD, n=3). In addition,
topological polar surface areas (TPSA) of 10–12 were calculated with MOE-2011.10 to be
132.9 Å2, which is higher than the value for L-dopa (103.8 Å2) and double that of dopamine
(66.5 Å2) (Table 16).
The dopamine prodrugs 10–12 showed good aqueous solubility at pH 7.4, their apparent
log D-values at the same pH were negative, and the TPSA of prodrugs were much higher
than the proposed maximum PSA (< 90 Å2) for molecules that can cross the BBB by passive
diffusion (van de Waterbeemd et al. 2001), indicating that the prodrugs are not very likely
to penetrate into the brain by passive diffusion. After evaluation of the in vitro data, it was
postulated that 10–12 permeated through the biological membranes via transporters or
paracellularly at physiological pH (Levin 1980). However, it is unlikely that the paracellular
pathway plays any major role in the brain permeation of polar solutes (Begley 2004). On the
other hand, it is worth bearing in mind that the hydro- or lipophilicity of a drug is not the
only parameter that can be used as a surrogate for drug brain penetration (Wager et  al.
2010) even though the log D-values of the majority of CNS-acting drugs were shown to be
0–4 (van de Waterbeemd et  al. 2001). It also needs to be noted that lipophilic drugs are
usually potential substrates of efflux transporters, extruding neurotherapeutics from the
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brain back to the bloodstream (Wager et al. 2010), and lipophilic derivatives are more likely
to  undergo extensive  unspecific  brain  tissue binding and plasma protein  binding (van de
Waterbeemd et al. 2001). Both of these properties, i.e. being a substrate for an efflux
transporter and binding to the brain tissue and plasma proteins, can decrease the unbound
brain concentration of an active drug. In addition, lipophilic compounds possess a high
volume of  distribution as  they are  able  to  cross  biological  membranes  in  general,  and the
specific fraction taken up into the brain might be relatively low. Thus, the influx transporter
utilizing prodrug strategies,  in  which the  parent  molecules  are  relatively  hydrophilic  and
the prodrugs are specific for certain influx transporter, are very attractive since they would
be predicted to enhance the drug delivery into the brain.
Table 16. Degradation rates of 10–12 in phosphate buffer (pH 7.4), in rat plasma, in rat brain
and rat liver homogenates (+37 °C) (t1/2, mean ± SD; n=3) and topological polar surface areas
(TPSAs) for 10–12, L-dopa and dopamine.
Prodrug
Buffer
(pH 7.4)
(h)
75% rat
plasma
(h)
20% rat brain
homogenate
(h)
50% rat liver
homogenate
(h)
TPSA
(Å2)
10 19.9 ± 2.6 1.5 ± 0.1 28.4 ± 5.5 2.7 ± 0.4 132.9
11 9.9 ± 0.04 3.2 ± 0.2 30.6a 5.3 ± 1.1 132.9
12 24.4 ± 3.3 4.8 ± 1.0 24.1 ± 8.1 4.4 ± 0.9 132.9
L-dopa n.a.b n.a.b n.a.b n.a.b 103.8
Dopamine n.a.b n.a.b n.a.b n.a.b 66.5
a Mean (n=2).
b n.a. = not analyzed
The stabilities of 10–12 and their bioconversion to dopamine were studied in aqueous
buffer (pH 7.4), in 20% rat brain homogenate, in 50% rat liver homogenate and in 75% rat
plasma at +37 °C (Table 16). The chemical and enzymatic degradation of 10–12 followed
pseudo-first-order kinetics, and the half-lives are presented in Table 16. The release of
dopamine was also verified quantitatively by an HPLC-EC method. The prodrugs
appeared to be reasonably stable in aqueous buffer at pH 7.4, having half-lives of
approximately 10 hours (11)  or  longer  (10 and 12).  The  half-lives  of  the  prodrugs  in  rat
plasma and in rat liver homogenates were notably shorter than those determined in the
aqueous buffer solution (Table 16) suggesting that the prodrugs released the parent drug
predominantly though enzymatic reactions. Enzymatic degradation rates of 10–12 in rat
plasma appeared to be relatively high when compared with those in the rat liver and brain
homogenates. This may be due to the fact that the plasma stability studies were conducted
in 75% rat plasma whereas the rat liver and brain tissue homogenates were diluted by
isotonic buffer (pH 7.4) to concentrations of 50% or 20%, respectively. Additionally, the
differences between the degradation rates of the prodrugs in rat brain and liver
homogenates probably correspond also to the distinct tissue distribution of the prodrug-
hydrolyzing esterases. Amide prodrugs in general may be too stable to release the parent
drug but  the  present  dopamine prodrugs seem to  belong to  those  amide prodrugs which
are capable of releasing the parent drug (Gong et  al. 2004, Elia et  al. 2007, Gynther et al.
2010). According to the in vitro data, 10–12 were suitable for further evaluation by the in situ
and in vivo methods in rats.
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7.2.2 Transporter-mediated brain uptake of the dopamine prodrugs by in situ rat brain
perfusion
Strong reduction in the permeability-surface area (PA) product of [14C]-L-leucine was
apparent when perfusing 0.2 μCi/mL [14C]-L-leucine (i.e. 0.64 μM) in the presence of 100 μM
prodrug 10 (Figure 22) as the PA product of [14C]-L-leucine decreased from 19.0 ± 3.6 μL/s/g
to 2.76 ± 0.72 μL/s/g (mean ± SD, n=3), respectively. The level of inhibition (about 85%) in
[14C]-L-leucine brain uptake obtained by 10 is  in  line  with  previous  results  which showed
that meta-substituted phenylalanine is a potential promoiety and carrier of anionic drugs
into the brain (See Chapter 5). In the present study, the promoiety has been applied also to
cationic  drugs,  and  this  modification  was  shown  to  be  capable  of  retaining  its  LAT1-
targeting property. In addition, this study demonstrates for the first time that hydrophilic
prodrugs can also have high binding affinity for LAT1. Moreover, the inhibition caused by
10 was significantly stronger than that observed after in situ rat  brain  perfusion  of  an
equivalent concentration of L-dopa (Figure 22) which was 66.3 ± 1.4% (mean ± SD, n=3).
This result indicates that 10 has better possibilities to compete with the endogenous LAT1
substrates than L-dopa  when  being  taken  up  into  the  brain  by  LAT1.  This  observation
encouraged us to study the brain uptake of 10 in more detail by using the in situ rat brain
perfusion  to  complement  the  [14C]-L-leucine brain uptake inhibition determination. In
contrast, prodrugs 11 and 12 did  not  possess  as  strong  affinity  for  LAT1  as 10, and they
were less potent than L-dopa in their ability to inhibit the brain uptake of L-leucine (Figure
22). 11 was able to decrease the PA product of [14C]-L-leucine by 38.80 ± 5.61% and 12 by
34.95 ± 10.44% (mean ± SD, n=3), respectively. This observation was not consistent with the
previous studies where the lysine derivative of ketoprofen, a structurally-related prodrug
to 11 and 12, achieved almost 80% inhibition of L-leucine brain uptake at the equivalent
concentration (Gynther et al. 2010) (Figure 22). Therefore, the alkyl amino acid promoiety in
general does not seem to act as such a favorable LAT1 substrate as its aromatic amino acid
counterpart,  and  the  alkyl  amino  acid  promoiety  cannot  be  generalized  to  be  able  to
function as a high-affinity LAT1 promoiety for every parent drug. However, the entire
prodrug molecule can act as a high-affinity LAT1 substrate as shown by the lysine-
ketoprofen prodrug.
Figure 22. LAT1 binding data of 100 μM prodrugs 10–12, 100 μM L-dopa  and  90  μM lysine-
ketoprofen. The brain uptake of 0.2 μCi/mL [14C]-L-leucine, 19.0 ± 3.6 μL/s/g, was reduced to
2.76 ± 0.72 μL/s/g in the presence of 10 (85.5% inhibition), 11.93 ± 1.10 μL/s/g in the
presence of 11 (38.8% inhibition) and to 12.68 μL/s/g in the presence of 12 (35.0% inhibition)
(means  ±  SD,  n=3).  As  a  comparison,  the  brain  uptake  of  [14C]-L-leucine was inhibited by
66.3% in the presence of L-dopa and by 79.3% in the presence of lysine-ketoprofen (Gynther et
al. 2010). The asterisk denotes a statistically significant difference from the respective control
(***P < 0.001, one-way ANOVA, followed by Dunnett t-test).
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The total amounts of the prodrugs 10 and 11 in the rat brain were also determined after
the in situ rat brain perfusion to confirm that the prodrugs were not only bound to LAT1
but were also translocated across the BBB. As illustrated in Figure 23, prodrug 10 possessed
the  ability  to  cross  the  rat  BBB  and  gain  entry  into  the  brain  tissue  during  the in situ rat
brain perfusion. In contrast, prodrug 11,  which  displayed  only  low  affinity  for  LAT1
(Figure 22), was not found to cross the rat BBB even at a concentration as high as 600 μM in
the perfusion fluid. The poor brain uptake of 11 may indicate that very high affinity for
LAT1 is needed for the brain uptake of LAT1-targeted prodrugs. This was the first time that
the translocation of the LAT1 prodrugs across the BBB was suggested to be dependent on
their high affinity for LAT1. This observation on the concentration dependent brain uptake
of 10 also further confirmed the proposal that 10 was  being  taken  up  into  the  brain  in  a
carrier-mediated manner. Since 11 and 12 lack affinity for LAT1 and 11 was not taken up
into the brain at detectable amounts, more comprehensive in vivo brain uptake studies were
performed only for 10.
Figure 23. Kinetics of the rat brain uptake of 10. Km and Vmax are 227.9 ± 52.0 μM and 0.99 ±
0.09 pmol/mg/min (mean ± SD, n=3) respectively.
Roles of reduced temperature and simultaneous LAT1 inhibition in the rat brain uptake
of 10 at 100 μM concentration were investigated by using cold perfusion (+5 °C) and 2 mM
L-phenylalanine as a competitive endogenous LAT1 substrate (Figure 24) to demonstrate
the role of LAT1 in the brain uptake of 10. A lower perfusion fluid temperature decreased
the brain uptake of 10 from 0.307 pmol/mg/min to 0.095 pmol/mg/min. This corresponded
to approximately 69% inhibition and was clear evidence of carrier-mediated brain uptake of
10. A similar reduction of about 61% inhibition in the brain uptake of 10 was shown when
co-perfusing the rat brain with 100 μM of 10 and 2 mM L-phenylalanine, and this further
confirmed the involvement of LAT1 in the brain uptake of 10.  However,  in  both
experiments, the uptake of 10 was not totally inhibited, and thus a competition study with 2
mM L-phenylalanine was also conducted at +5 °C to demonstrate that 10 was being taken
up into the brain by a carrier-mediated manner also at +5 °C (Figure 24). A significant
decrease in the brain uptake of 10 was observed when 10 was  co-perfused with 2  mM L-
phenylalanine at a reduced temperature, when compared to the results of the same
experiment conducted at +37 °C. However, there still remains a non-saturable, temperature-
insensitive part in the brain uptake of 10. This observation may indicate that the activity of
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LAT1 is not totally inhibited even in a cold perfusion medium. Alternatively, some part of
10 may be  transferred through the  BBB in  the  present  study by passive  diffusion.  On the
other  hand,  the  physicochemical  properties  of 10, i.e. high  aqueous  solubility  (over  10
mg/mL), low log D (-1.57) and high TPSA (132.9 Å2), do not indicate that 10 is likely to be
taken up by passive diffusion. Thus, the net brain uptake mechanism of 10 remains
undefined.
Figure 24. Rat  brain  uptake  of 10 after  cold  perfusion  and  co-perfusion  with  2  mM L-
phenylalanine (Phe). The uptake of 100 μM 10 significantly  decreased  from  0.307  ±  0.02
pmol/mg/min to 0.095 ± 0.01 pmol/mg/min (mean ± SD, n=3) (69.1% inhibition) in cold
perfusion  medium  (+5  °C).  A  comparable  inhibition  (60.8%)  was  observed  during  the  co-
perfusion of 100 μM 10 and 2 mM L-phenylalanine. When conducting the study with 2 mM L-
phenylalanine  at  +5  °C  the  uptake  of 10 was  inhibited  by  78.6%.  There  was  a  statistically
significant difference between the column 100 μM 10 (+37 °C) and the other columns (*** P <
0.001  one-way  ANOVA,  followed  by  Dunnett  t-test).  There  was  also  a  significant  difference
between columns 100 M 10 + 2 mM Phe (+37 °C) and 100 M 10 + 2 mM Phe (+5 °C) (* P <
0.05 one-way ANOVA, followed by Dunnett t-test).
To summarize the in vitro and in situ data, it seems that meta-substituted phenylalanine
can be a potential efficient promoiety for improving the brain uptake of small molecular
weight cationic drugs that are not readily transported into the brain by passive diffusion. 10
was taken up into the rat brain in a carrier-mediated manner, rapidly and in significant
amounts via LAT1 whereas the alkyl amino acid derivatives (11 and 12) did not possess
sufficiently high affinity for LAT1 and, hence, were not taken up into the brain in
appreciable amounts. Thus, it seemed reasonable to perform more comprehensive in vivo
brain uptake studies with 10.
7.2.3 Brain uptake and basic pharmacokinetic parameters of a dopamine prodrug after
intravenous administration
Encouraged by the in situ results, the brain uptake of 10 was determined after intravenous
administration in rats. A total of 25.35 μmol/kg solution of 10 was administered into the
right jugular vein of the rats. The results indicate that 10 was able to cross the BBB in vivo in
the  presence  of  competitive  endogenous  substrates  (Figure  25).  The  area  under  the  curve
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for 10 during  the  180  min  after  the  administration  in  the  brain  (AUCbrain) was 13.39
nmol*min/g and in plasma (AUCplasma) 1481 nmol*min/mL (Table 17). The half-life of 10 in
plasma during the distribution phase was as short as 3.10 min indicating that the prodrug
10 was being excreted rapidly as a hydrophilic compound or distributed rapidly into other
tissues of the rat (Table 17).
Figure 25. Mean plasma (A) and brain (B) concentration-time profiles of 10 after intravenous
bolus injection (25.35 μmol/kg) to rats (mean ± SD, n = 4–5).
Table 17. The  basic  pharmacokinetic  parameters  of 10 after intravenous bolus injection into
rats (Mean ± SD, n = 4)
Parameters Prodrug 10
dose (μmol/kg) 25.4
AUCbrain (nmol*min/g) (10–180 min) 13.4
AUCplasma (nmol*min/mL) (2–180 min) 1481
CL (mL/min/kg) 13.5 ± 3.9
t1/2 (min) 3.1 ± 0.6
7.2.4 Release of dopamine from a dopamine prodrug in the rat striatum after
intraperitoneal administration
In addition to the brain uptake studies in vivo, the ability of 10 to elevate the striatal
dopamine concentrations in the rats was also evaluated. This study compared the
dopamine concentrations in striatal samples after intraperitoneal administration of 10
against those induced after intraperitoneal administration of an equivalent dose of L-dopa.
A dose of 50.71 μmol/kg of 10 or L-dopa suspension was administered intraperitoneally to
rats,  which  had  been  pretreated  with  AADC-  and  COMT-inhibitors  (i.e. carbidopa (30
mg/kg) and entacapone (10 mg/kg), respectively) to prevent peripheral metabolism of L-
dopa to dopamine. The results indicated that 10 did not increase the striatal dopamine
concentrations in vivo, whereas the striatal concentrations of dopamine were significantly
increased 60 min after the L-dopa administration (Figure 26).
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Figure 26. Effect of 10 and L-dopa  on  rat  striatal  dopamine  concentrations  after  equivalent
intraperitoneal doses (50.71 μmol/kg). The rats were pretreated with carbidopa (30 mg/kg) and
entacapone (10 mg/kg) 30 min before the administration of L-dopa or 10. The asterisks denote
a statistically significant difference from the respective control (***P < 0.001, one-way ANOVA,
followed by Dunnett t-test).
Although the in vitro and in situ studies indicated that 10 was a promising LAT1-
transported prodrug, it did not evoke the desired pharmacological effects i.e. it could not
elevate the striatal dopamine levels in the in vivo situation (Figure 26), even though it was
taken up into the rat brain after intravenous administration (Figure 25). As a hydrophilic
compound, 10 may not reach the brain parenchyma in order to release dopamine
enzymatically. Most probably 10 may be cleared from the brain too rapidly to release
dopamine in pharmacologically significant amounts. However, LAT1 and other amino acid
transporters are known to be expressed also in the glia cells and astrocytes (Su et al. 1995,
Thurlow et al. 1996), and thus the rapid CNS elimination after intravenous administration
was unexpected because those amino acid transporters would be expected to carry 10 into
the cells and trap the prodrug or the active molecule within the cells. As a consequence, the
time period for 10 to release dopamine at the site of action may be too short to achieve any
favorable elevating effect on the striatal dopamine levels. In order to exert relevant
pharmacological actions, the CNS-acting drug must also gain access to its site of action
within the brain tissue after its passage into the brain.
Higher amounts of L-dopa were taken up into the brain than 10 and L-dopa was able to
elevate the striatal dopamine supply even though its affinity for LAT1 was relatively weak
(Figures 22 and 26). It is believed that the brain uptake of L-dopa occurs in both passive and
carrier-mediated manners (Nutt and Fellman 1984). This may explain why L-dopa was
superior in the in vivo situation when compared to 10.  The part of L-dopa being taken up
into the brain by passive diffusion is considered to increase when it is metabolized into 3-O-
methyl-dopa. This metabolite binds to LAT1 with much higher affinity than L-dopa itself,
and acts as a competitive inhibitor for L-dopa transport across the BBB (Gomes and Soares-
da-Silva 1999). This significantly higher LAT1 binding affinity of 3-O-methyl-dopa makes
the competing hypothesis more relevant even though the plasma levels of 3-O-methyl-dopa
are normally low.
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7.3 CONCLUSIONS
The present  study explored amino acid prodrugs (10–12) of dopamine and applied meta-
substituted phenylalanine to carry this cationic and polar drug into the brain via the LAT1
transporter.  Firstly,  it  was  found  that  these  prodrugs  possess  affinity  for  LAT1  at  the  rat
BBB during the in situ rat brain perfusion and they evoked a sustained release of dopamine
in in vitro stability studies, thus fulfilling the specifications required for tissue-targeted
prodrugs. Secondly, only the meta-substituted phenylalanine promoiety attached to
dopamine via an amide bond (10) exhibited adequate affinity for LAT1 for carrier-mediated
brain uptake. The aspartic acid (12) and adipidic acid (11) prodrugs did not possess as
favourable properties as LAT1 substrates as 10.  This  was  also  the  first  time  that  the
translocation of LAT1 prodrugs across the BBB was shown to be dependent on their high
affinity for LAT1. In addition to the in situ studies, it was observed that prodrug 10 was also
taken up into the rat brain after its intravenous administration in vivo in rats. Unfortunately,
it was not possible to detect any enhanced dopamine concentrations in the rat striata after
intraperitoneal administration of the prodrug 10 when compared with the corresponding
equimolar dose of L-dopa. This may be because 10 is too quickly eliminated from the brain
before it released dopamine due to its high polarity. The present in vivo data also
highlighted the problem that a prodrug that shows potential in vitro and in situ may not
necessarily function well in in vivo studies.
Taken together, these findings imply that LAT1 is a promising target for drug delivery
of poorly brain penetrating drugs to the brain, and the attachment of phenylalanine to the
parent drug via an amide bond from the meta-position of its aromatic ring is a feasible
promoiety for LAT1-targeting of cationic drugs in addition to the anionic drugs. However,
further  work needs to  be  conducted to  establish  whether  this  promoiety  can be  used as  a
drug  carrier  to  the  brain  also  in  conjunction  with  other  cationic  and  poorly  brain
penetrating parent drugs.
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8 3D Pharmacophore and Structure-Activity Study of
LAT1
Abstract. LAT1 has the potential to function as a drug carrier to improve drug delivery to
the brain which makes it an intriguing target protein for central nervous system disorders,
e.g. Alzheimer’s disease, Parkinson’s disease and brain tumors. However, the most
important molecular features of effective LAT1-binding compounds have not been clearly
clarified as the crystal structure and 3D homology model of LAT1 are not available due to
its complex transmembrane structure and low sequence similarity with the other system L
amino acid transporters. In this study, a ligand-based 3D pharmacophore was generated
using computer-aided drug design methods.  The 3D pharmacophore  was generated for  a
set of LAT1 substrates whose binding affinities were studied using competitive inhibition
of  the  brain  uptake  of  [14C]-L-leucine with an in situ rat brain perfusion method. The
pharmacophore highlights the most important molecular features shared by efficient LAT1-
binding compounds and elucidates their 3D-arrangement in detail. This clarifies the
structure-activity relationships of LAT1 substrates and provides insights for making a
binding hypothesis. The results can be further applied in the design of novel efficient LAT1
substrates.
Adapted  from:  Ylikangas  H.†,  Peura  L.†,  Malmioja  K.,  Leppänen  J.,  Laine  K.,  Poso  A.,
Lahtela-Kakkonen M., Rautio J. Structure–activity relationship study of compounds
binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in
situ rat brain perfusion. European Journal of Pharmaceutical Sciences 48:523-531, 2013. ©
2013 Elsevier B.V. All rights reserved.
† Authors equally contributed to this work.
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8.1 INTRODUCTION
As  discussed  previously  in  this  thesis,  LAT1  is  considered  as  one  of  the  most  promising
transporters which can be exploited to improve drug delivery to the brain via the prodrug
approach. However, limited structural data of LAT1 is available, and the structure-activity
relationships (SAR) between the substrate and the transporter have not been adequately
studied. In addition, there is lack of either ligand- or transporter-based computer-aided
models of LAT1. As a heterodimeric transmembrane protein, the structure of the
LAT1/4F2ch -complex is difficult to crystallize leading to the absence of transporter-based
computer-aided models. In addition, the low sequence similarity (25%) with other members
of system L amino acid transporters represents another obstacle for building a successful
3D homology model of the protein. Thus, ligand-based methods are more suitable for
generating a computer-aided model of LAT1.
The present study applied ligand-based molecular modeling methods to analyze the
molecular structures of efficient amino acid mimicking prodrugs, endogenous substrates of
LAT1 and other derivatives of amino acids (Table 18) with the aim to determine the most
important molecular features of effective LAT1-binding compounds. In this study, a three-
dimensional  (3D)  pharmacophore  for  compounds  that  bind  to  LAT1  has  been  generated
(Figure 27). The pharmacophore highlights the highest common denominator of a series of
active compounds, describing the steric and electronic features necessary for molecular
recognition (Leach et  al. 2010).  It  also  clarifies  the  specific  3D  arrangement  of  the  most
important molecular features of LAT1-binding compounds; these have not been reported
previously  in  such  detail.  In  addition,  the  SARs  of  a  diverse  series  of  compounds  were
examined based on their abilities to bind to LAT1 using competitive inhibition of the brain
uptake of an endogenous substrate [14C]-L-leucine in the in situ rat brain perfusion method.
SAR can improve our understanding of the molecular interactions that occur upon ligand
binding and allow optimization of the 3D pharmacophore for LAT1-binding compounds.
The SAR provides a valuable tool which can be applied in further design and optimization
of new compounds that bind effectively to LAT1 and have the potential to function as
promoieties for LAT1-transported prodrugs to improve drug delivery to the brain.
Figure 27. 3D pharmacophore for LAT1 substrates. The pharmacophore contains four
pharmacophoric features: (1) hydrogen bond acceptor (HBA) (pink, leftmost), (2) aromatic ring
(orange), (3) negatively charged group (red) and (4) hydrogen bond donor (HBD) (blue,
rightmost) aligned with valproic acid prodrug 3 (93% L-leucine uptake inhibition).
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Table 18. The  chemical  structures  of  the  compounds  selected  for  the  design  of  the  3D
pharmacopore and their ability to inhibit L-leucine brain uptake at 100 μM concentration in the
in situ rat brain perfusion (n=3, mean ± SD)
Nro. Structure
LAT1
affinitya
Nro. Structure
LAT
affinitya
1
NH2
O
OH
O
O
93 ± 3 23 38 ± 5
2 NH2
OH
O
O
O
64 ± 3 24 36 ± 7
3 93 ± 2 25 31±1
4 64 ± 4 26 25±7
13 99 ± 4 27 23 ± 3
14 88 ± 3 28 21 ± 7
15 86 ± 2 29 8 ± 5
16 81 ± 1 30 5 ± 10
17
79 ± 6
(conc. 70
μM)
31
0
(n=2)
18 75 ± 2 32
0
(n=2)
19 66 ± 1 33
0
(n=2)
20 59 ± 4 34
0
(n=2)
21 N
H
O
NH2
OH
O 57 ± 20 35
0
(n=2)
22 56 ± 3 36
0
(n=2)
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8.2 RESULTS AND DISCUSSION
8.2.1 Inhibition of [14C]-L-leucine brain uptake
In this study, the ability of the compounds 1–4 and 13–36 (Table 18) to bind to LAT1 was
determined by the in situ rat brain perfusion technique. The brain capillary permeability
surface  area  (PA)  product  of  0.2  μCi/mL  of  [14C]-L-leucine  (i.e. 0.64 μM) after 30 s brain
perfusion was determined to be 19.0 ± 3.6 mL/s/mg. The decrease of the PA product of L-
leucine caused by 100 μM of the studied compound was measured taking the PA product
of [14C]-L-leucine as a reference. Following from this, the relative LAT1 binding at the BBB
for the compounds could be determined even though the method did not assess their actual
brain uptake. Thus, the generated pharmacophore and SAR take into account only the
affinity of the studied compounds to LAT1. As shown in Table 18, the selected compounds
were  determined  to  span  a  broad  range  in  terms  of  their  binding  to  LAT1  in  the  co-
perfusion of  100  μM of  the  studied compound and 0.2  μCi/mL of  [14C]-L-leucine. The PA
product of [14C]-L-leucine  was  shown  to  be  most  extensively  decreased  by 13 (99%
inhibition) and least decreased by 30 (5% inhibition). Furthermore, compounds 31–36 did
not possess any affinity for LAT1 in this study. The compound selection was proven to be
successful as the binding affinities varied over a sufficiently wide range to allow successful
pharmacophore and SAR modeling (L-leucine uptake inhibition 0–100%).
The applied 100 μM concentration made it possible to study both weak and strong
substrates of LAT1 using the same study protocol. By using the in situ rat brain perfusion
technique, the paracellular pathway at the BBB was restricted and thus, the LAT1 affinity of
the low-affinity compounds could also be determined. However, the in situ method  has
some limitations. The saturation of LAT1 by the high-affinity compounds is known to occur
at concentrations even lower than 100 μM (see Chapter 5). Thus, the 100 μM concentration
of the test compounds is a compromise since it made it possible to study all the compounds
with the same experimental protocol. If only the best potential LAT1 substrates were to be
studied, then a lower concentration of the studied compounds should be used. However,
the optimization of the high affinity may not be the ideal way to design more efficient
substrates for LAT1 because it has been shown that the high affinity compounds may bind
to the transporter too tightly to allow them to be rapidly translocated across the BBB (Deves
and Krupka 1979, Takada et al. 1992). Slow Koff-constant may explain this phenomenon, but
results confirming this cannot be clearly found in the inhibition studies because the method
does not account for the real translocation of the studied compounds. However, it has to be
appreciated that the transport of a drug or a prodrug across a cell membrane is usually a
net effect of both passive and carrier-mediated transport mechanisms (Sugano et al. 2010),
and  thus,  there  may  be  several  other  reasons  for  the  compound  to  be  slowly  transported
across the cell membrane. Another limitation of the in situ method used in this study is that
only the competitive binding and relative affinities for LAT1 at the luminal side of the BBB
are determined, and the actual brain uptake of the compounds is not analyzed. However, it
has been shown that a LAT1 substrate that possesses only a modest affinity for LAT1 will
not be taken up into the brain via LAT1 in any detectable amounts (see Chapter 7)
indicating that high affinity for LAT1 is needed for efficient LAT1-mediated brain uptake.
The 3D pharmacophore model is based on the affinity data only, and the actual brain
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uptake of each prodrug designed by this model in the future will have to be determined to
ensure that the translocation across the BBB actually occurred.
8.2.2 3D pharmacophore
A ligand-based 3D pharmacophore was generated using alignment-independent methods
because the crystal structure of LAT1 is not available due to the challenges that its complex
heterodimeric transmembrane structure poses for crystallization. In addition, the low
sequence similarity (25%) with other members of system L transporters represents another
obstacle for building a successful 3D homology model of the protein. The pharmacophore
model was based on 28 structurally diverse compounds (Table 18) including endogenous
LAT1 substrates L-tryptophan (14) and L-phenylalanine (15), derivatives of phenylalanine
and other amino acids (16, 19, 20–32),  valproic acid and ketoprofen prodrugs (1–4, 13, 17,
33–36) (Table 18) and a new derivative of L-tryptophan (18),  which  binds  efficiently  to
LAT1 inhibiting 75% of L-leucine brain uptake. Compound 18 was discovered during this
study as a result of the virtual screening described in detail in Chapter 4.7. The resulting 4-
point pharmacophore contains the following features: hydrogen bond donor (HBD), a
negatively charged group, an aromatic ring and a hydrogen bond acceptor (HBA) (Figure
27). It also elucidates the 3D arrangement of the pharmacophoric features, i.e. the distances
and angles between them, which are reported here for the first time (Table 19). Information
about the 3D nature of the common molecular interactions of LAT1 substrates makes it
possible to identify alternative molecular scaffolds as the pharmacophore is not restricted to
any specific functional groups. The 3D pharmacophore also represents a resource for
determining the SAR of LAT1 substrates which is of the utmost importance in the design
and optimization of new LAT1-binding compounds.
Table 19. Intersite distances and angles linking the pharmacophoric features of LAT1 substrates
Feature pair Distance (Å)
HBA–HBD 8.4
HBA–Negative charge 6.3
HBA–Aromatic ring 3.8
HBD–Negative charge 3.0
HBD–Aromatic ring 5.9
Negative charge–Aromatic 4.3
Feature triplet Angle (°)
HBD–HBA–Negative charge 16
HBD–HBA–Aromatic ring 37
Negative charge–HBA–Aromatic ring 42
HBA–HBD–Negative charge 37
HBA–HBD–Aromatic ring 23
Negative charge–HBD–Aromatic ring 45
HBA–Negative charge–HBD 127
HBA–Negative charge–Aromatic ring 36
HBD–Negative charge–Aromatic ring 106
HBA–Aromatic ring–HBD 120
HBA–Aromatic ring–Negative charge 102
HBD–Aromatic ring–Negative charge 29
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8.2.3 Validation of the 3D pharmacophore
The 3D pharmacophore was validated by analyzing its ability to discriminate between
compounds assigned as inactive (0% L-leucine uptake inhibition) or active (>50% L-leucine
uptake inhibition) in the dataset. This was performed by aligning both high-affinity and
inactive compounds with the pharmacophore. The majority of the LAT1 substrates
assigned as being active (1–4, 13, 16–19, 22)  fit  well  with  the  4-point  pharmacophore.  The
inactive compounds contain some of the molecular features described by the
pharmacophore but they occupy regions where the high-affinity compounds 1–4, 13, 16–19,
22 do not protrude. This indicates that there are forbidden regions in the LAT1 binding
pocket weakening the affinity of a substrate for LAT1. The pharmacophore was further
validated by aligning the compounds with modest affinity for LAT1 (0% < 50% L-leucine
uptake inhibition) with the 4-point pharmacophore. The pharmacophore was able to
provide an explanation for their weak affinity in each case, thus enabling SAR analysis of
the dataset.
The pharmacophore was also validated using an external test set of compounds with
previously reported high affinity for LAT1 to examine whether the pharmacophore fits
such structures (Uchino et al. 2002, Smith 2005). The compounds (n=14) were pre-processed
similarly to the data series described in Chapter 4.7, and aligned with the 3D
pharmacophore. The alignment shows that high-affinity compounds such as L-
triiodothyronine, 3-O-methyldopa, L-tyrosine, L-methyldopa, O-benzyl-L-tyrosine and
thyroxine  fit  well  with  all  four  pharmacophoric  features  of  this  model.  In  addition, L-
melphalan, metasarcolysin and DL-2-amino-7-bis[2-chloroethyl]- amino]-1,2,3,4-tetrahydro-
2-naphtoic acid fit well with the aromatic region, HBD and negatively charged center
features. They also contain a tertiary amine which can act as a HBA although their
alignment with the 3D pharmacophore reveals that the amine is located outside the
tolerance zone of the pharmacophore’s HBA feature (1 Å).
8.2.4 SAR in view of the 3D pharmacophore
Negatively charged group and HBD
The amino acid moiety which is common to all known LAT1 substrates is represented by a
negatively charged group and HBD. The negatively charged group and the HBD
correspond to the primary amine function and carboxylic moiety of LAT1 substrates,
respectively (Figure 27). The 3D pharmacophore generated in this study indicates that
instead of purely electrostatic features, the amino acid moiety of efficient LAT1 substrates
can interact with the LAT1 binding site also via hydrogen bonding. Previously, the
interactions  of  the  amino acid moiety  with LAT1 binding site  have been postulated to  be
attributable to electrostatic potentials of the negatively charged -carboxyl and positively
charged -amino groups (Uchino et  al. 2002, Gynther et  al. 2008). As shown by the in situ
data, the negatively charged group and HBD features are clearly essential for good affinity
as removal or modifications on either one of these characteristics has a dramatic effect on
the binding ability of the compounds (i.e. 25, 27, 29, 33–36)  resulting in only weak affinity
(31% L-leucine uptake inhibition) or complete inability to bind to LAT1. In addition, the
pharmacophore suggests that the distance between the negative charge and HBD should
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not exceed ~3 Å. The data set includes amino acid derivatives (24–26), in which the carboxyl
group and primary amine function represented by the negative charge and HBD,
respectively,  are  further  away  than  3  Å  (6  Å).  These  compounds  possess  only  a  modest
affinity for LAT1; their affinity is comparable to compounds lacking either the negatively
charged group or HBD. The effect of this kind of modification becomes evident when one
compares  the  molecular  structures  of L-phenylalanine (15) and L-phenylalanine (24) in
which the primary amine group is attached to the -carbon instead of the -carbon. The
resulting 1.6 Å increase in the distance between the negative charge and HBD from 3.1 Å to
4.7 Å causes a significant reduction in LAT1 affinity as L-leucine brain uptake inhibition
declines from 86% (15)  to  36% (24).  Loss  of  a  negatively  charged group and HBD further
leads to a complete loss of affinity as illustrated by compound 31 in which the distance
between the features is ~8 Å. This indicates that the most important features for efficient
LAT1 substrates are HBD and negative charge, and that removing either one of them or
increasing their distance >>3 Å has a major impact on their affinity for LAT1.
Aromaticity
Another molecular feature postulated to be important for LAT1 binding is the aromatic
region that follows the negatively charged group and HBD (Figure 27). The aromatic region
corresponds to the side chain of the neutral amino acid substrates of LAT1, and it
corresponds to the hydrophobic region defined by Uchino et al. (2002) and Smith (2005).
LAT1 indeed also accepts substrates which do not contain an aromatic ring but instead a
hydrophobic alkyl side chain (Uchino et  al. 2002, Smith 2005), and such compounds have
also been included in this data set (Table 18). Compounds 17 and 20 are able to bind to
LAT1  but  their  binding  affinity  is  lower  than  the  affinity  of  the  compounds  with  the
corresponding aromatic side chains. Gabapentin (20), for example, contains a cyclohexyl
ring that  roughly corresponds to  the  position of  the  aromatic  region,  and it  has  a  modest
affinity for LAT1 (< 59% L-leucine uptake inhibition). Similarly, ketoprofen prodrug 17,
which contains a hydrophobic L-lysine promoiety, displays lower affinity for LAT1 (79% L-
leucine uptake inhibition) than ketoprofen prodrug 13 with the aromatic L-phenylalanine
promoiety (99% L-leucine inhibition). Moreover, compound 32 which contains an alkyl
chain instead of an aromatic ring following the amino acid moiety can be considered as
completely inactive (0% L-leucine uptake inhibition). This suggests that aromaticity is a
more preferable molecular feature than alkyl chain and it increases the affinity of LAT1
substrates. There is a clear difference between these present results and models proposed
earlier with respect to aromaticity vs. hydrophobicity. First, aromaticity is clearly related to
planarity which is in agreement with the SAR analysis of this dataset where planar
aromatic compounds (e.g. 1–4, 13–16 and 18–19) are more potent than the non-planar
structures (e.g. 17, 20, 21, 32). This effect may be due to preferred shape-complementarity
with the LAT1 binding site, which is further supported by the concept that planar aromatic
amino acids (14, 15) inhibit >85% of the brain uptake of L-leucine which has a branched
non-planar alkyl side chain in its structure. The increased affinity of aromatic over
hydrophobic LAT1 substrates can also be caused by atypical hydrogen bonds (so called
blue-shifting hydrogen bonds) (Tóth et  al. 2007) which are potential interactions favoring
aromatic groups instead of simple alkyl chain structures or charge transfer interactions
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which  again  favor  aromatic  structures.  In  addition,  it  should  be  noted  that  in  previous
studies (Uchino et al. 2002) the hydrophobicity of LAT1 substrates was determined solely
based on their log P -values, which do not differentiate between aromatic and non-aromatic
structures.
HBA feature
The HBA feature which follows the aromatic region is considered to improve the binding of
LAT1 substrates. Most of the compounds that possess HBA in their structures in addition to
a negatively charged center, HBD and aromatic region (1–4, 13, 16, 18–19) are as efficacious
or even more efficient than the endogenous substrates of LAT1, such as L-phenylalanine
(15) and L-tryptophan (14), which lack this feature. Although HBA cannot be considered as
a requisite for LAT1 substrates as its natural amino acid substrates 14 and 15 do not contain
this feature, it can, nevertheless, enhance binding affinity of novel ligands. There is a clear
preference for hydrogen bonding with amides or esters within the data set (>79% L-leucine
uptake  inhibition)  although  an  alkoxy  (18)  or  hydroxyl  (19, 22) can also participate in
hydrogen bonding. An electron-rich nitrogen in a triple-bonded nitrile as present in
compound 16 (81% L-leucine uptake inhibition) can also participate in strong hydrogen
bonding. It is proposed that compounds 18, 19 and 22 
75% L-leucine uptake inhibition)
are less efficient than the compounds containing an amide or ester bond or triple-bonded
nitrogen due to the internal molecular effects occurring in their side chains. The catecholic
hydroxyl groups of levodopa (19) are able to form intramolecular hydrogen bonds, which
can weaken or inhibit the compound’s ability to form hydrogen bonds with LAT1 due to a
shift in electron-density. Similarly, the methoxy group of compound 18 is able to transfer its
electrons towards the benzene ring which decreases the ability of the ether oxygen to act as
an HBA. Nonetheless, ether oxygen is a modest HBA at best and may not be able to form
strong  enough  hydrogen  bonds  with  the  LAT1  binding  site  in  an  optimal  manner.
Delocalization of electrons can also explain the modest affinity of compound 22 (56% L-
leucine  uptake inhibition),  as  the  phenolic  hydroxyl  group is  more  likely  to  act  as  a  HBD
than HBA (Rozas 2007). This could also explain why 14 and 15, which lack the HBA feature,
have higher affinities for LAT1 than 18, 19 and 22 which possess HBA fitting features.
SAR analysis also suggests that the HBA feature should be at a sufficient distance from
the aromatic region (~3.8 Å). The compounds with a shorter distance exhibit weaker affinity
for LAT1 than compounds fitting the distance requirement. This can be seen by comparing
18, 19 and 22 (75% L-leucine uptake inhibition) with the meta-substituted valproic acid
prodrugs 1 and 3 (93% L-leucine uptake inhibition). In 18, 19 and 22, the distance between
HBA and the aromatic region is 2.8 Å differing by ~1 Å from the distance proposed by the
3D pharmacophore. Instead, 1 and 3 correspond to the pharmacophore more accurately as
the distance between the aromatic region and HBA is 4.0 Å (Figure 28). The para-
substituted valproic acid prodrugs 2 and 4 (64 % L-leucine uptake inhibition) also contain
HBA at an optimal distance from the aromatic region but they show weaker affinity for
LAT1 than 1 and 3. This has been shown to be linked to the stereochemistry and meta-
versus para-positioning of the valproic acid moieties (See Chapter 5). The meta-para
positioning influences also the position and directionality of HBA, which can partly explain
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the differences in ligand efficiency of meta- (93% L-leucine uptake inhibition) and para-
substituted (64 % L-leucine uptake inhibition) valproic acid prodrugs (Figure 29).
Figure 28. The optimal distance between HBA and aromatic region. Valproic acid prodrug 3
(93% L-leucine uptake inhibition) (green) with 4.0 Å distance between the aromatic region and
HBA (a) fits the pharmacophore better than the less efficient compound 19 (66% L-leucine
uptake inhibition) (orange) with corresponding 2.8 Å distance (b).
Figure 29. Alignment  of  valproic  acid  prodrugs 1–4 with the pharmacophore. More efficient
meta-substituted prodrugs (red) (93% L-leucine  uptake  inhibition)  adopt  a  different  region  in
space than para-substituted prodrugs (blue) (64% L-leucine uptake inhibition) which indicates a
preferred binding conformation.  In addition,  the orientation of  HBA differs between the meta-
and para-substituted prodrugs.
In  summary,  the  3D  pharmacophore  model  identifies  molecular  features  which  can
promote  efficient  LAT1  binding:  1)  negatively  charged  center  and  HBD  at  ~3  Å  distance
from each other, 2) aromatic feature following HBD and the negative charge, 3) HBA next
to the aromatic region, at ~3.8 Å distance from the aromatic feature. It also includes
information about the 3D nature of the molecular features which help in finding a common
chemotype  for  compounds  with  high  affinity  for  LAT1.  This  is  the  first  time  that  the
molecular features and 3D arrangement of LAT1-binding compounds have been analyzed
in detail using modern computational modeling methods. The structural features of LAT1
substrates  have  been  studied  previously  (Uchino et  al. 2002, Smith 2005) but the relative
positions  or  intercharge  distances  of  important  binding  groups  in  space  (e.g. -carboxyl
group and -amine group) have not been reported. Moreover, the importance of
electrostatic interactions of LAT1 substrates has been determined based on charges
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calculated for single atoms. Due to electron delocalization of ð -electrons, the method used
to describe the charges of the system is critical. Single point charges are not able to describe
electron delocalization adequately and therefore, electrostatic effects have to be described
with molecular electrostatic potential maps.
The generated 3D pharmacophore model can accommodate 70% of the high-affinity
compounds (>50% L-leucine  uptake  inhibition)  examined  in  this  study,  and  also  the
external data set which contained compounds reported to exhibit high affinities for LAT1
(L-triiodothyronine, 3-O-methyldopa, L-tyrosine, L-methyldopa, O-benzyl-L-tyrosine,
thyroxine) (Uchino et al. 2002, Smith 2005). It is also able to distinguish inactive compounds
from  LAT1-binding  compounds.  This  allows  rationalization  of  the  SAR  of  the  series  of
compounds in Table 18. Aligning the inactive compounds (0% L-leucine uptake inhibition)
with the pharmacophore shows them to protrude into regions in space which extend
beyond the HBD and negatively charged centre.  As the compounds with high affinity for
LAT1 (>50% L-leucine uptake inhibition) do not reach into this area, this suggests that there
are  specific  positions  in  space  not  occupied  by  binding  to  the  LAT1.  It  can  be  speculated
that although compounds 33–36,  which lack either  the  carboxyl  or  primary amine group,
contain some molecular features fitting the pharmacophore, they cannot adopt an optimal
conformation for efficient binding and they interfere with the LAT1 binding pocket.
Moreover,  the  alignment  of  compounds  with  <  50% L-leucine uptake inhibition with the
pharmacophore  can  explain  their  modest  affinity,  and  further  suggest  regions  in  space
which  are  sterically  forbidden.  Compound 23 (38% L-leucine uptake inhibition), for
example, fits all features of the pharmacophore but its methyl-substituent protrudes into a
region which compounds 1–4, 13–19 and 22 (99–56% L-leucine uptake inhibition) do not
occupy. Similarly, compound 21 (57% L-leucine uptake inhibition) adopts a conformation
where  its  alkyl  chain  occupies  the  same  region  in  space  than  the  methyl-substituent  of
compound 23 (Figure  30).  It  is  possible  that  unwanted  steric  effects  account  for  these
compounds' weaker affinities. The alignment of valproic acid prodrugs (1–4) also indicates
that para-substituted prodrugs 2 and 4 reach sterically unfavorable regions not reached by
meta-substituted prodrugs (Figure 30).
Figure 30. Alignment  of  valproic  acid  prodrug  (3) with N-phenyl-L-glutamine (21) and -
methyl-L-tyrosine  (23). Compounds 21 (red)  and 23 (blue)  protrude  into  a  region  in  space
marked  with  a  yellow  sphere  which  can  interfere  with  LAT1  and  disturb  optimal  binding
interactions. More efficient LAT1 substrates represented here by 3 (grey) do not reach into the
same position.
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Although the  3D pharmacophore  can give  some indications  of  the  steric  boundaries  of
the  LAT1 binding site,  it  is  not  able  to  provide detailed information of  the  dimensions  of
LAT1 substrate binding pocket beyond the site which interacts with the negatively charged
centre, HBD, aromatic centre and HBA. In particular, the part of the binding site that
accommodates  the  valproic  acid and ketoprofen moieties  of  prodrugs needs to  be  further
analyzed. The prodrugs studied so far are reasonably flexible which complicates the
modeling of their bioactive conformation. Adding rigidity to the structures of the prodrugs
could enhance the understanding of the shape and volume of the LAT1 binding pocket and
enable pharmacophore-based virtual screening of novel LAT1-binding compounds.
8.3 CONCLUSIONS
In order to utilize the full  potential of LAT1 as a drug carrier and to design selective and
potent high affinity LAT1 promoieties, it is very important to identify the molecular
features required for efficient LAT1 binding. In this study, a 3D pharmacophore for
substrates of LAT1 was generated. This pharmacophore identifies the ensemble of the most
important molecular features for efficient LAT1-binding compounds, and highlights the 3D
arrangement  of  the  features  for  the  first  time  in  detail.  It  also  provides  a  resource  for
understanding the structure-activity relationships of LAT1 substrates and thus can be
viewed as a starting point for optimizing the structures of new efficient LAT1 substrates.
This information will be important in the rational design of novel prodrugs with improved
LAT1-mediated CNS permeation properties.
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9 General Discussion and Conclusions
9.1 LAT1 AS A TARGET OF PRODRUG DESIGN
LAT1 has been considered as a promising carrier to deliver poorly brain penetrable drugs
into the CNS by adopting a prodrug approach as discussed in the earlier chapters. This
stems from the relatively high expression of LAT1 at the BBB as compared with other
tissues and its important role in transporting neutral amino acids across the BBB. LAT1 also
possesses  much  higher  affinity  for  amino  acids  than  LAT2,  which  is  mainly  expressed  in
peripheral tissues (Pardridge 1983). Furthermore, the interest in LAT1 has recently
increased as the transporter has been linked with the intake of amino acids into tumor cells.
LAT1 is up-regulated in several malignant tumor cells (Kim et al. 2008), including cells
associated with ovarian (Fan et al. 2010), breast (Liang et al. 2011) and prostate cancer
(Sakata et al. 2009), where it might stimulate tumor growth through a nutrient pathway. In
addition to acting as a carrier of chemotherapeutics into the tumor cells, LAT1 is a potential
molecular target to deprive cancer cells of amino acids in an immunosuppressant manner
by inhibiting the amino acid intake into the tumor cells. For example, 2-aminobicyclo-
2(2,2,1)-heptane-2-carboxylic acid (BCH), a widely used LAT1 inhibitor, has been shown to
inhibit  cell  growth  of  several  human  cancer  cell  lines  (Kim et al. 2008, Shennan and
Thomson 2008, Fan et  al. 2010). Furthermore, a LAT1 selective inhibitor, KYT-0353 (also
known as JPH203), has been shown to significantly inhibit the cell growth in human colon
cancer-derived HT-29 cells at micromolar concentrations (Oda et al. 2010). The inhibitor also
reduced the growth of implanted HT-29 tumors in nude mice after intravenous
administration. As a consequence, the importance of LAT1 for the vitality of tumor cells is
clearly evidenced, which also makes LAT1 an intriguing target protein for anticancer
therapeutics.
Despite  the  promising features  of  LAT1 to  act  as  a  drug carrier  to  the  brain  or  tumors,
the ability of LAT1 to operate as a drug carrier has been criticized since LAT1 has been
shown to be saturated by the endogenous substrates under physiological circumstances
(del Amo et  al. 2008).  This  limitation  has  to  be  considered  in  LAT1  prodrug  design  by
developing LAT1 substrates which possess high enough affinity for LAT1 to be able to
compete with the endogenous amino acids for uptake into the tissue. Another drawback of
utilizing LAT1 is its rather selective expression at the BBB and other blood-tissue barriers
(Verrey 2003). Thus, the intestinal absorption of the LAT1 prodrugs via LAT1 may be low,
and the prodrug approach may need to be restricted to parenteral administration.
However, it is not clear whether a LAT1 prodrug will be able to cross the intestinal wall by
carrier-mediated transport or passive diffusion.  Therefore this aspect should be evaluated.
This  was,  however,  out  of  the  scope  of  this  thesis.  In  addition,  the  distribution  of  the
studied prodrugs to the tissues other than brain was not studied here, but will need to be
evaluated in future studies.
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9.2 THE METHODS USED IN THE THESIS
A wide range of in vivo, in situ, in vitro and computer-aided drug design methods can be
used to evaluate the extent and rate of drug delivery to the CNS as described in Chapter
2.2. The selection of the method is crucial as each method has both advantages and
disadvantages, which should be carefully considered. In this thesis, the in situ rat brain
perfusion technique and in vivo bolus intravenous injection methods were used to evaluate
the mechanism of drug delivery to the brain. Furthermore, the pharmacological effect of the
dopamine prodrug was evaluated by determining its ability to elevate the endogenous
dopamine levels in the rat striatum. In addition, several analytical and sample preparation
methods were developed in order to determine the concentrations of the parent drugs and
their prodrugs from brain tissue homogenate and plasma.
The in situ rat brain perfusion technique offers advantages over in vitro and in vivo
methods for drug brain uptake evaluation. Especially, the in situ method is valuable for
determining the brain uptake mechanism of drugs as the composition and temperature of
the perfusion fluid can be modified and saturable transport can be demonstrated. However,
only the total amount of the drug in the brain can be detected when using the in situ
method and the rate of crossing the BBB is the only parameter evaluated by the method. In
addition, the systemic pharmacokinetics, which may have a great effect on the brain uptake
of a drug, are not taken into account. Finally, due to the short perfusion time, the
bioconversion of prodrugs cannot be determined by the in situ method. Thus, in vivo
intravenous injections were also conducted to complement the in situ studies. The unbound
prodrug concentrations in the brain ECF were not determined because the prodrugs did not
achieve adequate bioconversion to the parent drug in the brain. If the prodrugs had
possessed the potential to release the parent drug, then brain microdialysis studies would
have been conducted and the free fraction of the prodrugs and the released parent drugs in
the site of action would have been determined.
Hundreds of laboratory animals have been used in the present studies. Thus, an in vitro
assay of mammalian brain endothelial cells expressing LAT1 to determine the LAT1
binding  would  be  a  very  valuable  tool  to  partly  replace  the in situ inhibition studies.
However, as discussed in Chapter 2.2, an ideal cell line for studying transporter-mediated
delivery across the BBB has not been established yet. By using the in situ rat brain perfusion
technique, the paracellular pathway at the BBB is restricted and thus, LAT1 affinity of low-
affinity compounds can also be determined.
The compounds were studied in rats, and this has to be considered when interpreting
the results and correlating them with corresponding findings in humans. LAT1 is expressed
at both rat and human brain endothelial cells. The similarity of the amino acid sequences of
LAT1 between these species is 94% (Prasad et  al. 1999), and the binding affinities of LAT1
have been shown to be similar in humans and rats (Choi and Pardridge 1986). However,
the expression levels of LAT and 4F2hc have been shown to be 5-fold lower in human than
in isolated brain microvessels in mice (Uchida et  al. 2011). The corresponding
measurements in rat brain have not yet been conducted. The expression levels of esterases,
which are likely responsible for the bioconversion of some of the studied prodrugs, are
much higher in rats than in humans (Liederer and Borchardt 2005) which has to be
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considered when interpreting the results of this thesis. In addition, the studies were carried
out in healthy animals. However, as discussed in Chapter 2.1.2, it could be beneficial to
conduct the brain transport evaluation studies in animals modeling the disease conditions
as these may have a major influence on the brain transport of drugs. In particular, the
tightness  of  the  BBB  and  the  expression  levels  of  the  transporters  at  the  BBB  may  be
different between the healthy and diseased animals.
The pharmacophore generated in this thesis is based on the affinity data only, and the
translocation of the studied compounds was not determined. However, a LAT1-expressing
in vitro model of the BBB could be highly valuable for revealing the translocation of LAT1
substrates  across  the  cell  membrane  and  could  expand  the  application  of  the  model  to
estimate also the translocation across the BBB in addition to the LAT1 binding. In addition,
the ligand-based computer-aided modeling studies could be extended to quantitative
structure-activity  relationship  (QSAR)  models  to  analyze  the  3D-QSAR  of  LAT1  in  the
three-dimensional molecular field (e.g. comparative molecular field analysis (COMFA)).
The 3D-QSAR modeling concerns the shape and volume as well as the steric hindrances
with more details than the 3D pharmacophore.
9.3 SUMMARY OF THE EVALUATION OF THE LAT1 PRODRUGS
Twelve LAT1 prodrugs were evaluated in this thesis using valproic acid, kynurenic acid or
dopamine as their parent drugs. The promoieties used in this thesis were mostly unnatural
analogues of amino acids. The best high-affinity LAT1 promoiety was phenylalanine
substituted at the meta-position of its aromatic ring. This promoiety was modified to
shuttle both anionic (i.e. valproic acid and kynurenic acid) and cationic (i.e. dopamine)
drugs into  the  brain.  The valproic  acid prodrugs using meta-substituted phenylalanine as
the promoiety exhibited 10-fold higher binding affinity to LAT1 and were translocated with
2-fold greater amounts into the brain than the corresponding para-substituted prodrugs in
the in situ rat brain perfusion. In addition, the brain uptake of the meta-substituted
analogues after intravenous administration to rats was 1.6-fold (3)  and 1.9-fold (5) greater
than that of the para-substituted analogue (4).  Similarly,  the  meta-substituted  prodrug  of
kynurenic acid (8) was able to inhibit the brain uptake of L-leucine with significantly much
higher affinity compared to the corresponding para-substituted derivative of kynurenic
acid (9). The in situ brain uptake was not determined for the kynurenic prodrugs as their
solubility to the perfusion fluid was poor. In contrast to the valproic acid prodrugs, their
kynurenic acid counterpart 8 was not able to cross the rat BBB in high amounts after
intravenous administration. As a lipophilic compound the kynurenic acid prodrug 8 is
most probably highly bound to plasma proteins leading to low free fraction of the prodrug
in the systemic circulation. The low free concentration of 8 in plasma may not be adequate
for LAT1 binding when the competing endogenous LAT1 substrates are present.
The potency of the meta-substituted phenylalanine to act as high-affinity LAT1
promoiety was also shown by using dopamine as a parent drug. The promoiety attached
through a carboxylic acid group on the meta-position of the phenylalanine was shown to be
superior, both in binding and brain uptake, when compared to the dopamine prodrugs
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with alkyl amino acids as the promoieties. In this part of the study, the LAT1 prodrug
technology was expanded also to a cationic and hydrophilic parent drug. The translocation
of LAT1 prodrugs were shown to be dependent on their high affinity for LAT1 as the alkyl
amino acid prodrugs of dopamine possessed only low binding affinity for LAT1 in the in
situ rat brain perfusion and they were not taken up into the brain. This observation of poor
LAT1  affinity  of  the  dopamine  prodrugs  with  the  alkyl  amino  acid  promoiety  was  not
consistent with the previous findings of the lysine-ketoprofen prodrug (Gynther et al. 2010).
Therefore,  in  the  present  study  alkyl  amino  acid  promoieties  were  concluded  to  be  less
favorable as LAT1 promoieties than their aromatic amino acid counterparts. However, the
whole prodrug structure including both the parent drug and promoiety can possess
features that are favorable for LAT1 binding as previously shown by the lysine-ketoprofen
prodrug. Another observation from the dopamine prodrugs was that the very high
hydrophilicity of a LAT1 prodrug may not be beneficial as the prodrug may be too quickly
eliminated from the brain. However, additional studies should be conducted to evaluate
the intracranial distribution of the dopamine prodrug in order to justify this hypothesis.
The optimization of the bioconversion of a brain-targeted prodrug to the parent drug is a
great challenge, and this problem was also encountered in the present study. The ester
derivatives have been considered as being too unstable in systemic circulation as they
usually undergo premature degradation by the esterases in plasma and liver before
reaching the desired tissue. Instead, amide derivatives have been considered as more stable
in  plasma  and  liver,  which  had  been  previously  shown  for  example  by  the  lysine-
ketoprofen LAT1 prodrug (Gynther et al. 2010). Thus, amide derivatives were studied in the
present study. However, the amide derivatives of valproic acid were shown to be too stable
to allow the release of valproic acid at high enough concentrations to achieve
pharmacological effect. The percentage of released valproic acid was increased from 5% to
8% when valproic acid was conjugated to the meta-substituted phenylalanine that had a
more flexible prodrug structure. However, the percentage of released valproic acid
remained too low. Amide prodrugs of kynurenic acid were also designed, synthesized and
studied in vitro and in rats. Unfortunately, the derivatives of kynurenic acid were also too
stable to allow the release of kynurenic acid in rat brain and in rat systemic circulation in
vivo. However, the dopamine prodrugs were able to release dopamine predominantly
enzymatically in vitro. The in vivo bioconversion of the amide prodrug of dopamine was not
detected because the prodrug was most probably rapidly eliminated from the brain.  In
conclusion, the bioconversion seems to be dependent on the parent drug, and therefore one
LAT1 promoiety cannot be used as a universal strategy for all drugs. The physicochemical
properties of the parent drug define the bioconversion of its prodrug, and a successful
prodrug strategy for improved drug delivery to the brain has to be tailor-made for each
parent drug. Amide prodrugs utilizing LAT1 may represent a potential alternative to
enhance the brain uptake of drugs with extremely poor brain uptake, since only a 5–10%
release of an active drug can be a great enhancement in the brain exposure of the drug.
In addition to enhanced drug delivery to the brain, LAT1-mediated prodrug design
could be extended to enhance the transport of chemotherapeutics into tumor cells as LAT1
is over-expressed in several tumor cells (e.g. Kim et al. 2008, Sakata et al. 2009, Fan et al. 2010,
Liang et al. 2011). Melphalan is an example of a LAT1-utilizing chemotherapeutic in clinical
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use (Goldenberg et al. 1979, Cornford et al. 1992). However, no attempts have been reported
to adopt the prodrug approach to transport chemotherapeutics to tumor cells via LAT1.
Since the pH of tumor cells is often lower (pH 4.5-6) than in blood or normal tissues
(Tannock and Rotin 1989), more tumor-specific release of the active drug could be achieved
by  utilizing  an  acid-sensitive  release  of  an  active  drug.  Thus,  acid-sensitive  bonds  (e.g.
acetal, acyl hydrazone and imine) between the promoiety and the parent drug could be
used. Moreover, reductive-sensitive disulfide bond could be used as the tumor tissue has a
hypoxic environment (Denny 2010).
9.4 SUMMARY OF THE MOLECULAR MODELING STUDIES
The 3D pharmacophore for LAT1 substrates was generated in this thesis. The
pharmacophore identifies for the first time the ensemble of the most important molecular
features required for compounds binding efficiently to LAT1 and highlights the 3D
arrangement of those features. The molecular features for efficient LAT1 binding were
shown to be:
1. Negatively charged center and HBD at ~3 Å distance from each other,
2. Aromatic feature following HBD and a negative charge,
3. HBA next to the aromatic region, at ~3.8 Å distance from the aromatic feature.
These structure-activity relationships of LAT1 substrates can be utilized in the design of
new promoieties to achieve improved drug delivery to those tissues expressing LAT1.
The  structural  features  of  LAT1  substrates  have  been  studied  previously  (Uchino et al.
2002, Smith 2005) but the relative positions or distances between important binding groups
in space (e.g.-carboxyl group and -amine group) have not been reported. Moreover, the
importance of electrostatic interactions of LAT1 substrates has been determined based on
charges calculated for single atoms. Thus, the electrostatic interactions of the generated
pharmacophore of LAT1 were described for the first time with molecular electrostatic
potential maps. In addition, the more efficient affinity of aromatic over hydrophobic LAT1
substrates was shown for the first time in the generated pharmacophore of LAT1. The HBA
feature, which follows the aromatic region, was another novel finding of the present study.
Most of the compounds that possess HBA in their structures in addition to a negatively
charged  center,  HBD  and  aromatic  region  were  shown  to  be  efficacious  or  even  more
efficient than the endogenous substrates of LAT1 lacking the HBA feature.
As the crystal structure of LAT1 remains undetermined, it is very important to identify
the  molecular  features  required  for  efficient  LAT1  binding  in  order  to  design  new
compounds that possess high enough affinity for LAT1 that they are able to compete with
the endogenous amino acids for tissue uptake. The 3D pharmacophore model in this thesis
was generated based on LAT1 affinities of different compounds. The affinities were
determined using the in situ rat brain perfusion technique. The 3D pharmacophore model
fits 70% of the high-affinity compounds applied in this study and outside our dataset
(Uchino et al. 2002, Smith 2005). It is also able to distinguish inactive compounds from
LAT1-binding compounds.
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Although the 3D pharmacophore of LAT1 can give some indications of the dimensions
of LAT1 binding site interacting with the negatively charged centre, HBD, aromatic centre
and HBA, it is not able to provide detailed information about the steric boundaries of LAT1
substrate binding pocket. The prodrugs studied so far are reasonably flexible which
complicates the modeling of their bioactive conformation. If the structures of the prodrugs
could be made more rigid, it might reveal new information about the shape and volume of
the LAT1 binding pocket and enable successful pharmacophore-based virtual screening of
novel LAT1-binding compounds.
Furthermore, as the pharmacophore is solely based on the affinity data, it does not define
the transport ability of the prodrug. Thus, the actual brain uptake of each prodrug designed
by this model has to be determined to ensure the translocation across the BBB. However, it
has been shown in the present doctoral study that a LAT1 substrate that possesses only a
modest affinity for LAT1 is not translocated across the BBB via LAT1 at any detectable
amounts, which evidences that high affinity for LAT1 is needed for efficient LAT1-
mediated brain uptake.
9.5 CONCLUSIONS
The following conclusions can be made based on the results of the thesis:
1. Phenylalanine substituted at the meta-position of its aromatic ring can be
used as a high-affinity and versatile promoiety for LAT1-targeting.
 By using unnatural amino acids as promoieties both the affinity for
LAT1 and the translocation across the BBB can be increased.
 The high-affinity promoiety can be used to design LAT1 utilizing
prodrugs of both anionic and cationic drugs.
 Hydrophilic prodrugs can also be ferried across the BBB via LAT1.
2. The aromatic amino acid promoieties bind to LAT1 with higher affinity than
the corresponding alkyl amino acid promoieties.
3. High affinity for LAT1 is required for translocation of LAT1 substrates across
the BBB.
4. The optimization of the biotransformation of tissue-targeted prodrugs is
challenging, and one LAT1 promoiety cannot be universally generalized for
all  poorly  brain  penetrable  drugs.  The  physicochemical  properties  of  the
parent drug need to be considered carefully when designing LAT1 prodrugs.
5. The generated 3D pharmacophore model of LAT1 is able to distinguish
LAT1-binding compounds from compounds having low LAT1 binding
affinity and the model can be used to design novel promoieties for improved
LAT1-mediated drug delivery to the desired target tissues.
The novel promoieties designed and explored in the present study and by the generated
3D pharmacophore model of LAT1 can be further applied to optimize the brain delivery of
poorly brain penetrable drugs. A novel application of the findings of this thesis could also
be the development of tumor-targeted LAT1 prodrugs.
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This doctoral thesis presents novel 
promoieties and carriers to enhance 
the blood-brain barrier (BBB) perme-
ation of drugs by targeting the pro-
drugs to large amino acid transporter 
1 (LAT1). The thesis describes for 
the first time unnatural amino acids 
as LAT1 promoieties which enable 
the BBB permeation of both anionic 
and cationic drugs in addition to lipid 
soluble and water soluble prodrugs 
across the BBB. In addition, the thesis 
presents a 3D pharmacophore of LAT1 
that highlights the most important 
molecular features for efficient 
LAT1 binding.
